Insights from linking police domestic abuse data and health data in South Wales, UK: a linked routine data analysis using decision tree classification

Natasha Kennedy, Tint Lwin Win, Amrita Bandyopadhyay, Jonathan Kennedy, Benjamin Rowe, Cynthia McNemey, Julie Evans, Karen Hughes, Mark A Bellis, Angela Jones, Karen Harrington, Simon Moore, Sinead Brophy

Summary
Background Exposure to domestic abuse can lead to long-term negative impacts on the victim's physical and psychological wellbeing. The 1998 Crime and Disorder Act requires agencies to collaborate on crime reduction strategies, including data sharing. Although data sharing is feasible for individuals, rarely are whole-agency data linked. This study aimed to examine the knowledge obtained by integrating information from police and health-care datasets through data linkage and analyse associated risk factor clusters.

Methods This retrospective cohort study analyses data from residents of South Wales who were victims of domestic abuse resulting in a Public Protection Notification (PPN) submission between Aug 12, 2015 and March 31, 2020. The study links these data with the victims’ health records, collated within the Secure Anonymised Information Linkage databank, to examine factors associated with the outcome of an Emergency Department attendance, emergency hospital admission, or death within 12 months of the PPN submission. To assess the time to outcome for domestic abuse victims after the index PPN submission, we used Kaplan-Meier survival analysis. We used multivariable Cox regression models to identify which factors contributed the highest risk of experiencing an outcome after the index PPN submission. Finally, we created decision trees to describe specific groups of individuals who are at risk of experiencing a domestic abuse incident and subsequent outcome.

Findings After excluding individuals with multiple PPN records, duplicates, and records with a poor matching score or missing fields, the resulting clean dataset consisted of 8709 domestic abuse victims, of whom 6257 (71.8%) were female. Within a year of a domestic abuse incident, 3650 (41.9%) individuals had an outcome. Factors associated with experiencing an outcome within 12 months of the PPN included younger victim age (hazard ratio 1·183 [95% CI 1·053–1·329]; p=0·0048), further PPN submissions after the initial referral (1·383 [1·295–1·476]; p<0·0001), injury at the scene (1·484 [1·368–1·609]; p<0·0001), assessed high risk (1·600 [1·444–1·773]; p<0·0001), referral to other agencies (1·518 [1·358–1·697]; p<0·0001), history of violence (1·229 [1·134–1·333]; p=0·0001), attempted strangulation (1·311 [1·148–1·497]; p=0·0001), and pregnancy (1·372 [1·142–1·648]; p=0·0007). Health-care data before the index PPN established that previous Emergency Department and hospital admissions, smoking, smoking cessation advice, obstetric codes, and prescription of antidepressants and antibiotics were associated with having a future outcome following a domestic abuse incident.

Interpretation The results indicate that vulnerable individuals are detectable in multiple datasets before and after involvement of the police. Operationalising these findings could reduce police callouts and future Emergency Department or hospital admissions, and improve outcomes for those who are vulnerable. Strategies include querying previous Emergency Department and hospital admissions, providing a high-risk assessment for a pregnant victim, and facilitating data linkage to identify vulnerable individuals.

Funding National Institute for Health Research.

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
harassment.\textsuperscript{12} The DASH questionnaire comprises a series of methodically constructed questions that capture vital aspects of the situation, such as the perpetrator’s behaviour, the victim’s response, and the level of threat to the victim’s safety. The collected data are analysed to determine the risk of further harm, and the results are used to implement effective interventions to safeguard the victim.\textsuperscript{7}

Domestic abuse—defined here to include domestic violence and intimate partner violence, as per the DASH questionnaire—encompasses a range of incidents characterised by coercive, controlling, and abusive behaviours directed towards another individual.\textsuperscript{1} These behaviours manifest in various forms, such as coercive control and emotional, financial, physical, psychological, or sexual violence or threats.\textsuperscript{14} A lifetime incidence of domestic abuse has been estimated to affect 27% of women globally,\textsuperscript{7} with a former intimate partner or spouse as the predominant perpetrator.\textsuperscript{2}

Studies have indicated that exposure to domestic abuse results in long-term negative impacts on the victim’s physical and psychological wellbeing.\textsuperscript{14} Research into the long-term consequences of repeated victimisation is minimal; however, about two-thirds of female domestic abuse victims are revictimised.\textsuperscript{7} When a cycle of revictimisation is present, it exacerbates the consequences of domestic abuse, such as affecting new relationships, introducing negative health behaviours in the form of addictions, and developing mental health disorders, including post-traumatic stress disorder.\textsuperscript{65–30} This cycle of revictimisation also increases the use of health-care services. Domestic abuse victims interact more frequently with Emergency Departments than people from the general population.\textsuperscript{13,12}

Although domestic abuse victims attend Emergency Departments frequently, these visits rarely result in the disclosure of abuse to staff or reports to the police.\textsuperscript{1,12} Research into the identification of domestic abuse by Emergency Department staff indicated that, of 259 visits in 1999–2001 in a semi-rural county in the USA, physicians were more likely to document the violence (83% documented by the physician) than triage nurses (62%) or treatment nurses (44%).\textsuperscript{9} In the context of emergency care, it is expected that clinical personnel proactively identify and address vulnerabilities that extend beyond the initial presenting symptoms. In addition to patients’ disclosure, clinicians routinely assess their medical history using available data. Consequently, clinicians can enact safeguarding measures, including referring patients to an Independent Domestic Violence Advocate, if they perceive that the patient is at risk, even in cases where disclosure is absent. Further studies have indicated that domestic abuse victims frequently present to the Emergency Department
for non-injury-related complaints. Additionally, they also have an increased likelihood of having accompanying medical records documenting mental health and substance abuse issues.\textsuperscript{3,13–15} Consequently, the Emergency Department and hospital setting offers a crucial opportunity for intervention and prevention, prioritising the health and wellbeing of domestic abuse victims. However, it is necessary to establish a robust infrastructure to gather additional information to effectively address the victims’ needs.

This study aimed to examine knowledge obtained by integrating information from police PPN records and health-care datasets through data linkage. The study was conducted by investigating associations with information from numerous datasets, and examining the clustering patterns of related factors, as well as their association with Emergency Department attendance, emergency hospital admission, or death within 12 months of the index PPN submission, thereby identifying opportunities to improve ascertainment of individuals at high risk of domestic abuse without disclosure.

Methods
Study design and setting
We conducted a retrospective cohort study to ascertain the risk factors associated with victims who will experience an outcome (ie, Emergency Department admission, emergency admission to hospital, or death) in the 12 months following a PPN submission for domestic abuse. The cohort was composed of residents in the South Wales Police Force Region who were domestic abuse victims resulting in a PPN submission between Aug 12, 2015 and March 31, 2020. The cohort was based on the PPN dataset that also comprises records formed from the DASH risk identification and assessment model.\textsuperscript{1} Data of anonymised identified persons were linked on the individual level to health record data within the Secure Anonymised Information Linkage (SAIL) databank.\textsuperscript{16–18} The SAIL databank is a data repository containing over 10 billion anonymised records, with a population coverage of 100% for hospital and general practitioner (GP) data for this South Wales dataset, thus enabling person-based data linkage across numerous datasets. Each individual is assigned an encrypted anonymised linking field; this field is used to link anonymised individuals across datasets, thus facilitating longitudinal analysis of the individual’s progression through the different datasets.\textsuperscript{19} The linked data includes the primary care Wales Longitudinal General Practice dataset to identify reasons for contact with health-care professionals in general practice; data collected by GPs are captured via Read Codes, version 2, which relate to diagnosis, medication, and process-of-care codes. Hospital inpatient and outpatient data are collated in the Patient Episode Database for Wales, which encompasses clinical information pertaining to patients’ hospital admissions, diagnoses, operations, and discharges using the International Classification of Diseases, 10th revision (ICD-10) clinical classification system. The Emergency Department Dataset for Wales uses three-digit alphanumeric codes to capture data regarding activity and information from Emergency Department and Minor Injury Units. The Office of National Statistics mortality dataset held within the Annual District Death Extract dataset contains demographic data, place of death, and underlying cause of death as ICD-10 codes. The Welsh Demographic Service dataset was used to identify all patients registered with a GP practice and to flag when people move in and out of Wales.

Variables
The outcomes for all analyses were Emergency Department attendance, emergency hospital admission, and death due to any cause within 12 months of the index PPN submission; where the time to event is reported, it is the time to the first event for cases where an individual had multiple events (ie, emergency admission followed by death). An Emergency Department admission includes Emergency Department attendance or emergency admission to hospital. For women, we ensured that the hospital admissions and Emergency Department attendances were non-obstetric. Emergency Department, hospital, and GP data were examined for up to 1 and 3 years before receiving the index PPN submission to highlight early risk factors of experiencing an outcome following a domestic abuse incident (appendix 1 p 1).

In terms of exposures and confounders, all variables recorded at the index PPN from the DASH questionnaire\textsuperscript{2} were included: attempted strangulation, conflict over a child (ie, conflict regarding contact with the child), hurt other people, history of further violence, injury, multi-agency risk assessment conference (MARAC) referral, pregnant, and past pregnancy. Subsequent PPN visits following the initial index PPN were also included as an explanatory variable. Additionally, for the decision tree analysis, information from Emergency Department and GP (ie, diagnoses, medications, procedures, and referrals) and hospital admissions (ie, cause of admission and date) were included in the analysis up to 1 and 3 years before the index PPN. Specific codes included are in the code list in appendix 2; these were filtered to include codes that possessed a frequency of greater than or equal to 250 within the cohort. The majority of the variables from the dataset were presented in a binary form, with 1 representing the presence of a concept and 0 representing its absence. The age of individuals was 16–18. The cohort was composed of residents in the South Wales Police Force Region who were domestic abuse victims resulting in a PPN submission between Aug 12, 2015 and March 31, 2020. The cohort was based on the PPN dataset that also comprises records formed from the DASH risk identification and assessment model.\textsuperscript{1} The linked data includes the primary care Wales Longitudinal General Practice dataset to identify reasons for contact with health-care professionals in general practice; data collected by GPs are captured via Read Codes, version 2, which relate to diagnosis, medication, and process-of-care codes. Hospital inpatient and outpatient data are collated in the Patient Episode Database for Wales, which encompasses clinical information pertaining to patients’ hospital admissions, diagnoses, operations, and discharges using the International Classification of Diseases, 10th revision (ICD-10) clinical classification system. The Emergency Department Dataset for Wales uses three-digit alphanumeric codes to capture data regarding activity and information from Emergency Department and Minor Injury Units. The Office of National Statistics mortality dataset held within the Annual District Death Extract dataset contains demographic data, place of death, and underlying cause of death as ICD-10 codes. The Welsh Demographic Service dataset was used to identify all patients registered with a GP practice and to flag when people move in and out of Wales.
held in the SAIL databank are anonymised; therefore, ethical approval is not mandatory in accordance with the Health Research Authority guidance and there is no legal requirement for explicit consent to participate under the Data Protection Act and UK General Data Protection Regulation. Furthermore, permission has been obtained from the relevant Caldicott Guardian or Data Protection Officer for all data contained in SAIL. In addition, proposals using SAIL data are subject to review by an Information Governance Review Panel (IGRP) to secure approval. The IGRP approval number for this study is 0916.

Statistical analysis
After the exclusion of multiple PPN records and records with missing fields or duplicates, missing values were visualised; individuals with 25% or more of missing data were removed. The missing values for the remaining individuals were replaced with a new category, NR (no response). Any categorical variables were altered to factors for analysis.

Descriptive statistics were generated to assess the rates of experiencing an outcome, stratified by both gender and age for the domestic abuse victims who were the subject of a PPN submission. We used Kaplan-Meier survival analysis to examine the time to outcome for the domestic abuse victim after the index PPN submission, censoring individuals who moved out of Wales. We used multivariable Cox proportional-hazard models, adjusted for confounders, to identify which factors contributed the highest risk of experiencing an outcome after the index PPN submission. The hazard ratios (HRs) were reported with 95% CIs and a significance level accepted at p<0.05. The reference groups were No for most factors; otherwise, the reference group was Male for gender, Standard Risk for the risk assessment factor, and the age group 20–29 years for age comparisons.

We created decision trees to identify specific groups of individuals who are at risk of experiencing a domestic abuse incident and subsequent outcome. The decision trees were not used to develop a predictive model, they were utilised in the context of descriptive epidemiology to investigate the clustering of risk factors within individuals (ie, everything represented by codes in the code list [appendix 2]). This approach facilitated the identification of the relevant nodes that could be used to classify an individual considering their risk factor clusters. The data handling and preparation were performed in SQL, using Eclipse 2020-03 (version 4.15). Final data preparation was performed in R Studio, version 4.1.3, whereas the decision trees were conducted in IBM SPSS, version 28.0.0.0.

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
The PPN dataset contained 26762 records; of these, 15189 individuals had multiple PPN records. The exclusion of multiple PPN records resulted in a dataset comprising only the index PPN record, generating a cohort of 11573 domestic abuse victims. We also excluded records with a poor matching score (n=344; appendix 1 p 1), duplicates (n=424), missing gender (n=60), and an empty PPN record (n=27). Individuals with 25% or more of missing data were removed (n=2009), resulting in a 3% decrease of male victims, disproportionate to female victims, in the 20–39-year age range.

The resulting cohort comprised 8709 individuals (figure 1), of whom 6257 (71·8%) were female (table 1). The age groups of 20–29 years (30·0%) and 30–39 years (26·4%) contributed the highest proportion of domestic abuse victims; conversely, the age groups 0–9 (0·6%) and 80 years or older (0·7%) contributed the lowest proportion of domestic abuse victims.

3650 (41·9%) individuals had an outcome within a year of a domestic abuse incident; 2661 (72·9%) were female and 989 (27·1%) were male (table 1). 3544 individuals attended an Emergency Department, of whom 1085 individuals were then transferred to hospital. Overall, 1182 had an emergency hospital admission. The age distribution of the outcome cohort indicates that more women than men had an outcome in the age range 20–39 years, which comprises the largest
proportion of domestic abuse victims. The total Emergency Department attendance rate was 572 (95% CI 554–591) per 1000 person-years and the hospitalisation rate was 185 (175–197) per 1000 person-years.

In comparison with the base age group of 20–29 years, those aged 10–19 years had an increased risk of experiencing an outcome (HR 1.183 [95% CI 1.053–1.329], p=0.0048; table 2; appendix 1 pp 1–4). Conversely, individuals aged 30–69 years had a decreased risk of experiencing an outcome (30–39 years: 0.882 [0.808–0.962], p=0.0045; 40–49 years: 0.801 [0.724–0.887], p < 0.0001; 50–59 years: 0.772 [0.681–0.874], p < 0.0001; 60–69 years: 0.728 [0.602–0.879], p < 0.0001).

Cases involving attempted strangulation of the victim were associated with a higher risk of a future outcome (HR 1.311 [95% CI 1.148–1.497]; p < 0.0001) than cases for which attempted strangulation was not present. Furthermore, victims had a higher risk of experiencing an outcome in the year proceeding a domestic abuse incident when the incident resulted in an injury (1.484 [1.368–1.609]; p < 0.0001) than when it did not. Cases involving a pregnant household member had an increased risk of a future non-obstetric outcome (1.372 [1.142–1.648]; p < 0.0007). Incidences where the perpetrator has hurt other people (1.218 [1.028–1.444]; p < 0.023) or has a history of further violence (1.229 [1.134–1.333]; p < 0.0001) resulted in an increased risk of the victim undergoing an outcome. Similarly, households that were subject to a MARAC referral (1.518 [1.358–1.697]; p < 0.0001) or received multiple subsequent police visits after the index PPN (1.383 [1.295–1.476]; p < 0.0001) have an increased risk of experiencing an outcome. Cases assessed as high risk, medium risk, or receiving no response from the responding police officer (high risk: 1.600 [1.444–1.773]; p < 0.0001; medium risk: 1.117 [1.034–1.206]; p < 0.0051; no response: 1.188 [1.075–1.312]; p = 0.0007) were associated with a higher risk of experiencing an outcome than cases assessed as standard risk. Incidents involving conflict over a child had a lower risk of undergoing an outcome (0.856 [0.774–0.947]; p < 0.0026) than those that did not. Furthermore, if a household member has had a child in the 18 months before the domestic abuse incident (past pregnancy), then the risk of an outcome is lowered (0.812 [0.722–0.913]; p < 0.0005).

A decision tree combining knowledge gathered from GP and Emergency Department admissions up to a year before the domestic abuse incident, as well as information obtained by the police during the PPN submission, indicated that any Emergency Department admission before the domestic abuse incident is the most significant risk factor of experiencing an outcome (figure 2). Those with an Emergency Department admission 1 year before the event were further classified with the quantity (PPN count) and severity (MARAC referral) of their interactions with the police. Those who are known to the health-care system and go on to have further contact with the police were the most at risk of having an outcome after the domestic abuse incident.

Individuals with up to one Emergency Department admission and who had subsequent interactions with the police were further split by the prescription of CNS drugs; those who were prescribed these drugs were more likely to experience an outcome. These drugs were mostly prescribed for anxiety, depression, and sleep disorders. Individuals who were not prescribed CNS drugs were split on age; the extreme age groups, 10–19 years and 80 years and older, were classified as being at greater risk of undergoing an outcome after a domestic abuse incident than those in other age groups.

For individuals who had minimal interactions with the health-care and police systems, the question about history of further violence was important as it is asked when there is an injury at the scene. Therefore, in scenarios where this question was asked, the risk of a future outcome was higher than scenarios where this question was not asked and marked as NA (ie, not applicable).
The smoking status of the victim was indicated as an important factor for those for whom NA was the answer to history of further injury; the presence of smoking behaviour related to an increased risk of experiencing an outcome.

Incorporating additional information provided by the health-care system up to 3 years preceding the index PPN submission further indicated that multiple Emergency Department admissions before the domestic abuse incident was significantly associated with experiencing an outcome (figure 3). The individuals who were most at risk of undergoing an outcome after the domestic abuse incident were those who had more than seven Emergency Department admissions in the 3 years before and who received smoking cessation advice from their GP. Individuals who had more than three Emergency Department admissions but less than seven admissions, and have had more than two PPN submissions, are also at high risk; those who were classified as a cigarette smoker by their GP had a greater risk of experiencing an outcome than those who were not. Individuals with less than three Emergency Department admissions were split by future PPN count; overall, those with a PPN count of less than one were at the lowest risk of having an outcome compared with the entire cohort. However, those individuals who were not known to the health-care or police systems but had been prescribed CNS drugs by their GP and who were in the extreme age group categories of 0–29 years and 70–79 years were at risk of undergoing an outcome.

**Discussion**

This study shows how communication between separate services can be utilised to identify points of early intervention for victims of domestic abuse up to 3 years before a potential police PPN submission. The findings demonstrate several risk factors that reflect vulnerability; when the perpetrator exhibited a pre-existing pre-disposition for violence, either in hurting others or with a history of violence, the domestic abuse victims were found to have an increased vulnerability for future outcomes. Furthermore, pregnant victims showed heightened vulnerability and had poorer outcomes; research has indicated that domestic abuse has been independently associated with the birth of a low-birthweight baby.19

<table>
<thead>
<tr>
<th>Age group, years</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–29</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>0–9</td>
<td>1.400 (0.938–2.092)</td>
<td>0.10</td>
</tr>
<tr>
<td>10–19</td>
<td>1.183 (1.053–1.329)</td>
<td>0.0048</td>
</tr>
<tr>
<td>30–39</td>
<td>0.882 (0.808–0.962)</td>
<td>0.0045</td>
</tr>
<tr>
<td>40–49</td>
<td>0.801 (0.724–0.887)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>50–59</td>
<td>0.772 (0.681–0.874)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>60–69</td>
<td>0.728 (0.602–0.879)</td>
<td>0.0010</td>
</tr>
<tr>
<td>70–79</td>
<td>1.087 (0.860–1.374)</td>
<td>0.48</td>
</tr>
<tr>
<td>≥80</td>
<td>1.110 (0.767–1.607)</td>
<td>0.58</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attempted strangulation</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>0.970 (0.602–1.552)</td>
<td>0.90</td>
</tr>
<tr>
<td>Yes</td>
<td>1.311 (1.148–1.497)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conflict over a child</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>1.060 (0.709–1.584)</td>
<td>0.78</td>
</tr>
<tr>
<td>Yes</td>
<td>0.856 (0.774–0.947)</td>
<td>0.0026</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hurt other people</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>0.570 (0.285–1.440)</td>
<td>0.11</td>
</tr>
<tr>
<td>Yes</td>
<td>1.218 (1.028–1.444)</td>
<td>0.023</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>History of further violence</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>0.905 (0.649–1.263)</td>
<td>0.56</td>
</tr>
<tr>
<td>Yes</td>
<td>1.229 (1.134–1.333)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1.071 (0.996–1.152)</td>
<td>0.066</td>
</tr>
</tbody>
</table>

(Continued from previous column)

<table>
<thead>
<tr>
<th>Injury</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>1.143 (0.571–2.288)</td>
<td>0.71</td>
</tr>
<tr>
<td>Yes</td>
<td>1.484 (1.368–1.609)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MARAC referral</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>1.024 (0.956–1.097)</td>
<td>0.51</td>
</tr>
<tr>
<td>Yes</td>
<td>1.518 (1.358–1.697)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Multiple police visits (PPNs)</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.383 (1.295–1.476)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Past pregnancy</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>0.784 (0.516–1.193)</td>
<td>0.26</td>
</tr>
<tr>
<td>Yes</td>
<td>0.812 (0.722–0.913)</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pregnant</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>0.929 (0.514–1.679)</td>
<td>0.81</td>
</tr>
<tr>
<td>Yes</td>
<td>1.372 (1.142–1.648)</td>
<td>0.0007</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk assessment</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Ref</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No response</td>
<td>1.188 (1.075–1.312)</td>
<td>0.0007</td>
</tr>
<tr>
<td>Medium</td>
<td>1.117 (1.034–1.206)</td>
<td>0.0051</td>
</tr>
<tr>
<td>High</td>
<td>1.600 (1.444–1.773)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

MARAC=multi-agency risk assessment conference. PPN=Public Protection Notification.
Additionally, victims were shown to be known to Emergency Departments before the police are involved. Highly vulnerable individuals might interact frequently with Emergency Department health-care services but remain unknown to the police until a domestic abuse incident that requires an intervention; the most vulnerable individuals have been identified as those who had more than seven Emergency Department admissions up to 3 years before the index PPN submission.11

The decision tree analysis highlighted several risk profiles with differing clusters of risk factors that might reflect different pathways through police contact, health care, and individual contexts. Our findings corroborated previous observations that the highest risk group of people experiencing domestic abuse are those well known to Emergency Department health-care services.11

In our decision tree analysis, we found that an additional indicator for high risk was having had interactions with their GP, either for smoking cessation advice or by being identified as a cigarette smoker. This observation is in line with research that indicated that domestic abuse is associated with adverse health behaviours, such as substance abuse and addiction.4,7–11 Smoking could be indicative of an addiction behaviour that might serve as a coping mechanism.24 Furthermore, smoking behaviour has been shown to be more prevalent in individuals from an economically deprived background;21–23 which has been found to be associated with domestic abuse within the household.6

A further set of factors suggested a subset of victims that are at high risk for a major health outcome. These individuals are repeatedly in contact with police after the index PPN submission and before the subsequent outcome event. Both decision trees indicated that those at the highest risk are split by the presence of more than two police visits. Individuals with less than two police visits but with a MARAC referral were also considered to be at high risk. This finding might indicate a progressively worsening home situation. These findings are similar to what has been found in victims of intimate partner violence; a study in the USA observed that Emergency Department use was associated with an increased number of police calls,4 whereas another study in Canada found it was associated with more violent abuse than for those who do not use the Emergency Department.7 These findings indicate that the manifestation of domestic abuse, specifically intimate partner violence in these studies, has shifted from a situation of coercive control to physical violence.
In contrast another group comprised individuals who were less often in contact with Emergency Department health-care services. This group consists of people who have had more than one police visit after the domestic abuse incident, with less than three Emergency Department admissions up to 3 years before, or less than one Emergency Department admission up to 1 year before the domestic abuse incident. Obstetric codes recorded by the victim’s GP up to 3 years before were indicative of those at highest risk within this group: mothers with young children. Several studies have observed that victims of intimate partner violence, which is included in the definition of domestic abuse by the DASH questionnaire, are more likely to be in their childbearing years; those who suffer abuse during pregnancy reported that it worsened throughout the duration, whereas for some who previously suffered abuse, they indicated that it was a protective period. Research has indicated that having a child can increase economic pressures; economic hardship increases stress on relationships, which has been shown to escalate the incidence of abuse. The survival analysis also highlighted that victims who are pregnant at the time of PPN submission were more likely to have an outcome in the following year. Conversely, cases characterised by conflict over child contact had a decreased risk of experiencing a future outcome, which might be interpreted that a co-parent and potential perpetrator no longer cohabits within the same household, which could decrease exposure to abusive behaviour.

Finally, we identified a group that was relatively unknown to both Emergency Department health-care services and police, but who nonetheless could be considered vulnerable individuals from the presence of GP codes. Those who had less than one police visit after the PPN submission were more likely to experience an outcome if they have been prescribed CNS drugs and were in the extreme age groups of 0–29 years or 70–79 years, compared with those who have not been prescribed these drugs or who are in different age groups. Furthermore, victims who were questioned by the police about the perpetrator’s violent tendencies at the incident and were prescribed both CNS drugs and drugs used in infections are more likely to experience the outcome compared to those who are not prescribed such drugs. These codes could suggest a stressful home environment, which is associated with adverse mental health symptoms. The presence of infection codes might indicate that these people have injuries or poor living conditions.

Our findings suggest that people who are attended to by the police for cases of abuse in the household have previously been in contact with various service providers, including GPs and Emergency Department health care. The linking of data from different organisations might enhance the efficiency and effectiveness of these
organisations’ response systems. By using anonymised data sharing and linkage across multiple agencies we could identify warning signs, such as frequent visits to an Emergency Department. It could also help refine the DASH questionnaire adding additional risk factors that have been identified from linked data research, such as questions regarding previous Emergency Department admissions and the prescription of antidepressants or antibiotics from their GP. The use of an anonymised linkage system with a trusted third party enables research and system learning while preserving confidentiality and anonymity of the individuals. However, the implementation of cross-organisational data linkage at the national level for long-term purposes beyond research to identify individuals requires consultation with the public and consensus on the appropriate data types, linkage objectives, and purpose for linkage. Consensus is necessary to ensure that data sharing between organisations does not prevent individuals seeking help from Emergency Departments or similar services due to fear of being identified by the police, as such awareness has potential to deter help-seeking behaviours. The results of this study underscore the importance of providing training for Emergency Department personnel to recognise and address potential cases of abuse.

There are several limitations to this study. The PPN dataset comprises records spanning 2015–20 as PPN records were not available before 2015. Consequently, left-censoring arose in this study. In addition, the inclusion criteria required that the victim first has a PPN submission before experiencing a domestic abuse-related outcome. As such, those individuals who are experiencing domestic abuse without engaging with the police are excluded from this analysis. Furthermore, the index PPN submission within this study might not be the actual first PPN submission; thus, the actual time to event might be different to the calculated time to event between the index PPN and the outcome event. Moreover, this study is predominantly descriptive; therefore factors identified cannot be used to establish cause and effect and residual confounding might operate. Finally, restricting the analysis to non-obstetric Emergency Department admissions for women might have resulted in an underestimation of the influence of household abuse in pregnancy. Notably, some events, such as pre-term delivery, which could be triggered by abuse, would have been excluded.

Highly vulnerable individuals frequently interact with health-care services but remain unknown to the police before an incident that requires an intervention. This finding underscores the potential value of linking data across different agencies to facilitate targeted prevention measures instead of reactive ones. Moreover, identifying individuals at high risk following a police interaction could enable the establishment of protective measures. The data generated by this study have the potential to identify risk without relying on disclosure, forming a foundation for enhanced integration. Further research is needed to validate these findings and examine whether early identification of these groups by the police or in the health-care setting could lead to improved outcomes, in addition to examining the outcomes stratified by demographic profiles.

**Contributors**

MAB, AJ, KHa, SM, and SB conceptualised the study. AB and SM designed the study. SB secured funding, contributed to the methodology, and undertook the role of project principal investigator. NK, TLW, and CM collected the data, with NK and TLW responsible for verifying the underlying data. NK, TLW, AB, and JK undertook the data analysis. NK, JK, and SB interpreted the data. NK and JK generated the figures. NK drafted the report. BR, CM, JE, KHu, MAB, AJ, SM, and SB all undertook project supervisory and advisory roles for their specialties. KHa acted as a patient and public involvement advisor. All authors contributed to revisions, approved the final version, and were responsible for the decision to submit the manuscript for publication.

**Declaration of interests**

We declare no competing interests.

**Data sharing**

The data that support the findings of this study are available from the Secure Anonymised Information Linkage (SAIL) databank, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. Interested individuals can apply to the SAIL databank for access, and once approved, can apply to the corresponding author.

**Acknowledgments**

This research was funded by the National Institute for Health Research, Public Health Research Board (reference number NIHR133680: Unlocking Data to Inform Public Health Policy and Practice). The study was also supported by Health Care Research Wales through the National Centre for Population Health and Wellbeing Research, supported by ESRC through Administrative Data Research Wales, and received infrastructure support through Health Data Research UK. This study makes use of anonymised data held in the SAIL databank. We would like to acknowledge all the data providers who made anonymised data available for research.

**References**

Supplementary appendix 1

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Appendix

Appendix A. Dataset date span diagram.

Appendix B. Poor Matching Scores.

A reliable intermediary assigns a unique anonymous identifier, known as an ALF, to each individual in a received dataset following a rigorous matching process. The matching algorithm was collaboratively designed and assessed by the trustworthy third party and SAIL. The algorithm compares numerous personal identifiers between the received dataset and the Welsh Demographic Service dataset. It starts with NHS numbers and then moves on to first name, surname, date of birth, and postcode. The algorithm’s development ensures a high matching accuracy, with specific thresholds for match accuracy reported to SAIL within the anonymised dataset. A poor matching score indicates incomplete or inaccurate personal information provided by an individual or a lack of registration on the NHS database.

Appendix C. Survival plot of those experiencing an outcome after the PPN visit.
Appendix D. Survival plots split by different factors from the DASH Report.

App D.a Time to outcome after a PPN by age.

App D.b Time to outcome after a PPN by incidence of attempted strangulation.

App D.c Time to outcome after a PPN by incidence of conflict over a child.

App D.d Time to outcome after a PPN by incidence of hurting other people.

App D.e Time to outcome after a PPN by incidence of history of further violence.

App D.f Time to outcome after a PPN by incidence of injury.
App D.g Time to outcome after a PPN by incidence of MARAC referral.

App D.h Time to outcome after a PPN by incidence of multiple police visits (PPNs).

App D.i Time to outcome after a PPN by incidence of past pregnancies within the household.

App D.j Time to outcome after a PPN by incidence of whether a member of the household is pregnant.

App D.k Time to outcome after a PPN by incidence of assessed risk.
Appendix E. Percentage drop of the population at 0 days, indicating the amount of PPN’s which resulted in an attendance.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Outcome</th>
<th>Percentage attending ED on day of PPN (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival</td>
<td></td>
<td>6.96</td>
</tr>
<tr>
<td>Age Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-9</td>
<td></td>
<td>&lt; 20.00</td>
</tr>
<tr>
<td>10-19</td>
<td></td>
<td>8.08</td>
</tr>
<tr>
<td>20-29</td>
<td></td>
<td>6.50</td>
</tr>
<tr>
<td>30-39</td>
<td></td>
<td>7.00</td>
</tr>
<tr>
<td>40-49</td>
<td></td>
<td>6.92</td>
</tr>
<tr>
<td>50-59</td>
<td></td>
<td>7.34</td>
</tr>
<tr>
<td>60-69</td>
<td></td>
<td>7.44</td>
</tr>
<tr>
<td>70-79</td>
<td></td>
<td>&lt; 6.58</td>
</tr>
<tr>
<td>80+</td>
<td></td>
<td>&lt; 17.24</td>
</tr>
<tr>
<td>Attempted Strangulation</td>
<td>NR</td>
<td>&lt; 29.41</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>6.32</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>15.88</td>
</tr>
<tr>
<td>Conflict over a Child</td>
<td>NR</td>
<td>&lt; 20.83</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>7.47</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>3.04</td>
</tr>
<tr>
<td>Hurt Other People</td>
<td>NR</td>
<td>&lt; 62.5</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>7.13</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>&lt; 3.62</td>
</tr>
<tr>
<td>History of Further Violence</td>
<td>NR</td>
<td>0.00</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>4.95</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>15.03</td>
</tr>
<tr>
<td>Gender</td>
<td>M</td>
<td>6.77</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>7.03</td>
</tr>
<tr>
<td>Injury</td>
<td>N</td>
<td>2.09</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>26.58</td>
</tr>
<tr>
<td>MARAC Referral</td>
<td>NR</td>
<td>5.74</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>4.19</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>25.27</td>
</tr>
<tr>
<td>Multiple Police Visits (PPNs)</td>
<td>N</td>
<td>7.08</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>6.81</td>
</tr>
<tr>
<td>Past Pregnancy</td>
<td>NR</td>
<td>&lt; 19.23</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>6.91</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>7.12</td>
</tr>
<tr>
<td>Pregnant</td>
<td>NR</td>
<td>&lt; 45.45</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>6.73</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>12.71</td>
</tr>
<tr>
<td>Risk Assessment</td>
<td>NR</td>
<td>7.23</td>
</tr>
<tr>
<td></td>
<td>Standard</td>
<td>2.47</td>
</tr>
<tr>
<td></td>
<td>Medium</td>
<td>6.70</td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>22.25</td>
</tr>
</tbody>
</table>

*Percentages have been censored to <5 individuals when the real value has been considered disclosive.
<table>
<thead>
<tr>
<th>LOCATION</th>
<th>CODE</th>
<th>DESC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDW</td>
<td>A</td>
<td>Cholera</td>
</tr>
<tr>
<td>PEDW</td>
<td>B</td>
<td>Herpesviral [herpes simplex] infections</td>
</tr>
<tr>
<td>PEDW</td>
<td>C</td>
<td>Malignant neoplasm of lip</td>
</tr>
<tr>
<td>PEDW</td>
<td>D</td>
<td>Carcinoma in situ of oral cavity, oesophagus and stomach</td>
</tr>
<tr>
<td>PEDW</td>
<td>E</td>
<td>Congenital iodine-deficiency syndrome</td>
</tr>
<tr>
<td>PEDW</td>
<td>F</td>
<td>Dementia in Alzheimer’s disease</td>
</tr>
<tr>
<td>PEDW</td>
<td>G</td>
<td>Bacterial meningitis, not elsewhere classified</td>
</tr>
<tr>
<td>PEDW</td>
<td>H</td>
<td>Hordeolum and chalazion</td>
</tr>
<tr>
<td>PEDW</td>
<td>I</td>
<td>Rheumatic fever without mention of heart involvement</td>
</tr>
<tr>
<td>PEDW</td>
<td>J</td>
<td>Acute nasopharyngitis [common cold]</td>
</tr>
<tr>
<td>PEDW</td>
<td>K</td>
<td>Disorders of tooth development and eruption</td>
</tr>
<tr>
<td>PEDW</td>
<td>L</td>
<td>Staphylococcal scalded skin syndrome</td>
</tr>
<tr>
<td>PEDW</td>
<td>M</td>
<td>Pyogenic arthritis</td>
</tr>
<tr>
<td>PEDW</td>
<td>N</td>
<td>Acute nephritic syndrome</td>
</tr>
<tr>
<td>PEDW</td>
<td>O</td>
<td>Ectopic pregnancy</td>
</tr>
<tr>
<td>PEDW</td>
<td>Q</td>
<td>Anencephaly and similar malformations</td>
</tr>
<tr>
<td>PEDW</td>
<td>R</td>
<td>Abnormalities of heart beat</td>
</tr>
<tr>
<td>PEDW</td>
<td>S</td>
<td>Superficial injury of head</td>
</tr>
<tr>
<td>PEDW</td>
<td>T</td>
<td>Superficial injuries involving multiple body regions</td>
</tr>
<tr>
<td>PEDW</td>
<td>V</td>
<td>Pedestrian injured in collision with pedal cycle</td>
</tr>
<tr>
<td>PEDW</td>
<td>W</td>
<td>Fall on same level involving ice and snow</td>
</tr>
<tr>
<td>PEDW</td>
<td>X</td>
<td>Exposure to uncontrolled fire in building or structure</td>
</tr>
<tr>
<td>PEDW</td>
<td>Y</td>
<td>Assault by blunt object</td>
</tr>
<tr>
<td>PEDW</td>
<td>Z</td>
<td>General examination and investigation of persons without complaint and reported diagnosis</td>
</tr>
<tr>
<td>PEDW</td>
<td>A0</td>
<td>Cholera</td>
</tr>
<tr>
<td>PEDW</td>
<td>B3</td>
<td>Viral conjunctivitis</td>
</tr>
<tr>
<td>PEDW</td>
<td>B9</td>
<td>Sequelae of tuberculosis</td>
</tr>
<tr>
<td>PEDW</td>
<td>D2</td>
<td>Benign neoplasm of soft tissue of retroperitoneum and peritoneum</td>
</tr>
<tr>
<td>PEDW</td>
<td>D6</td>
<td>Acquired pure red cell aplasia [erythroblastopenia]</td>
</tr>
<tr>
<td>PEDW</td>
<td>E0</td>
<td>Congenital iodine-deficiency syndrome</td>
</tr>
<tr>
<td>PEDW</td>
<td>E1</td>
<td>Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>PEDW</td>
<td>E7</td>
<td>Disorders of aromatic amino-acid metabolism</td>
</tr>
</tbody>
</table>
Mental and behavioural disorders due to use of alcohol

Manic episode

Phobic anxiety disorders

Epilepsy

Disorders of trigeminal nerve

Other strabismus

Otitis externa

Essential (primary) hypertension

Angina pectoris

Acute myocarditis

Phlebitis and thrombophlebitis

Acute nasopharyngitis [common cold]

Influenza due to other identified influenza virus

Acute bronchitis

Vasomotor and allergic rhinitis

Bronchitis, not specified as acute or chronic

Disorders of tooth development and eruption

Oesophagitis

Functional dyspepsia

Inguinal hernia

Crohn disease [regional enteritis]

Fissure and fistula of anal and rectal regions

Cholelithiasis

Intestinal malabsorption

Staphylococcal scalded skin syndrome

Gout

Acquired deformities of fingers and toes

Cervical disc disorders

Soft tissue disorders related to use, overuse and pressure

Osteoporosis with pathological fracture

Acute tubulo-interstitial nephritis

Cystitis

Salpingitis and oophoritis
<p>| PEDW   | N8       | Endometriosis                                      |
| PEDW   | N9       | Other noninflammatory disorders of vulva and perineum |
| PEDW   | O0       | Ectopic pregnancy                                 |
| PEDW   | O1       | Pre-existing hypertension complicating pregnancy, childbirth and the puerperium |
| PEDW   | O2       | Haemorrhage in early pregnancy                    |
| PEDW   | O3       | Multiple gestation                                |
| PEDW   | O4       | Polyhydramnios                                    |
| PEDW   | O6       | Preterm labour and delivery                       |
| PEDW   | O7       | Perineal laceration during delivery                |
| PEDW   | O8       | Single spontaneous delivery                       |
| PEDW   | O9       | Complications of the puerperium, not elsewhere classified |
| PEDW   | R0       | Abnormalities of heart beat                       |
| PEDW   | R1       | Abdominal and pelvic pain                         |
| PEDW   | R2       | Disturbances of skin sensation                    |
| PEDW   | R3       | Pain associated with micturition                  |
| PEDW   | R4       | Somnolence, stupor and coma                       |
| PEDW   | R5       | Fever of unknown origin                           |
| PEDW   | R6       | Oedema, not elsewhere classified                  |
| PEDW   | S0       | Superficial injury of head                        |
| PEDW   | S5       | Superficial injury of forearm                     |
| PEDW   | S6       | Superficial injury of wrist and hand              |
| PEDW   | S8       | Superficial injury of lower leg                   |
| PEDW   | T3       | Burn and corrosion, body region unspecified       |
| PEDW   | T4       | Poisoning by narcotics and psychodysleptics [hallucinogens] |
| PEDW   | T5       | Poisoning by diuretics and other and unspecified drugs, medicaments and biological substances |
| PEDW   | T8       | Complications following infusion, transfusion and therapeutic injection |
| PEDW   | W0       | Fall on same level involving ice and snow         |
| PEDW   | W1       | Fall on and from stairs and steps                 |
| PEDW   | W2       | Struck by thrown, projected or falling object     |
| PEDW   | X4       | Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics |
| PEDW   | X5       | Overexertion and strenuous or repetitive movements |</p>
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>X6</td>
<td>Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics</td>
</tr>
<tr>
<td>Y0</td>
<td>Assault by blunt object</td>
</tr>
<tr>
<td>Y8</td>
<td>Physical medicine devices associated with adverse incidents</td>
</tr>
<tr>
<td>Z0</td>
<td>General examination and investigation of persons without complaint and reported diagnosis</td>
</tr>
<tr>
<td>Z3</td>
<td>Contraceptive management</td>
</tr>
<tr>
<td>Z4</td>
<td>Prophylactic surgery</td>
</tr>
<tr>
<td>Z5</td>
<td>Care involving use of rehabilitation procedures</td>
</tr>
<tr>
<td>Z7</td>
<td>Counselling related to sexual attitude, behaviour and orientation</td>
</tr>
<tr>
<td>Z8</td>
<td>Family history of malignant neoplasm</td>
</tr>
<tr>
<td>Z9</td>
<td>Acquired absence of organs, not elsewhere classified</td>
</tr>
<tr>
<td>B34</td>
<td>Viral infection of unspecified site</td>
</tr>
<tr>
<td>B95</td>
<td>Streptococcus and staphylococcus as the cause of diseases classified to other chapters</td>
</tr>
<tr>
<td>B96</td>
<td>Other bacterial agents as the cause of diseases classified to other chapters</td>
</tr>
<tr>
<td>D64</td>
<td>Other anaemias</td>
</tr>
<tr>
<td>E11</td>
<td>Non-insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td>E78</td>
<td>Disorders of lipoprotein metabolism and other lipidaemias</td>
</tr>
<tr>
<td>F10</td>
<td>Mental and behavioural disorders due to use of alcohol</td>
</tr>
<tr>
<td>F17</td>
<td>Mental and behavioural disorders due to use of tobacco</td>
</tr>
<tr>
<td>F32</td>
<td>Depressive episode</td>
</tr>
<tr>
<td>F41</td>
<td>Other anxiety disorders</td>
</tr>
<tr>
<td>G40</td>
<td>Epilepsy</td>
</tr>
<tr>
<td>I10</td>
<td>Essential (primary) hypertension</td>
</tr>
<tr>
<td>I25</td>
<td>Chronic ischaemic heart disease</td>
</tr>
<tr>
<td>I84</td>
<td>Haemorrhoids</td>
</tr>
<tr>
<td>J03</td>
<td>Acute tonsillitis</td>
</tr>
<tr>
<td>J06</td>
<td>Acute upper respiratory infections of multiple and unspecified sites</td>
</tr>
<tr>
<td>J18</td>
<td>Pneumonia, organism unspecified</td>
</tr>
<tr>
<td>J22</td>
<td>Unspecified acute lower respiratory infection</td>
</tr>
<tr>
<td>J44</td>
<td>Other chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>J45</td>
<td>Asthma</td>
</tr>
<tr>
<td>K02</td>
<td>Dental caries</td>
</tr>
<tr>
<td>PEDW</td>
<td>K21</td>
</tr>
<tr>
<td>PEDW</td>
<td>K29</td>
</tr>
<tr>
<td>PEDW</td>
<td>K44</td>
</tr>
<tr>
<td>PEDW</td>
<td>K52</td>
</tr>
<tr>
<td>PEDW</td>
<td>K59</td>
</tr>
<tr>
<td>PEDW</td>
<td>K62</td>
</tr>
<tr>
<td>PEDW</td>
<td>K80</td>
</tr>
<tr>
<td>PEDW</td>
<td>K92</td>
</tr>
<tr>
<td>PEDW</td>
<td>M25</td>
</tr>
<tr>
<td>PEDW</td>
<td>M54</td>
</tr>
<tr>
<td>PEDW</td>
<td>M79</td>
</tr>
<tr>
<td>PEDW</td>
<td>N39</td>
</tr>
<tr>
<td>PEDW</td>
<td>N73</td>
</tr>
<tr>
<td>PEDW</td>
<td>N83</td>
</tr>
<tr>
<td>PEDW</td>
<td>N92</td>
</tr>
<tr>
<td>PEDW</td>
<td>N93</td>
</tr>
<tr>
<td>PEDW</td>
<td>O02</td>
</tr>
<tr>
<td>PEDW</td>
<td>O20</td>
</tr>
<tr>
<td>PEDW</td>
<td>O21</td>
</tr>
<tr>
<td>PEDW</td>
<td>O23</td>
</tr>
<tr>
<td>PEDW</td>
<td>O26</td>
</tr>
<tr>
<td>PEDW</td>
<td>O32</td>
</tr>
<tr>
<td>PEDW</td>
<td>O34</td>
</tr>
<tr>
<td>PEDW</td>
<td>O36</td>
</tr>
<tr>
<td>PEDW</td>
<td>O42</td>
</tr>
<tr>
<td>PEDW</td>
<td>O46</td>
</tr>
<tr>
<td>PEDW</td>
<td>O47</td>
</tr>
<tr>
<td>PEDW</td>
<td>O48</td>
</tr>
<tr>
<td>PEDW</td>
<td>O60</td>
</tr>
<tr>
<td>PEDW</td>
<td>O63</td>
</tr>
<tr>
<td>PEDW</td>
<td>O68</td>
</tr>
<tr>
<td>PEDW</td>
<td>O70</td>
</tr>
<tr>
<td>PEDW</td>
<td>O72</td>
</tr>
</tbody>
</table>
PEDW O75 Other complications of labour and delivery, not elsewhere classified
PEDW O80 Single spontaneous delivery
PEDW O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium
PEDW R00 Abnormalities of heart beat
PEDW R06 Abnormalities of breathing
PEDW R07 Pain in throat and chest
PEDW R10 Abdominal and pelvic pain
PEDW R11 Nausea and vomiting
PEDW R31 Unspecified haematuria
PEDW R51 Headache
PEDW R55 Syncope and collapse
PEDW R56 Convulsions, not elsewhere classified
PEDW S02 Fracture of skull and facial bones
PEDW S09 Other and unspecified injuries of head
PEDW S52 Fracture of forearm
PEDW S61 Open wound of wrist and hand
PEDW S82 Fracture of lower leg, including ankle
PEDW T39 Poisoning by nonopioid analgesics, antipyretics and antirheumatics
PEDW T40 Poisoning by narcotics and psychodysleptics [hallucinogens]
PEDW T42 Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs
PEDW T43 Poisoning by psychotropic drugs, not elsewhere classified
PEDW T51 Toxic effect of alcohol
PEDW T81 Complications of procedures, not elsewhere classified
PEDW W19 Unspecified fall
PEDW X40 Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW X41 Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified
PEDW X60 Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics
PEDW X61 Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified
Intentional self-poisoning by and exposure to alcohol
Assault by bodily force

Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or
of later complication, without mention of misadventure at the time of the procedure
Medical observation and evaluation for suspected diseases and conditions
Contraceptive management
Pregnant state, incidental
Supervision of normal pregnancy
Outcome of delivery
Other medical care
Persons encountering health services for specific procedures, not carried out
Problems related to lifestyle
Personal history of certain other diseases
Personal history of other diseases and conditions
Personal history of allergy to drugs, medicaments and biological substances
Personal history of risk-factors, not elsewhere classified
Personal history of medical treatment
Viral infection, unspecified
Escherichia coli [E. coli] as the cause of diseases classified to other chapters
Type 2 diabetes mellitus
Pure hypercholesterolaemia
Mental and behavioural disorders due to use of alcohol
Mental and behavioural disorders due to use of alcohol
Mental and behavioural disorders due to use of tobacco
Depressive episode, unspecified
Anxiety disorder, unspecified
Essential (primary) hypertension
Acute tonsillitis, unspecified
Acute upper respiratory infection, unspecified
Unspecified acute lower respiratory infection
Asthma, unspecified
Dental caries, unspecified
Gastro-oesophageal reflux disease without oesophagitis
Gastritis, unspecified
Diaphragmatic hernia without obstruction or gangrene
Noninfective gastroenteritis and colitis, unspecified
Constipation
Dorsalgia, unspecified
Pain in limb
Urinary tract infection, site not specified
Other and unspecified ovarian cysts
Excessive and frequent menstruation with regular cycle
Abnormal uterine and vaginal bleeding, unspecified
Missed abortion
Haemorrhage in early pregnancy, unspecified
Unspecified infection of urinary tract in pregnancy
Other specified pregnancy-related conditions
Maternal care due to uterine scar from previous surgery
Maternal care for poor fetal growth
Maternal care for other specified fetal problems
Premature rupture of membranes, unspecified
Antepartum haemorrhage, unspecified
False labour before 37 completed weeks of gestation
False labour at or after 37 completed weeks of gestation
Prolonged pregnancy
Preterm delivery
Prolonged second stage (of labour)
Labour and delivery complicated by fetal heart rate anomaly
Labour and delivery complicated by fetal stress, unspecified
First degree perineal laceration during delivery
Second degree perineal laceration during delivery
Perineal laceration during delivery, unspecified
Spontaneous vertex delivery
Other chest pain
Chest pain, unspecified
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>R101</td>
<td>Pain localized to upper abdomen</td>
</tr>
<tr>
<td>R102</td>
<td>Pelvic and perineal pain</td>
</tr>
<tr>
<td>R103</td>
<td>Pain localized to other parts of lower abdomen</td>
</tr>
<tr>
<td>R104</td>
<td>Other and unspecified abdominal pain</td>
</tr>
<tr>
<td>R11X</td>
<td>Nausea and vomiting</td>
</tr>
<tr>
<td>R31X</td>
<td>Unspecified haematuria</td>
</tr>
<tr>
<td>R51X</td>
<td>Headache</td>
</tr>
<tr>
<td>R55X</td>
<td>Syncope and collapse</td>
</tr>
<tr>
<td>S099</td>
<td>Unspecified injury of head</td>
</tr>
<tr>
<td>T391</td>
<td>Poisoning: 4-Aminophenol derivatives</td>
</tr>
<tr>
<td>T424</td>
<td>Poisoning: Benzodiazepines</td>
</tr>
<tr>
<td>T432</td>
<td>Poisoning: Other and unspecified antidepressants</td>
</tr>
<tr>
<td>T510</td>
<td>Toxic effect: Ethanol</td>
</tr>
<tr>
<td>X409</td>
<td>Accidental poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics</td>
</tr>
<tr>
<td>X419</td>
<td>Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>X600</td>
<td>Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics</td>
</tr>
<tr>
<td>X609</td>
<td>Intentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics</td>
</tr>
<tr>
<td>X619</td>
<td>Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified</td>
</tr>
<tr>
<td>Z301</td>
<td>Insertion of (intrauterine) contraceptive device</td>
</tr>
<tr>
<td>Z302</td>
<td>Sterilization</td>
</tr>
<tr>
<td>Z33X</td>
<td>Pregnant state, incidental</td>
</tr>
<tr>
<td>Z349</td>
<td>Supervision of normal pregnancy, unspecified</td>
</tr>
<tr>
<td>Z370</td>
<td>Single live birth</td>
</tr>
<tr>
<td>Z512</td>
<td>Other chemotherapy</td>
</tr>
<tr>
<td>Z538</td>
<td>Procedure not carried out for other reasons</td>
</tr>
<tr>
<td>Z720</td>
<td>Tobacco use</td>
</tr>
<tr>
<td>Z864</td>
<td>Personal history of psychoactive substance abuse</td>
</tr>
<tr>
<td>Z867</td>
<td>Personal history of diseases of the circulatory system</td>
</tr>
</tbody>
</table>
Personal history of allergy to penicillin

Personal history of self-harm

Occupations

Examination / Signs

Diagnostic procedures

Laboratory procedures

Radiology/physics in medicine

Preventive procedures

Operations, procedures, sites

Other therapeutic procedures

GASTRO-INTESTINAL DRUGS

Infectious and parasitic diseases

CARDIOVASCULAR DRUGS

Neoplasms

Endocrine, nutritional, metabolic and immunity disorders

RESPIRATORY DRUGS

CENTRAL NERVOUS SYSTEM DRUGS

Diseases of blood and blood-forming organs

DRUGS USED IN INFECTIONS

Mental disorders

ENDOCRINE DRUGS

Nervous system and sense organ diseases

Circulatory system diseases

OBS/GYNAE/UTI DRUGS

CHEMOTHERAPY/IMMUNOSUPPRESSANT DRUGS

Respiratory system diseases

HAEMATOLOGY/DIETETIC DRUGS

Digestive system diseases

MUSCULOSKELETAL DRUGS

EYE DRUGS

Genitourinary system diseases

Complications of pregnancy, childbirth and the puerperium

ENT DRUGS
<table>
<thead>
<tr>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Obstetric examination</td>
</tr>
<tr>
<td>29</td>
<td>Motor/sensory systems exam.</td>
</tr>
<tr>
<td>31</td>
<td>Special diagnostic procedures</td>
</tr>
<tr>
<td>32</td>
<td>Electrocardiography</td>
</tr>
<tr>
<td>33</td>
<td>Physiological function tests</td>
</tr>
<tr>
<td>36</td>
<td>Endoscopy / administration</td>
</tr>
<tr>
<td>38</td>
<td>Misc. diagnostic procedures</td>
</tr>
<tr>
<td>41</td>
<td>Laboratory procedures - general</td>
</tr>
<tr>
<td>42</td>
<td>Haematology</td>
</tr>
<tr>
<td>43</td>
<td>Immunology</td>
</tr>
<tr>
<td>44</td>
<td>Blood chemistry</td>
</tr>
<tr>
<td>45</td>
<td>Chemical function tests</td>
</tr>
<tr>
<td>46</td>
<td>Urine examination</td>
</tr>
<tr>
<td>47</td>
<td>Examination of faeces</td>
</tr>
<tr>
<td>51</td>
<td>Radiology/physics - general</td>
</tr>
<tr>
<td>52</td>
<td>Plain radiography</td>
</tr>
<tr>
<td>53</td>
<td>Soft tissue imaging - plain</td>
</tr>
<tr>
<td>54</td>
<td>Contrast radiography excl.CVS</td>
</tr>
<tr>
<td>56</td>
<td>Other X-ray diagn. procedures</td>
</tr>
<tr>
<td>61</td>
<td>Contraception</td>
</tr>
<tr>
<td>62</td>
<td>Patient pregnant</td>
</tr>
<tr>
<td>63</td>
<td>Birth details</td>
</tr>
<tr>
<td>64</td>
<td>Child health care</td>
</tr>
<tr>
<td>65</td>
<td>Infectious dis:prevent/control</td>
</tr>
<tr>
<td>66</td>
<td>Chronic disease monitoring</td>
</tr>
<tr>
<td>67</td>
<td>Counselling/health education</td>
</tr>
<tr>
<td>68</td>
<td>Screening</td>
</tr>
<tr>
<td>69</td>
<td>Special examinations</td>
</tr>
<tr>
<td>70</td>
<td>Nervous system operations</td>
</tr>
<tr>
<td>72</td>
<td>Eye operations</td>
</tr>
<tr>
<td>73</td>
<td>Ear operations</td>
</tr>
<tr>
<td>74</td>
<td>Respiratory tract operations</td>
</tr>
<tr>
<td>75</td>
<td>Mouth operations</td>
</tr>
</tbody>
</table>
Upper digestive tract operations
Lower digestive tract operations
Other abdominal organ operations
Removal of unwanted material
Other mechanical procedures
Respiratory procedures
Pre/post-operative procedures
Genitourinary symptoms
Nervous system symptoms
Ear/nose/throat symptoms
General symptom description
Dietary history
Suspected condition
Pain
Behaviours and observations relating to behaviour
History of substance misuse
Central nervous system exam.
Haemopoietic system exam.
Ear, nose + throat examination
Examination of fever
Examination of skin
Examination of the extremities
Orthopaedic examination
General sign qualifications
General clinical states
Miscellaneous samples
Microbiology
General pathology
Generic biochemistry levels
Patient reviewed
Urinary operations
Male genital organ operations
Lower female genital tract operations
Upper female genital tract operations
Obstetric operations
Skin operations
Soft tissue operations
Other bone and joint operations
Miscellaneous operations
Subsidiary classification of methods of operation
Subsidiary classification of laterality and operation sites
Diagnostic imaging, testing and rehabilitation
Monitoring of patient
Other therapy
Other care
Physiotherapy/remedial therapy
Psychotherapy/sociotherapy
Referral for further care
Procedure not carried out
Patient requested procedure
Removal of surgical material and sutures
Mental health administration
Intestinal infectious diseases
COMPOUND ANTACIDS
Other bacterial diseases
ANTISPASMODICS/GASTRO-INTESTIN TRACT MOTILITY ALTERING DRUGS
Viral diseases with exanthem
ULCER-HEALING DRUGS
Other viral and chlamydial diseases
ANTIDIARRHOEAL-MOTILITY REDUCTION
BULK FORMING DRUGS [GASTRO-INTESTINAL USE]
Mycoses
Helminthiases
STIMULANT LAXATIVES
Other infectious and parasitic diseases
OSMOTIC LAXATIVES
RECTALLY GIVEN LAXATIVES
RECTAL SOOTHING AGENTS
RECTAL COMPOUNDS WITH STEROIDS
PERIPHERALLY ACTING ANTI OBESITY DRUGS
THIAZIDE DIURETICS
LOOP DIURETICS
Benign neoplasms
[M] Morphology of neoplasms
BETA-ADRENOCEPTOR BLOCKERS
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
VASODILATORS USED IN ANGINA PECTORIS
ANTIPLATELET DRUGS
ANTIFIBRINOLYTICS/HAEMOSTATICS
LIPID-LOWERING DRUGS
Disorders of thyroid gland
Other endocrine gland diseases
SELECTIVE BETA-ADRENOCEPTOR STIMULANT
ANTICHOLINERGIC BRONCHODILATORS
Other metabolic and immunity disorders
CORTICOSTEROIDS [RESPIRATORY USE]
ANTI HISTAMINES
COUGH SUPPRESSANTS
EXpectorants/COUGH COMPOUNDS
SYSTEMIC NASAL DECONGESTANTS
Deficiency anaemias
HYPNOTICS
ANXIOLYTICS
OTHER ANTIDEPRESSANT DRUGS
NAUSEA AND VERTIGO DRUGS
NON-NARCOTIC ANALGESICS
NARCOTIC ANALGESICS
<table>
<thead>
<tr>
<th>Section</th>
<th>Code</th>
<th>Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Migraine Treatment</td>
<td>dl</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis of Migraine</td>
<td>dm</td>
<td></td>
</tr>
<tr>
<td>Control of Epilepsy</td>
<td>dn</td>
<td></td>
</tr>
<tr>
<td>Alcohol/Drug Dependency Drugs</td>
<td>du</td>
<td></td>
</tr>
<tr>
<td>Non-organic Psychoses</td>
<td>E1</td>
<td>Non-organic psychoses</td>
</tr>
<tr>
<td>Penicillinase Sensitive Penicillins</td>
<td>e1</td>
<td>PENICILLINASE SENS PENICILLINS</td>
</tr>
<tr>
<td>Neurotic, Personality and Other Nonpsychotic Disorders</td>
<td>E2</td>
<td>Neurotic, personality and other nonpsychotic disorders</td>
</tr>
<tr>
<td>Penicillinase-Resistant Penicillins</td>
<td>e2</td>
<td>PENICILLINASE-RESISTANT PENICILLINS</td>
</tr>
<tr>
<td>Broad Spectrum Penicillins</td>
<td>e3</td>
<td>BROAD SPECTRUM PENICILLINS</td>
</tr>
<tr>
<td>Cephalosporins &amp; Cephamycins</td>
<td>e6</td>
<td>CEPHALOSPORINS &amp; CEPHAMYCINS</td>
</tr>
<tr>
<td>Tetracyclines [Systemic]</td>
<td>e7</td>
<td>TETRACYCLINES [SYSTEMIC]</td>
</tr>
<tr>
<td>Macrolides</td>
<td>e9</td>
<td>MACROLIDES</td>
</tr>
<tr>
<td>Penicillinase Sensitive Penicillins</td>
<td>ec</td>
<td></td>
</tr>
<tr>
<td>Penicillinase-Resistant Penicillins</td>
<td>ef</td>
<td></td>
</tr>
<tr>
<td>Broad Spectrum Penicillins</td>
<td>eg</td>
<td></td>
</tr>
<tr>
<td>Cephalosporins &amp; Cephamycins</td>
<td>eh</td>
<td></td>
</tr>
<tr>
<td>Tetracyclines [Systemic]</td>
<td>ei</td>
<td></td>
</tr>
<tr>
<td>Macrolides</td>
<td>EM</td>
<td></td>
</tr>
<tr>
<td>Sulphonamides &amp; Trimethoprim</td>
<td>eq</td>
<td></td>
</tr>
<tr>
<td>Metronidazole &amp; Tinidazole</td>
<td>Eu</td>
<td></td>
</tr>
<tr>
<td>Urinary antimicrobial drugs</td>
<td>F2</td>
<td></td>
</tr>
<tr>
<td>Antifungal Drugs</td>
<td>F3</td>
<td></td>
</tr>
<tr>
<td>Antiviral Drugs</td>
<td>F4</td>
<td></td>
</tr>
<tr>
<td>Antifungal Drugs</td>
<td>F5</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial drugs</td>
<td>F6</td>
<td></td>
</tr>
<tr>
<td>Antifungal Drugs</td>
<td>F7</td>
<td></td>
</tr>
<tr>
<td>Antiviral Drugs</td>
<td>F8</td>
<td></td>
</tr>
<tr>
<td>Drugs for Threadworms</td>
<td>F9</td>
<td></td>
</tr>
<tr>
<td>Mental and Behavioural Disorders</td>
<td>Fe</td>
<td></td>
</tr>
<tr>
<td>Other Central Nervous System Disorders</td>
<td>ff</td>
<td></td>
</tr>
<tr>
<td>Peripheral Nervous System Disorders</td>
<td>Fg</td>
<td></td>
</tr>
<tr>
<td>Biguanides</td>
<td>fh</td>
<td></td>
</tr>
<tr>
<td>Disorders of Eye and Adnexa</td>
<td>f9</td>
<td></td>
</tr>
<tr>
<td>Diseases of Ear and Mastoid Process</td>
<td>F9</td>
<td></td>
</tr>
<tr>
<td>Thyroid Hormones</td>
<td>fe</td>
<td></td>
</tr>
<tr>
<td>Corticosteroid Clinical Use</td>
<td>ff</td>
<td></td>
</tr>
<tr>
<td>Oestrogens</td>
<td>fg</td>
<td></td>
</tr>
<tr>
<td>Progestogens</td>
<td>fh</td>
<td></td>
</tr>
<tr>
<td>Combined Oestrogen + Progestogen Preparations</td>
<td>f9</td>
<td></td>
</tr>
<tr>
<td>Hypertensive Disease</td>
<td>G2</td>
<td></td>
</tr>
<tr>
<td>Genital Antifungal Preparations</td>
<td>G4</td>
<td></td>
</tr>
<tr>
<td>Other Forms of Heart Disease</td>
<td>G5</td>
<td></td>
</tr>
</tbody>
</table>
VAGINAL ANTIBACTERIAL PREPARATIONS

COMBINED ORAL CONTRACEPTIVE - ETHINYL OESTRADIOL

Vein, lymphatic and circulatory diseases NOS

PROGESTOGEN ONLY CONTRACEPTIVE

ENURESIS FREQUENCY INCONTINENCE

Acute respiratory infections

Other upper respiratory tract diseases

Pneumonia and influenza

Chronic obstructive pulmonary disease

Other respiratory system diseases

PROGESTOGENS IN MALIGNANCY

IRON DEFICIENCY - ORAL IRON

MEGALOBLASTIC ANAEMIAS

ELECTROLYTES-ORAL-SODIUM

SUPPLEMENT & COMPLETE FEEDS

VITAMIN B GROUP

VITAMIN D

MULTIVITAMIN PREPARATIONS

Oral cavity, salivary glands and jaw diseases

ASPIRIN AND THE SALICYLATES

Oesophageal, stomach and duodenal diseases

NON-Steroidal ANTI-INFLAMMATORY DRUGS

Herna of abdominal cavity

LOCAL CORTICOSTEROID INJECTIONS

Noninfective enteritis and colitis

Other diseases of the intestines and peritoneum

Liver, biliary, pancreas + gastrointestinal diseases NEC

RUBEFAICIENTS + TOPICAL ANTI-RHEUMATICS

Other urinary system diseases

Male genital organ diseases

Disorders of breast

TOPICAL PREPARATIONS [EYE]

Female pelvic inflammatory diseases
Other female genital tract disorders
CORTICOSTER + ANTI-INFL [EYE]
TEAR DEFICIENCY PREPARATIONS
Pregnancy with abortive outcome
Pregnancy complications
Risk factors in pregnancy
AURAL ANTI-INFECTIVE PREPARATIONS
Complications occurring during labour and delivery
AURAL ANTI-INFECTIVE COMPOUNDS
REMOVAL OF EAR WAX
NASAL ALLERGY DRUGS
TOPICAL NASAL DECONGESTANTS
ANTI-INFECTIVE NASAL PREPS.
APHTHOUS MOUTH ULCER DRUGS
OROPHARYNGEAL ANTI-INFECTIVES
MOUTH-WASHES/GARGLES/DENTIFRICES
Skin and subcutaneous tissue infections
Other skin and subcutaneous tissue inflammatory conditions
VEHICLES AND DILUENTS
EMOLLIENTS + BARRIER PREPARATIONS
Other skin and subcutaneous tissue disorders
LOCAL ANAESTHETIC/ANTIPRURITIC
TOPICAL CORTICOSTEROIDS
PSORIASIS AND ECZEMA PREPARATIONS
ACNE - TOPICAL PREPARATIONS
WARTS AND CALLUSES
SCALP PREPARATIONS
ANTIBACTERIAL TOPICAL PREPARATIONS
ANTIBACT. - SYSTEMIC USE ALSO
ANTIFUNGAL PREPARATIONS
ANTIVIRAL PREPARATIONS
PARASITICIDAL PREPARATIONS
DISINFECTING/CLEANSING AGENTS
WLGP  N0  Arthropathies and related disorders
WLGP  N1  Vertebral column syndromes
WLGP  N2  Rheumatism, excluding the back
WLGP  N3  Osteopathies, chondropathies and acquired musculoskeletal deformities
WLGP  n4  VACCINES AND ANTI SERA
WLGP  oa  LOCAL ANAESTHESIA
WLGP  p1  ABSORB COTTONS LINTS DRESSINGS
WLGP  p4  RESPIRATORY APPLIANCES
WLGP  p5  BANDAGES & SURGICAL TAPES
WLGP  ph  HYPODERMIC NEEDLES & SYRINGES
WLGP  ps  STOCKINETTES
WLGP  pu  REAGENTS & ANALYSIS SETS
WLGP  R0  [D]Symptoms
WLGP  R1  [D]Nonspecific abnormal findings
WLGP  S0  Fracture of skull
WLGP  S2  Fracture of upper limb
WLGP  S3  Fracture of lower limb
WLGP  S4  Dislocations and subluxations
WLGP  S5  Sprains and strains of joints and adjacent muscles
WLGP  S6  Intracranial injury excluding those with skull fracture
WLGP  S8  Open wound of head, neck and trunk
WLGP  S9  Open wound of upper limb
WLGP  SD  Superficial injury
WLGP  SE  Contusion (bruise) with intact skin
WLGP  SH  Burns
WLGP  SK  Traumatic complications and unspecified injuries
WLGP  SL  Poisoning
WLGP  SN  Other and unspecified external effect causes
WLGP  SP  Surgical and medical care complications NEC
WLGP  T1  Motor vehicle traffic accidents (MVTA)
WLGP  TC  Accidental falls
WLGP  TE  Accidents due to natural and environmental factors
WLGP  TJ  Drugs, medicines and biological substances causing adverse effects in therapeutic use
Suicide and self-inflicted injury
[X] Intentional self-harm
[X] Assault
[V] Factors influencing health status and contact with health services
Uterus operations
Family history
Past medical history
Gynaecological history
General symptoms
Exam. of respiratory system
Exam. of cardiovascular system
Exam. of genitourinary system
Electrocardiography
Laboratory procedures - general
Haematology
Urine examination
Plain radiography
Contraception
Patient pregnant
Birth details
Child health care
Infectious dis: prevent/control
Counselling/health education
Screening
Fallopian tube operations
No significant medical history
No relevant family history
FH: Neoplasm - *
FH: Endocrine disorders
FH: Mental disorder
FH: CNS disorder
Personal status
Alcohol consumption
Tobacco consumption
Exercise grading
H/O: infectious disease
H/O: psychiatric disorder
H/O: CNS disorder
Menstrual data
Parity status
Contraceptive history
H/O: menstrual disorder
H/O: abnormal uterine bleeding
H/O: gynaecological problem NOS
Weight symptom
Temperature symptoms
Sweating symptom
Tiredness symptom
Cough
Breathlessness
C/O - catarrh
Palpitations
Chest pain
Oedema
Tooth symptoms
Mouth symptoms
Indigestion symptoms
Type of GIT pain
Site of GIT pain
Nausea
Vomiting
O/E - method fever registered
Patient examined
O/E - general observations
O/E - state of mind
O/E - height
Depth of resp. system examn.
O/E - rate of respiration
O/E - pulse rate
O/E - pulse rhythm
O/E - blood pressure reading
Depth of GIT examination
O/E - bi-manual vaginal exam.
O/E - vaginal speculum exam.
O/E - gravid uterus size
O/E - VE for pelvic assessment
Neurological diagnostic proced
Visual testing
ECG - general
Tuberculin test - mantoux
Lung volume testing
Respiratory flow rates
Endoscopy: general admin
Procedures related to diagn.
Miscellaneous scales
Laboratory test requested
Sample sent to lab. for test
Haematology - general
Haemoglobin estimation
Full blood count - FBC
Haematocrit - PCV
Red blood cell (RBC) count
Mean corpusc. haemoglobin(MCH)
Mean corpusc. Hb. conc. (MCHC)
Rubella antibody titre
Thyroid hormone tests
Gonadotrophin levels
Serum pregnancy test (B-HCG)
Female sex hormones - serum
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>447</td>
<td>Male sex hormones - serum</td>
</tr>
<tr>
<td>451</td>
<td>Renal function tests</td>
</tr>
<tr>
<td>461</td>
<td>Urine exam. - general</td>
</tr>
<tr>
<td>465</td>
<td>Urine pregnancy test</td>
</tr>
<tr>
<td>466</td>
<td>Urine test for glucose</td>
</tr>
<tr>
<td>467</td>
<td>Urine protein test</td>
</tr>
<tr>
<td>468</td>
<td>Urine ketone test</td>
</tr>
<tr>
<td>469</td>
<td>Urine blood test</td>
</tr>
<tr>
<td>511</td>
<td>Radiology - general</td>
</tr>
<tr>
<td>525</td>
<td>Plain X-ray spine</td>
</tr>
<tr>
<td>527</td>
<td>Plain X-ray pelvis</td>
</tr>
<tr>
<td>528</td>
<td>Plain X-ray shoulder/arm</td>
</tr>
<tr>
<td>529</td>
<td>Plain X-ray hand</td>
</tr>
<tr>
<td>535</td>
<td>Standard chest X-ray</td>
</tr>
<tr>
<td>537</td>
<td>Soft tissue X-ray breast</td>
</tr>
<tr>
<td>567</td>
<td>Computerised axial tomography</td>
</tr>
<tr>
<td>569</td>
<td>Nuclear magnetic resonance</td>
</tr>
<tr>
<td>585</td>
<td>Other diagnostic ultrasound</td>
</tr>
<tr>
<td>588</td>
<td>Physics - other measurements</td>
</tr>
<tr>
<td>611</td>
<td>General contraceptive advice</td>
</tr>
<tr>
<td>614</td>
<td>Oral contraceptive</td>
</tr>
<tr>
<td>615</td>
<td>Intra-uterine contr. device</td>
</tr>
<tr>
<td>621</td>
<td>Patient currently pregnant</td>
</tr>
<tr>
<td>633</td>
<td>Outcome of delivery</td>
</tr>
<tr>
<td>634</td>
<td>Sex of baby</td>
</tr>
<tr>
<td>635</td>
<td>Maturity of baby</td>
</tr>
<tr>
<td>652</td>
<td>Typhoid vaccination</td>
</tr>
<tr>
<td>653</td>
<td>Tuberculosis (BCG) vaccination</td>
</tr>
<tr>
<td>654</td>
<td>Diphtheria vaccination</td>
</tr>
<tr>
<td>655</td>
<td>Pertussis vaccination</td>
</tr>
<tr>
<td>656</td>
<td>Tetanus vaccination</td>
</tr>
<tr>
<td>657</td>
<td>Other bacterial vaccinations</td>
</tr>
<tr>
<td>658</td>
<td>Polio vaccination</td>
</tr>
</tbody>
</table>
Chronic disease - general
Cardiac disease monitoring
Respiratory disease monitoring
Psych. disorder monitoring
Counselling - general
Medical counselling
Health education - general
Health education - subject
Screening - general
Cervical neoplasia screening
Other neoplasm screening
Mental/dev. handicap screen
Ovary and broad ligament operations
External ear and external auditory canal operations
Mastoid and middle ear operations
Nose operations
Lung and mediastinum operations
Tooth and gingiva operations
Tonsil and other parts of mouth operations
Stomach and pylorus operations
Appendix operations
Colon operations and sigmoidoscopy of rectum
Gall bladder operations
Other respiratory procedures
Informed consent for procedure
O/E - level of fever
Occupations
History / symptoms
FH: Cardiovascular disease
FH: Respiratory disease
Diet - patient initiated
Drug user
Personal milestones
Family milestones
Employment milestones
Family bereavement
Sickness/invalidity benefit
Family circumstance NOS
Social/personal history NOS
History of road traffic accident
H/O: respiratory disease
H/O: skin disorder
H/O: musculoskeletal disease
H/O: injury
H/O: drug allergy
H/O: non-drug allergy
H/O: risk factor
H/O: regular medication
History of abuse
Dyspareunia
Stiff neck symptom
Backache symptom
Feels unwell
Swelling
General symptom NOS
Flatulence/wind
Constipation
Faeces/motions - symptoms
Diarrhoea symptoms
Diarrhoea and vomiting
Genitourinary symptoms
Micturition frequency
Micturition control
Genitourinary pain
Vaginal discharge symptom
Breast lump symptom
<table>
<thead>
<tr>
<th>WLGP</th>
<th>1AZ</th>
<th>Genitourinary symptoms NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>1B1</td>
<td>General nervous symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1B4</td>
<td>Sensory symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1B5</td>
<td>Incoordination symptom</td>
</tr>
<tr>
<td>WLGP</td>
<td>1B6</td>
<td>Disturbance of consciousness</td>
</tr>
<tr>
<td>WLGP</td>
<td>1B8</td>
<td>Eye symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1B9</td>
<td>Headache site</td>
</tr>
<tr>
<td>WLGP</td>
<td>1BD</td>
<td>Harmful thoughts</td>
</tr>
<tr>
<td>WLGP</td>
<td>1BO</td>
<td>Mood swings</td>
</tr>
<tr>
<td>WLGP</td>
<td>1BT</td>
<td>Depressed mood</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C</td>
<td>Ear/nose/throat symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C1</td>
<td>Hearing symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C3</td>
<td>Earache symptoms</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C6</td>
<td>Nose bleed symptom</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C8</td>
<td>Nasal symptoms OS</td>
</tr>
<tr>
<td>WLGP</td>
<td>1C9</td>
<td>Sore throat symptom</td>
</tr>
<tr>
<td>WLGP</td>
<td>1D1</td>
<td>C/O: a general symptom</td>
</tr>
<tr>
<td>WLGP</td>
<td>1D2</td>
<td>Symptom distribution</td>
</tr>
<tr>
<td>WLGP</td>
<td>1FA</td>
<td>Diet good</td>
</tr>
<tr>
<td>WLGP</td>
<td>1J</td>
<td>Suspected condition</td>
</tr>
<tr>
<td>WLGP</td>
<td>1J4</td>
<td>Suspected UTI</td>
</tr>
<tr>
<td>WLGP</td>
<td>1M</td>
<td>Pain</td>
</tr>
<tr>
<td>WLGP</td>
<td>1M0</td>
<td>Pain in upper limb</td>
</tr>
<tr>
<td>WLGP</td>
<td>1M1</td>
<td>Pain in lower limb</td>
</tr>
<tr>
<td>WLGP</td>
<td>2..</td>
<td>Examination / Signs</td>
</tr>
<tr>
<td>WLGP</td>
<td>22A</td>
<td>O/E - weight</td>
</tr>
<tr>
<td>WLGP</td>
<td>22K</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>WLGP</td>
<td>22N</td>
<td>Circumference measurements</td>
</tr>
<tr>
<td>WLGP</td>
<td>24E</td>
<td>O/E - peripheral pulses R.-leg</td>
</tr>
<tr>
<td>WLGP</td>
<td>24F</td>
<td>O/E - peripheral pulses L.leg</td>
</tr>
<tr>
<td>WLGP</td>
<td>26A</td>
<td>O/E - vaginal discharge</td>
</tr>
<tr>
<td>WLGP</td>
<td>26B</td>
<td>O/E - general breast exam.</td>
</tr>
<tr>
<td>WLGP</td>
<td>29B</td>
<td>O/E - tactile sensation</td>
</tr>
</tbody>
</table>
O/E - visual acuity R-eye
O/E - visual acuity L-eye
O/E - lymphadenopathy
Ear, nose + throat examination
ENT examination - general
O/E - painful ear
O/E - auditory canal
O/E - general skin exam.
O/E - skin cyst
O/E - foot
O/E - general sign
Health assessment
Further miscellaneous scales
Additional miscellaneous scales
Laboratory procedures
Laboratory test due
Patient informed - test result
Sample obtained
Mean corpuscular volume (MCV)
Plasma viscosity
Blood haematinic levels
Haematology test
Haematology screening test
Total white cell count
Neutrophil count
Other coagulation/bleeding tests
Eosinophil count
Basophil count
Lymphocyte count
Monocyte count
Platelet count
Coagulation/bleeding tests
Serum iron tests
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>42T</td>
<td>Serum vitamin B12</td>
</tr>
<tr>
<td>42U</td>
<td>Blood folate</td>
</tr>
<tr>
<td>42W</td>
<td>Hb. A1C - diabetic control</td>
</tr>
<tr>
<td>42Y</td>
<td>Other haematology test</td>
</tr>
<tr>
<td>42Z</td>
<td>Haematology NOS</td>
</tr>
<tr>
<td>43A</td>
<td>Infectious mononucleosis test</td>
</tr>
<tr>
<td>43a</td>
<td>Other autoantibody titre</td>
</tr>
<tr>
<td>43c</td>
<td>Immunology screening test</td>
</tr>
<tr>
<td>43d</td>
<td>Viral antibody level</td>
</tr>
<tr>
<td>43F</td>
<td>Rheumatoid factor</td>
</tr>
<tr>
<td>43G</td>
<td>Autoantibody titres</td>
</tr>
<tr>
<td>43J</td>
<td>Immunoglobulins</td>
</tr>
<tr>
<td>43j</td>
<td>Nucleic acid detection</td>
</tr>
<tr>
<td>43U</td>
<td>Chlamydia antigen test</td>
</tr>
<tr>
<td>43W</td>
<td>Specific antibody level</td>
</tr>
<tr>
<td>43Z</td>
<td>Immunology NOS</td>
</tr>
<tr>
<td>44a</td>
<td>Tumour marker levels</td>
</tr>
<tr>
<td>44C</td>
<td>Enzymes/specific proteins</td>
</tr>
<tr>
<td>44D</td>
<td>Liver function tests - general</td>
</tr>
<tr>
<td>44E</td>
<td>Serum bilirubin level</td>
</tr>
<tr>
<td>44F</td>
<td>Serum alkaline phosphatase</td>
</tr>
<tr>
<td>44f</td>
<td>Serum glucose level</td>
</tr>
<tr>
<td>44G</td>
<td>Liver enzymes</td>
</tr>
<tr>
<td>44g</td>
<td>Plasma glucose level</td>
</tr>
<tr>
<td>44h</td>
<td>Blood electrolyte levels</td>
</tr>
<tr>
<td>44H</td>
<td>Cardiac enzymes</td>
</tr>
<tr>
<td>44I</td>
<td>Serum electrolytes</td>
</tr>
<tr>
<td>44J</td>
<td>Blood urea/renal function</td>
</tr>
<tr>
<td>44K</td>
<td>Blood urate</td>
</tr>
<tr>
<td>44L</td>
<td>Blood trace elements/vitamins</td>
</tr>
<tr>
<td>44M</td>
<td>Serum / plasma proteins</td>
</tr>
<tr>
<td>44O</td>
<td>Serum lipids</td>
</tr>
</tbody>
</table>
Biochemical test
Biochemical screening test
Serum cholesterol
Serum triglycerides
Blood glucose method
Blood glucose result
Blood gases
Blood chemistry NOS
Urine pH test
Urine electrolytes
Urine protein
Urine drug levels
Urine levels NOS
Urine culture
Urine microalbumin
Urine nitrite
Faeces examination - organisms
Sample examination - general
Type of sample
Microbiology
Sample - microbiological exam
Sample: virology - general
E.N.T. swab taken
Urine sample for organism
GUT sample taken for organism
Microbiology screening test
General pathology
Histology
Cervical smear result
Cervical smear - inflam.change
Cytology - general
Trace element level
Radiology/physics in medicine
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>52A</td>
<td>Plain X-ray hip/leg</td>
</tr>
<tr>
<td>52B</td>
<td>Plain X-ray foot</td>
</tr>
<tr>
<td>58D</td>
<td>Ultrasound scan</td>
</tr>
<tr>
<td>61A</td>
<td>Post-coital contraception</td>
</tr>
<tr>
<td>61B</td>
<td>Depot contraceptive</td>
</tr>
<tr>
<td>61K</td>
<td>Subcutaneous contraceptive</td>
</tr>
<tr>
<td>61M</td>
<td>Emergency contraception</td>
</tr>
<tr>
<td>62B</td>
<td>Delivery booking place</td>
</tr>
<tr>
<td>62G</td>
<td>Antenatal ultrasound scan</td>
</tr>
<tr>
<td>62N</td>
<td>Antenatal examinations</td>
</tr>
<tr>
<td>62P</td>
<td>Infant feeding method</td>
</tr>
<tr>
<td>62R</td>
<td>Postnatal visits</td>
</tr>
<tr>
<td>62S</td>
<td>Maternal P/N 6 week exam.</td>
</tr>
<tr>
<td>64B</td>
<td>Child exam. - birth</td>
</tr>
<tr>
<td>64D</td>
<td>Child 6 week exam.</td>
</tr>
<tr>
<td>64E</td>
<td>Child 8-9 month examination</td>
</tr>
<tr>
<td>64F</td>
<td>Child 18 month exam.</td>
</tr>
<tr>
<td>64L</td>
<td>Child exam.: general/head</td>
</tr>
<tr>
<td>64M</td>
<td>Child exam.: special senses</td>
</tr>
<tr>
<td>64N</td>
<td>Child exam.: trunk/limbs</td>
</tr>
<tr>
<td>65a</td>
<td>Diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination</td>
</tr>
<tr>
<td>65A</td>
<td>Measles vaccination</td>
</tr>
<tr>
<td>65B</td>
<td>Rubella vaccination</td>
</tr>
<tr>
<td>65E</td>
<td>Influenza vaccination</td>
</tr>
<tr>
<td>65F</td>
<td>Other viral vaccinations</td>
</tr>
<tr>
<td>65H</td>
<td>Triple - DTP - vaccination</td>
</tr>
<tr>
<td>65I</td>
<td>DTP (triple)+polio vaccination</td>
</tr>
<tr>
<td>65J</td>
<td>Double - DT - vaccination</td>
</tr>
<tr>
<td>65K</td>
<td>DT (double)+polio vaccination</td>
</tr>
<tr>
<td>65M</td>
<td>Other combined vaccinations</td>
</tr>
<tr>
<td>65P</td>
<td>Communicable disease contact</td>
</tr>
<tr>
<td>66A</td>
<td>Diabetic monitoring</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>66C</td>
<td>Obesity monitoring</td>
</tr>
<tr>
<td>66R</td>
<td>Repeat prescription monitoring</td>
</tr>
<tr>
<td>66U</td>
<td>Menopause monitoring</td>
</tr>
<tr>
<td>66Y</td>
<td>Other respiratory disease monitoring</td>
</tr>
<tr>
<td>67A</td>
<td>Pregnancy advice</td>
</tr>
<tr>
<td>67E</td>
<td>Foreign travel advice</td>
</tr>
<tr>
<td>67H</td>
<td>Lifestyle counselling</td>
</tr>
<tr>
<td>67I</td>
<td>Advice</td>
</tr>
<tr>
<td>68A</td>
<td>Neurolog./special sense screen</td>
</tr>
<tr>
<td>68N</td>
<td>Immunisation status screen</td>
</tr>
<tr>
<td>68P</td>
<td>Adult screening</td>
</tr>
<tr>
<td>68R</td>
<td>New patient screen</td>
</tr>
<tr>
<td>69D</td>
<td>Health exam. of sub-groups</td>
</tr>
<tr>
<td>6A</td>
<td>Patient reviewed</td>
</tr>
<tr>
<td>6A1</td>
<td>Patient reviewed at hospital</td>
</tr>
<tr>
<td>6A6</td>
<td>Mental health review</td>
</tr>
<tr>
<td>7B2</td>
<td>Bladder operations</td>
</tr>
<tr>
<td>7D1</td>
<td>Vagina operations</td>
</tr>
<tr>
<td>7F1</td>
<td>Induction and delivery operations</td>
</tr>
<tr>
<td>7G0</td>
<td>Removal of skin or subcutaneous tissue</td>
</tr>
<tr>
<td>7G2</td>
<td>Other skin,subcutaneous tissue and wound procedures</td>
</tr>
<tr>
<td>7H2</td>
<td>Peritoneum operations</td>
</tr>
<tr>
<td>7K1</td>
<td>Bone operations</td>
</tr>
<tr>
<td>7K6</td>
<td>Other joint operations</td>
</tr>
<tr>
<td>7L1</td>
<td>Other miscellaneous operations</td>
</tr>
<tr>
<td>7N8</td>
<td>[SO]Soft tissue</td>
</tr>
<tr>
<td>7NA</td>
<td>[SO]Other bones and joints</td>
</tr>
<tr>
<td>7NB</td>
<td>[SO]Other operation sites and laterality</td>
</tr>
<tr>
<td>7P0</td>
<td>Diagnostic imaging</td>
</tr>
<tr>
<td>81H</td>
<td>Dressing of wound</td>
</tr>
<tr>
<td>85D</td>
<td>Injection given</td>
</tr>
<tr>
<td>8A4</td>
<td>Respiratory monitoring</td>
</tr>
<tr>
<td>8B1</td>
<td>Emergency treatment</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>8B2</td>
<td>Therapeutic prescription</td>
</tr>
<tr>
<td>8B3</td>
<td>Drug therapy</td>
</tr>
<tr>
<td>8B4</td>
<td>Previous treatment continue</td>
</tr>
<tr>
<td>8B6</td>
<td>Prophylactic drug therapy</td>
</tr>
<tr>
<td>8BA</td>
<td>Other misc. therapy</td>
</tr>
<tr>
<td>8BI</td>
<td>Other medication review</td>
</tr>
<tr>
<td>8BM</td>
<td>Other medication management</td>
</tr>
<tr>
<td>8C1</td>
<td>Nursing care</td>
</tr>
<tr>
<td>8C9</td>
<td>Reassurance given</td>
</tr>
<tr>
<td>8CA</td>
<td>Patient given advice</td>
</tr>
<tr>
<td>8CB</td>
<td>Had a chat to patient</td>
</tr>
<tr>
<td>8CE</td>
<td>Self-help advice leaflet given</td>
</tr>
<tr>
<td>8CM</td>
<td>Care plan</td>
</tr>
<tr>
<td>8E</td>
<td>Physiotherapy/remedial therapy</td>
</tr>
<tr>
<td>8GA</td>
<td>Psychological nursing</td>
</tr>
<tr>
<td>8H</td>
<td>Referral for further care</td>
</tr>
<tr>
<td>8H2</td>
<td>Emergency hospital admission</td>
</tr>
<tr>
<td>8H3</td>
<td>Non-urgent hospital admission</td>
</tr>
<tr>
<td>8H4</td>
<td>Referral to physician</td>
</tr>
<tr>
<td>8H5</td>
<td>Referral to surgeon</td>
</tr>
<tr>
<td>8H6</td>
<td>Referral to other doctor</td>
</tr>
<tr>
<td>8H7</td>
<td>Other referral</td>
</tr>
<tr>
<td>8H8</td>
<td>Follow-up arranged</td>
</tr>
<tr>
<td>8H9</td>
<td>Planned telephone contact</td>
</tr>
<tr>
<td>8HA</td>
<td>No follow-up arranged</td>
</tr>
<tr>
<td>8Hc</td>
<td>Referral to mental health team</td>
</tr>
<tr>
<td>8Hd</td>
<td>Admission to hospital</td>
</tr>
<tr>
<td>8HE</td>
<td>Discharged from hospital</td>
</tr>
<tr>
<td>8HH</td>
<td>Referred - other care</td>
</tr>
<tr>
<td>8HJ</td>
<td>Self-referral to hospital</td>
</tr>
<tr>
<td>8Hk</td>
<td>Referred to service</td>
</tr>
<tr>
<td>8HM</td>
<td>Listed for admission to hosp.</td>
</tr>
<tr>
<td>8HQ</td>
<td>Refer for imaging</td>
</tr>
</tbody>
</table>
WLGP 8HR Refer for physiology investign
WLGP 8HT Referral to clinic
WLGP 8I2 Procedure contraindicated
WLGP 8I3 Procedure refused
WLGP 8I6 Treatment not indicated
WLGP 8IA Procedure declined
WLGP 8IE Procedure declined - additional
WLGP 8M6 Requests pregnancy termination
WLGP 9H9 Mental health annual physical examination done
WLGP A07 Intestinal infection due to other organisms
WLGP A08 Ill-defined intestinal tract infections
WLGP a23 COMPOUND PROPRIETARY ANTACIDS D-L
WLGP a24 COMPOUND PROPRIETARY ANTACIDS M-Z
WLGP a47 HYOSCINE BUTYLBROMIDE
WLGP a4d ALVERINE CITRATE
WLGP a4e MEBEVERINE HYDROCHLORIDE
WLGP a4f PEPPERMINT OIL
WLGP A52 Chickenpox - varicella
WLGP A53 Herpes zoster
WLGP A54 Herpes simplex
WLGP A57 Other viral exanthemata
WLGP a62 RANITIDINE
WLGP a6b OMEPRAZOLE
WLGP a6c LANSOPRAZOLE
WLGP A78 Other viral or chlamydial diseases
WLGP A79 Specific viral infections
WLGP a81 CODEINE PHOSPHATE [GASTRO-INTESTINAL TRACT USE]
WLGP a83 LOPERAMIDE HYDROCHLORIDE
WLGP AB0 Dermatophytosis including tinea or ringworm
WLGP AB1 Dermatophytosis other and unspecified
WLGP AB2 Candidiasis
WLGP ab2 ISPAGHULA HUSK [GASTRO-INTESTINAL BULK LAXATIVE]
WLGP AC7 Other intestinal helminthiases
PROMETHAZINE HYDROCHLORIDE [ANTIHISTAMINE]
CETIRIZINE DIHYDROCHLORIDE
LORATADINE
FEXOFENADINE
DESLORATADINE
CODEINE PHOSPHATE
PHOLCODINE
GENERIC EXPECTORANTS/COUGH COMPOUND PREPARATIONS
EPHEDRINE SYSTEMIC DECONGESTANTS
Iron deficiency anaemias
TEMAZEPAM [HYPNOTIC]
ZOPICLONE
DIAZEPAM [ANXIOLYTIC]
QUETIAPINE
AMITRIPTYLINE HYDROCHLORIDE [ANTIDEPRESSANT]
DOSULEPIN HYDROCHLORIDE
LOFEPRAMINE
TRAZODONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE
VENLAFAXINE
CITALOPRAM
MIKTAZAPINE
ESCITALOPRAM
BETAHISTINE HYDROCHLORIDE
CYCLIZINE
DOMPERIDONE (NAUSEA)
METOCLOPRAMIDE HYDROCHLORIDE
PROCHLORPERAZINE [NAUSEA]
PARACETAMOL
COMPOUND ANALGESICS A-L
COMPOUND ANALGESICS M-Z
COMPOUND ANALGESICS

MORPHINE SALTS (CENTRAL NERVOUS SYSTEM USE)

CODEINE PHOSPHATE (ANALGESIC)

DIHYDROCODEINE TARTRATE

TRAMADOL

ANALGESICS WITH ANTI-EMETICS

SUMATRIPTAN SUCCINATE

PIZOTIFEN

GABAPENTIN

PREGABALIN

NICOTINE

NICOTINE 2

VARENICLINE

Affective psychoses

PHENOXYMETHYLPENICILLIN

Neurotic disorders

FLUCLOXACILLIN

Sexual deviations or disorders

FLUCLOXACILLIN

Alcohol dependence syndrome

Drug dependence

Nondependent abuse of drugs

Psychogenic syndromes NEC

Adjustment reaction

Depressive disorder NEC

Disturbance of conduct NEC

AMOXICILLIN

AMPICILLIN

AMoxicillin + Penicillinase-Resistant Penicillin

AMOXICILLIN [GENERIC ADDITIONS]

CEFACLOR

CEFALEXIN

DOXYCYCLINE

LYMECYCLINE
OXYTETRACYCLINE
ERYTHROMYCIN
CLARITHROMYCIN
AZITHROMYCIN DIHYDRATE
TRIMETHOPRIM
METRONIDAZOLE
NITROFURANTOIN
CIPROFLOXACIN
NYSTATIN [SYSTEMIC]
FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE [1]
ACICLOVIR [SYSTEMIC]
MEBENDAZOLE
NA
Mood - affective disorders
Neurotic, stress - related and somoform disorders
Epilepsy
Migraine
Mononeuritis of upper limb and mononeuritis multiplex
METHFORMIN HYDROCHLORIDE
Disorders of conjunctiva
Inflammation of eyelids
Strabismus and other disorders of binocular eye movements
Disorders of external ear
Nonsuppurative otitis media + eustachian tube disorders
Suppurative and unspecified otitis media
Vertiginous syndromes and other disorders of vestibular system
Other ear disorders
Hearing loss
LEVOTHYROXINE SODIUM
PREDNISOLONE [ENDOCRINE]
NORETHISTERONE [ENDOCRINE]
MENSTRUAL SYMPTOMS - COMBINED PREPARATIONS
Hypertensive disease

Essential hypertension

CLOTRIMAZOLE

DESOGESTREL

LEVONORGESTREL [COMBINED ORAL CONTRACEPTIVE]

Varicose veins of the legs

Haemorrhoids

NORETHINSTERONE ACETATE [COMBINED ORAL CONTRACEPTIVE]

GESTODENE [COMBINED ORAL CONTRACEPTIVE]

NORGESTIMATE [COMBINED OC]

DROSPIRENONE

LEVONORGESTREL [PROGESTOGEN CONTRACEPTIVE]

MEDROXYPROGESTERONE ACETATE [PROGESTOGEN ORAL CONTRACEPTIVE]

NORETHISTERONE [PROGESTOGEN ORAL CONTRACEPTIVE]

ETONOGESTREL

DESOGESTREL [PROGESTOGEN ONLY CONTRACEPTIVE]

SOLIFENACIN

DULOXETINE

Acute nasopharyngitis

Acute sinusitis

Acute pharyngitis

Acute tonsillitis

Acute laryngitis and tracheitis

Other acute upper respiratory infections

Acute bronchitis and bronchiolitis

Chronic pharyngitis and nasopharyngitis

Allergic rhinitis

Influenza

Asthma

MEDROXYPROGEST AC [MALIGNANCY]

FERROUS FUMARATE

FERROUS SULPHATE

IRON & FOLIC ACID
FOLIC ACID
SODIUM SALTS
THIAMINE HYDROCHLORIDE
VITAMIN B COMPLEX
CHOLECALCIFEROL OR ERGOCALCIFEROL
MULTIVITAMINS
Pulp and periapical tissue disease
Oral soft tissue disease
Diseases of oesophagus
ASPIRIN [MUSCULOSKELETAL USE]
Gastritis and duodenitis
Disorders of stomach function
DICLOFENAC SODIUM
IBUPROFEN [MUSCULOSKELETAL USE]
MEFENAMIC ACID [MUSCULOSKELETAL USE]
NAPROXEN
METHYLPPREDNIS. ACETATE [MUSCULOSKELETAL USE]
Other non-infective inflammatory gastroenteritis and colitis
Functional gastrointestinal tract disorders NEC
Other disorders of intestine
Cholelithiasis
TOPICAL ANTI-INFLAMMATORY PREP[1]
TOPICAL ANTI-INFLAMMATORY PREP[2]
TOPICAL ANTI-INFLAMMATORY PREP[3]
Cystitis
Other urethral and urinary tract disorders
Other male genital organ disorders
Other breast disorders
CHLORAMPHENICOL [EYE]
FUSIDIC ACID [EYE]
Ovarian, fallopian tube and pelvic inflammatory diseases
Cervical, vaginal and vulval inflammatory diseases
Female genital organ symptoms
Menstruation disorders
Menopausal and postmenopausal disorders
SODIUM CROMOGLICATE [EYE]
CARBOMERS
Spontaneous abortion
Haemorrhage in early pregnancy
Excessive pregnancy vomiting
Normal delivery in a completely normal case
Clioquinol
GENTAMICIN [EAR]
Other complications of labour and delivery NEC
AURAL ANTI-INFECTIVE COMPOUNDS
REMOVAL OF EAR WAX
BECLOMETASONE DIPROPIONATE [NOSE]
FLUTICASONE [NOSE]
MOMETASONE FUROATE MONOHYDRATE [NOSE]
XYLOMETAZOLINE HYDROCHLORIDE
ANTI-INFECTIVE NASAL PREPS.
BENZYDAMINE HYDROCHLORIDE
CORTICOSTEROIDS FOR OROPHARYNX
MICONAZOLE [OROPHARYNGEAL]
CHLORHEXIDINE GLUCONATE
Skin and subcutaneous tissue infections
Furuncle - boil
Cellulitis and abscess of finger and toe
Other cellulitis and abscesses
Impetigo
Other local infections of skin and subcutaneous tissue
Skin and subcutaneous tissue infection NOS
Erythematousquamous dermatosis
Atopic dermatitis and related conditions
VEHICLES + DILUENTS : CREAMS
Contact dermatitis and other eczemas
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>m12</td>
<td>VEHICLES+DILUENTS : OINTMENTS</td>
</tr>
<tr>
<td>M15</td>
<td>Erythematous conditions</td>
</tr>
<tr>
<td>M16</td>
<td>Psoriasis and similar disorders</td>
</tr>
<tr>
<td>M18</td>
<td>Pruritus and related conditions</td>
</tr>
<tr>
<td>m21</td>
<td>EMOLLIENTS/BARRIER CREAMS: A-E</td>
</tr>
<tr>
<td>M21</td>
<td>Other atrophic and hypertrophic conditions of skin</td>
</tr>
<tr>
<td>m22</td>
<td>EMOLLIENTS/BARRIER CREAMS: F-O</td>
</tr>
<tr>
<td>M22</td>
<td>Other dermatoses</td>
</tr>
<tr>
<td>M23</td>
<td>Diseases of nail</td>
</tr>
<tr>
<td>m23</td>
<td>EMOLLIENTS/BARRIER CREAMS: P-Z</td>
</tr>
<tr>
<td>M24</td>
<td>Hair and hair follicle diseases</td>
</tr>
<tr>
<td>M25</td>
<td>Disorders of sweat glands</td>
</tr>
<tr>
<td>m25</td>
<td>EMOLLIENT BATH ADDITIVES</td>
</tr>
<tr>
<td>M26</td>
<td>Sebaceous gland diseases</td>
</tr>
<tr>
<td>m27</td>
<td>ANTISEPTIC EMOLLIENTS</td>
</tr>
<tr>
<td>M28</td>
<td>EMOLLIENTS/BARRIER CREAMS:A-E (1)</td>
</tr>
<tr>
<td>M28</td>
<td>Urticaria</td>
</tr>
<tr>
<td>M2y</td>
<td>Other specified diseases of skin or subcutaneous tissue</td>
</tr>
<tr>
<td>m31</td>
<td>CALAMINE</td>
</tr>
<tr>
<td>m32</td>
<td>CROTAMITON [ANTIPRURITIC]</td>
</tr>
<tr>
<td>m41</td>
<td>HYDROCORTISONE CREAMS</td>
</tr>
<tr>
<td>m42</td>
<td>HYDROCORTISONE OINTMENTS</td>
</tr>
<tr>
<td>m45</td>
<td>HYDROCORTISONE+ANTIMICROBIALS</td>
</tr>
<tr>
<td>m48</td>
<td>BETAMETHASONE ESTERS</td>
</tr>
<tr>
<td>m49</td>
<td>BETAMETHASONE + ANTIMICROBIALS</td>
</tr>
<tr>
<td>m4a</td>
<td>CLOBETASOL PROPIONATE</td>
</tr>
<tr>
<td>m4b</td>
<td>CLOBETASONE BUTYRATE [SKIN]</td>
</tr>
<tr>
<td>m4q</td>
<td>MOMETASONE FUROATE [TOPICAL]</td>
</tr>
<tr>
<td>m59</td>
<td>CALCIOPOTRIOL</td>
</tr>
<tr>
<td>m67</td>
<td>ERYTHROMYCIN [SKIN]</td>
</tr>
<tr>
<td>m68</td>
<td>CLINDAMYCIN [SKIN]</td>
</tr>
<tr>
<td>m6D</td>
<td>ADAPALENE</td>
</tr>
<tr>
<td>m6z</td>
<td>BENZOYL PEROXIDE [GENERIC ADDITIONS]</td>
</tr>
</tbody>
</table>
SALICYLIC ACID [CALLOSITY]
SHAMPOOS
SCALP APPLICATIONS
MUPIROCIN
FUSIDIC ACID
CLOTRIMAZOLE [SKIN]
MICONAZOLE NITRATE [SKIN]
TERBINAFINE HYDROCHLORIDE [2]
ACICLOVIR [SKIN]
MALATHION
PHENOTHIRIN
PERMETHRIN
SODIUM CHLORIDE [SKIN]
Osteoarthritis and allied disorders
Other and unspecified arthropathies
Other and unspecified joint disorders
Other cervical disorders
Other and unspecified back disorders
Peripheral enthesopathies and allied syndromes
Other disorders of the synovium, tendon and bursa
Muscle, ligament and fascia disorders
Other soft tissue disorders
Other bone and cartilage disorders
DIPHTHERIA VACCINES
INFLUENZA VACCINES
TYPHOID VACCINE
HEPATITIS A VACCINE
LIDOCAINE HCL [ANAESTHESIA]
LIDOCAINE [GENERIC ADDIT]
DRESSING PERFORATED FILM ABSORBENT STERILE
STERILE DRESSING PACK
POVIDONE-IODINE DRESSING
NON-WOVEN FABRIC BACKED ADHESIVE DRESSING
RESERVOIR CHAMBER LARGE VOLUME
PEAK FLOW METERS
PERMEABLE NON-WOVEN SURGICAL ADHESIVE TAPE
LANCETS-STERILE SINGLE-USE
STOCKINETTE ELASTIC TUBULAR 1
BLOOD GLUCOSE TESTING STRIPS
[D]General symptoms
[D]Symptoms affecting skin and other integumentary tissue
[D]Nutrition, metabolic and developmental symptoms
[D]Head and neck symptoms
[D]Cardiovascular system symptoms
[D]Respiratory system and chest symptoms
[D]Digestive system symptoms
[D]Other abdominal and pelvic symptoms
Fracture of radius and ulna
Fracture of carpal bone
Fracture of metacarpal bone
Fracture of one or more phalanges of hand
Fracture of ankle
Fracture of one or more tarsal and metatarsal bones
Fracture of unspecified bones
Sprain of wrist and hand
Sprain of ankle and foot
Sprain of other parts of back
Intracranial injury NOS
Open wound of head, neck and trunk NOS
Superficial injury
Other specified injury
Poisoning
Adverse effects NEC
Other procedure complication NEC
Motor vehicle traffic accidents (MVTA)
Accidental falls
Other injury caused by animals
Suicide and selfinflicted injury
[X]Intentional self poisoning by and exposure to noxious substances
[X]Assault
[V]Encounter due to reproduction and development problems
[V]Persons with a condition influencing their health status
[V]Specified procedures and aftercare
[V]Other reasons for encounter
[V]Well persons examination, investigation and screening
Excision of cervix uteri
No relevant family history
FH: Neoplasm - *
Alcohol consumption
Exercise grading
Menstrual data
Parity status
H/O: abnormal uterine bleeding
Temperature symptoms
Tiredness symptom
Cough
Breathlessness
Palpitations
Chest pain
Tooth symptoms
Type of GIT pain
Nausea
Vomiting
O/E - height
O/E - rate of respiration
O/E - pulse rate
O/E - blood pressure reading
O/E - gravid uterus size
O/E - VE for pelvic assessment
Tuberculin test - mantoux
Laboratory test requested
Sample sent to lab. for test
Haemoglobin estimation
Full blood count - FBC
Haematocrit - PCV
Red blood cell (RBC) count
Mean corpusc. haemoglobin(MCH)
Mean corpusc. Hb. conc. (MCHC)
Thyroid hormone tests
Serum pregnancy test (B-HCG)
Renal function tests
Urine exam. - general
Urine pregnancy test
Urine test for glucose
Urine protein test
Radiology - general
Plain X-ray spine
Plain X-ray pelvis
Plain X-ray hand
Standard chest X-ray
Soft tissue X-ray breast
Computerised axial tomography
Nuclear magnetic resonance
Other diagnostic ultrasound
General contraceptive advice
Oral contraceptive
Patient currently pregnant
Outcome of delivery
Maturity of baby
Typhoid vaccination
Tuberculosis (BCG) vaccination
Cardiac disease monitoring
Respiratory disease monitoring
Health education - subject
Screening - general
Cervical neoplasia screening
Biopsy of cervix uteri
Informed consent for procedure
No known allergies
No FH: Stroke/TIA
No FH: Ischaemic heart disease
No FH: Hypertension
No family history diabetes
FH: Diabetes mellitus
Single
Teetotaller
Trivial drinker - <1u/day
Light drinker - 1-2u/day
Moderate drinker - 3-6u/day
Stopped drinking alcohol
Never smoked tobacco
Trivial smoker - < 1 cig/day
Light smoker - 1-9 cigs/day
Moderate smoker - 10-19 cigs/d
Heavy smoker - 20-39 cigs/day
Ex-moderate smoker (10-19/day)
Avoids even trivial exercise
Enjoys light exercise
Enjoys moderate exercise
H/O: depression
Last menstrual period -1st day
Estimated date of confinement
Wishes to postpone menstruation.
Tired all the time
Night cough present
Night cough absent
Chesty cough
Wheeze
Shortness of breath
Heartburn
Abdominal pain
Epigastric pain
Right iliac fossa pain
Left iliac fossa pain
Nausea present
Vomiting
Patient’s condition improved
Patient’s condition the same
O/E - rash present
Resp. system examined - NAD
O/E - pulse rhythm regular
O/E - BP reading normal
Abdomen examined - NAD
Fundoscopy
Standard ECG
Lung vital capacity
Peak exp. flow rate: PEFR/PFR
Forced vital capacity - FVC
Blood test requested
Stool sample sent to lab.
Blood sample -> Haematol Lab
Blood sample -> Biochem Lab
Blood sample -> Lab NOS
Urine sample sent to Lab
Swab sent to Lab
Packed cell volume
Haematocrit
Nucleated red blood cell count
Serum T4 level
Free T4 level
Follicle stim. hormone - F.S.H
Serum progesterone
Serum oestradiol level
Serum testosterone
Free androgen index
Urinalysis = no abnormality
MSU sent to lab.
Urine dipstick test
Urine pregnancy test negative
High sensitivity urine pregnancy test
Urine glucose test not done
Urine glucose test negative
Urine protein test not done
Urine protein test negative
Urine ketone test negative
Urine blood test = negative
Plain X-ray cervical spine
Plain X-ray lumbar spine
U-S heart scan
U-S abdominal scan
U-S pelvic scan
Spirometry
Oral contraceptive started
Oral contraceptive repeat
Combined oral contraceptive
Progestagen only oral contrac.
IUD fitted
IUD removed
IUD checked - no problems
Patient ? pregnant
Single live birth
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6521</td>
<td>First typhoid vaccination</td>
</tr>
<tr>
<td>6523</td>
<td>Booster typhoid vaccination</td>
</tr>
<tr>
<td>6541</td>
<td>First diphtheria vaccination</td>
</tr>
<tr>
<td>6542</td>
<td>Second diphtheria vaccination</td>
</tr>
<tr>
<td>6543</td>
<td>Third diphtheria vaccination</td>
</tr>
<tr>
<td>6544</td>
<td>Booster diphtheria vaccination</td>
</tr>
<tr>
<td>6551</td>
<td>First pertussis vaccination</td>
</tr>
<tr>
<td>6552</td>
<td>Second pertussis vaccination</td>
</tr>
<tr>
<td>6553</td>
<td>Third pertussis vaccination</td>
</tr>
<tr>
<td>6554</td>
<td>Booster pertussis vaccination</td>
</tr>
<tr>
<td>6561</td>
<td>First tetanus vaccination</td>
</tr>
<tr>
<td>6562</td>
<td>Second tetanus vaccination</td>
</tr>
<tr>
<td>6563</td>
<td>Third tetanus vaccination</td>
</tr>
<tr>
<td>6564</td>
<td>Booster tetanus vaccination</td>
</tr>
<tr>
<td>6571</td>
<td>Meningitis vaccination</td>
</tr>
<tr>
<td>6572</td>
<td>Pneumococcal vaccination</td>
</tr>
<tr>
<td>6581</td>
<td>First polio vaccination</td>
</tr>
<tr>
<td>6582</td>
<td>Second polio vaccination</td>
</tr>
<tr>
<td>6583</td>
<td>Third polio vaccination</td>
</tr>
<tr>
<td>6584</td>
<td>Booster polio vaccination</td>
</tr>
<tr>
<td>6636</td>
<td>Inhaler technique shown</td>
</tr>
<tr>
<td>6637</td>
<td>Inhaler technique observed</td>
</tr>
<tr>
<td>6775</td>
<td>Sterilisation counselling</td>
</tr>
<tr>
<td>6776</td>
<td>Preg. termination counselling</td>
</tr>
<tr>
<td>6777</td>
<td>Contraception counselling</td>
</tr>
<tr>
<td>6781</td>
<td>Health education offered</td>
</tr>
<tr>
<td>6791</td>
<td>Health ed. - smoking</td>
</tr>
<tr>
<td>6792</td>
<td>Health ed. - alcohol</td>
</tr>
<tr>
<td>6793</td>
<td>Health ed. - cervical cytology</td>
</tr>
<tr>
<td>6795</td>
<td>Health ed. - breast exam.</td>
</tr>
<tr>
<td>6798</td>
<td>Health ed. - exercise</td>
</tr>
<tr>
<td>6799</td>
<td>Health ed. - diet</td>
</tr>
<tr>
<td>6852</td>
<td>Ca cervix screen - offered</td>
</tr>
<tr>
<td>6853</td>
<td>Ca cervix screen - not wanted</td>
</tr>
</tbody>
</table>
6857  Ca cervix screen -not attended
6859  Ca cervix - screen done
6862  Breast neoplasm screen
6896  Depression screening using questions
7305  Clearance of external auditory canal
7313  Drainage of middle ear
7530  Excision of tonsil
7700  Emergency excision of appendix
7701  Other excision of appendix
7810  Excision of gall bladder
8923  Consent given for minor surgery procedure
44E3  Total bilirubin
7E04  Abdominal excision of uterus
7E08  Other evacuation of contents of uterus
7E09  Intrauterine contraceptive device procedure
65E9  PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given
2E27  O/E - tympanic temperature
2E31  O/E - temperature normal
0...  Occupations
1...  History / symptoms
12..  Family history
12C.  FH: Cardiovascular disease
12C1  FH: Hypertension
12C2  FH: Ischaemic heart dis. <60
12C3  FH: Ischaemic heart dis. >60
12C4  FH: CVA/stroke
12C5  FH: Myocardial infarction
12D2  FH: Asthma
133F  Marital state unknown
136J  Social drinker
137G  Trying to give up smoking
137L  Current non-smoker
137P  Cigarette smoker
Current smoker
Ex smoker
Exercise grading NOS
Diet - patient initiated
Patient initiated diet NOS
Unwanted pregnancy
Bereavement
Home problems
Child in care
Child on protection register
Employment milestones
Unemployed
Problems at work
Past medical history
H/O: viral illness
H/O: deliberate self harm
History of road traffic accident
H/O: asthma
H/O: eczema
H/O: significant knee disorder
H/O: fracture
H/O: drug allergy
H/O: penicillin allergy
H/O: non-drug allergy
H/O: regular medication
Gynaecological history
Dyspareunia
General symptoms
Backache symptom
Backache
C/O - low back pain
Back pain without radiation NOS
Feels unwell
Nocturnal cough / wheeze
MRC Breathlessness Scale: grade 2
Rib pain
Lower abdominal pain
Flatulence/wind
Constipation
Diarrhoea symptoms
Diarrhoea symptom NOS
Diarrhoea and vomiting
Genitourinary symptoms
Micturition frequency
Enuresis
Lumbar ache - renal
Dysuria
C/O pelvic pain
Vaginal discharge symptom
Breast lump symptom
Fertility problem
Anxiousness
Depressed
Cannot sleep - insomnia
Headache
Stress related problem
Symptoms of depression
Behavioural problem
Incoordination symptom
Disturbance of consciousness
Eye symptoms
Frontal headache
Suicidal ideation
Mood swings
Depressed mood
Ear/nose/throat symptoms
WLGP 1C12 Hearing difficulty
WLGP 1C14 Blocked ear
WLGP 1C3 Earache symptoms
WLGP 1C6 Nose bleed symptom
WLGP 1C8 Nasal symptoms OS
WLGP 1C9 Sore throat symptom
WLGP 1D11 C/O: a swelling
WLGP 1D13 C/O: a pain
WLGP 1D14 C/O: a rash
WLGP 1D15 C/O: itching
WLGP 1FA Diet good
WLGP 1J Suspected condition
WLGP 1J4 Suspected UTI
WLGP 1M Pain
WLGP 1M10 Knee pain
WLGP 1M11 Foot pain
WLGP 2.. Examination / Signs
WLGP 212G Asthma resolved
WLGP 22A O/E - weight
WLGP 22K Body Mass Index
WLGP 22K4 Body mass index index 25-29 - overweight
WLGP 22K5 Body mass index 30+ - obesity
WLGP 22K8 Body mass index 20-24 - normal
WLGP 22N0 Waist circumference
WLGP 23.. Examn. of respiratory system
WLGP 24.. Exam. of cardiovascular system
WLGP 26.. Exam. of genitourinary system
WLGP 26B O/E - general breast exam.
WLGP 2B6 O/E - visual acuity R-eye
WLGP 2B7 O/E - visual acuity L-eye
WLGP 2D.. Ear, nose + throat examination
WLGP 2D7 O/E - painful ear
WLGP 2D82 O/E - wax in auditory canal
O/E - level of fever
O/E - dry skin
O/E - skin cyst
O/E - Right diabetic foot at low risk
O/E - Left diabetic foot at low risk
O/E - a lump
Electrocardiography
Peak flow rate before bronchodilation
Peak flow rate after bronchodilation
FEV1/FVC ratio
Forced expired volume in 1 second
FEV1/FVC percent
Percent predicted FEV1
Patient health questionnaire (PHQ-9) score
HAD scale: depression score
QRISK2 cardiovascular disease 10 year risk score
Biopsychosocial assessment
Laboratory procedures
Blood test due
Patient informed - test result
Test result to patient by phone
Test result to patient personally
Blood sample taken
Haematology
Blood film microscopy
Mean corpuscular volume (MCV)
Plasma viscosity
Erythrocyte sedimentation rate
Transferrin saturation index
Haematology test
Total white cell count
Clotting screening test
<table>
<thead>
<tr>
<th>WLGP</th>
<th>42J.</th>
<th>Neutrophil count</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>42JG</td>
<td>APTT</td>
</tr>
<tr>
<td>WLGP</td>
<td>42K.</td>
<td>Eosinophil count</td>
</tr>
<tr>
<td>WLGP</td>
<td>42L.</td>
<td>Basophil count</td>
</tr>
<tr>
<td>WLGP</td>
<td>42M.</td>
<td>Lymphocyte count</td>
</tr>
<tr>
<td>WLGP</td>
<td>42N.</td>
<td>Monocyte count</td>
</tr>
<tr>
<td>WLGP</td>
<td>42P.</td>
<td>Platelet count</td>
</tr>
<tr>
<td>WLGP</td>
<td>42Q5</td>
<td>Prothrombin time</td>
</tr>
<tr>
<td>WLGP</td>
<td>42QE</td>
<td>International normalised ratio</td>
</tr>
<tr>
<td>WLGP</td>
<td>42Qn</td>
<td>Fibrinogen level</td>
</tr>
<tr>
<td>WLGP</td>
<td>42R4</td>
<td>Serum ferritin</td>
</tr>
<tr>
<td>WLGP</td>
<td>42R7</td>
<td>Serum iron level</td>
</tr>
<tr>
<td>WLGP</td>
<td>42T.</td>
<td>Serum vitamin B12</td>
</tr>
<tr>
<td>WLGP</td>
<td>42U5</td>
<td>Serum folate</td>
</tr>
<tr>
<td>WLGP</td>
<td>42W4</td>
<td>HbA1c level (DCCT aligned)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Haemoglobin A1c level - International Federation of Clinical Chemistry and Laboratory Medicine standardised</td>
</tr>
<tr>
<td>WLGP</td>
<td>42W5</td>
<td>B12/folate level</td>
</tr>
<tr>
<td>WLGP</td>
<td>42YD</td>
<td>Mean platelet volume</td>
</tr>
<tr>
<td>WLGP</td>
<td>42Z5</td>
<td>Red blood cell distribution width</td>
</tr>
<tr>
<td>WLGP</td>
<td>42Z7</td>
<td>Infectious mononucleosis test</td>
</tr>
<tr>
<td>WLGP</td>
<td>43A.</td>
<td>Anti-tissue transglutaminase level</td>
</tr>
<tr>
<td>WLGP</td>
<td>43ad</td>
<td>Tissue transglutaminase IgA level</td>
</tr>
<tr>
<td>WLGP</td>
<td>43F.</td>
<td>Rheumatoid factor</td>
</tr>
<tr>
<td>WLGP</td>
<td>43G1</td>
<td>Anti-nuclear factor</td>
</tr>
<tr>
<td>WLGP</td>
<td>43Gd</td>
<td>Thyroid peroxidase antibody level</td>
</tr>
<tr>
<td>WLGP</td>
<td>43J3</td>
<td>IgG</td>
</tr>
<tr>
<td>WLGP</td>
<td>43J4</td>
<td>IgM</td>
</tr>
<tr>
<td>WLGP</td>
<td>43J5</td>
<td>IgA</td>
</tr>
<tr>
<td>WLGP</td>
<td>43U.</td>
<td>Chlamydia antigen test</td>
</tr>
<tr>
<td>WLGP</td>
<td>43U3</td>
<td>Chlamydia trachomatis antigen test</td>
</tr>
<tr>
<td>WLGP</td>
<td>43W9</td>
<td>Helicobacter pylori IgG antibody level</td>
</tr>
<tr>
<td>WLGP</td>
<td>43WA</td>
<td>Helicobacter pylori antibody level</td>
</tr>
<tr>
<td>Code</td>
<td>Test Description</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------</td>
<td></td>
</tr>
<tr>
<td>43Z2</td>
<td>Prostate specific antigen</td>
<td></td>
</tr>
<tr>
<td>442A</td>
<td>TSH - thyroid stim. hormone</td>
<td></td>
</tr>
<tr>
<td>442J</td>
<td>Thyroid function test</td>
<td></td>
</tr>
<tr>
<td>442V</td>
<td>Serum free T4 level</td>
<td></td>
</tr>
<tr>
<td>442W</td>
<td>Serum TSH level</td>
<td></td>
</tr>
<tr>
<td>443e</td>
<td>Serum LH level</td>
<td></td>
</tr>
<tr>
<td>443h</td>
<td>Serum FSH level</td>
<td></td>
</tr>
<tr>
<td>443j</td>
<td>Serum prolactin level</td>
<td></td>
</tr>
<tr>
<td>44a6</td>
<td>CA125 level</td>
<td></td>
</tr>
<tr>
<td>44CB</td>
<td>Serum transferrin</td>
<td></td>
</tr>
<tr>
<td>44CC</td>
<td>Plasma C reactive protein</td>
<td></td>
</tr>
<tr>
<td>44CD</td>
<td>Serum sex hormone binding globulin level</td>
<td></td>
</tr>
<tr>
<td>44CN</td>
<td>Serum amylase level</td>
<td></td>
</tr>
<tr>
<td>44CS</td>
<td>Serum C reactive protein level</td>
<td></td>
</tr>
<tr>
<td>44D.</td>
<td>Liver function tests - general</td>
<td></td>
</tr>
<tr>
<td>44D6</td>
<td>Liver function test</td>
<td></td>
</tr>
<tr>
<td>44E.</td>
<td>Serum bilirubin level</td>
<td></td>
</tr>
<tr>
<td>44EC</td>
<td>Serum total bilirubin level</td>
<td></td>
</tr>
<tr>
<td>44F.</td>
<td>Serum alkaline phosphatase</td>
<td></td>
</tr>
<tr>
<td>44f.</td>
<td>Serum glucose level</td>
<td></td>
</tr>
<tr>
<td>44f0</td>
<td>Serum random glucose level</td>
<td></td>
</tr>
<tr>
<td>44f1</td>
<td>Serum fasting glucose level</td>
<td></td>
</tr>
<tr>
<td>44F3</td>
<td>Total alkaline phosphatase</td>
<td></td>
</tr>
<tr>
<td>44G.</td>
<td>Liver enzymes</td>
<td></td>
</tr>
<tr>
<td>44g.</td>
<td>Plasma glucose level</td>
<td></td>
</tr>
<tr>
<td>44g0</td>
<td>Plasma random glucose level</td>
<td></td>
</tr>
<tr>
<td>44g1</td>
<td>Plasma fasting glucose level</td>
<td></td>
</tr>
<tr>
<td>44G3</td>
<td>ALT/SGPT serum level</td>
<td></td>
</tr>
<tr>
<td>44G4</td>
<td>Gamma - G.T. level</td>
<td></td>
</tr>
<tr>
<td>44G9</td>
<td>Serum gamma-glutamyl transferase level</td>
<td></td>
</tr>
<tr>
<td>44GB</td>
<td>Serum alanine aminotransferase level</td>
<td></td>
</tr>
<tr>
<td>44h0</td>
<td>Blood potassium level</td>
<td></td>
</tr>
<tr>
<td>44HB</td>
<td>AST serum level</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum creatine kinase level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum electrolytes</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum potassium</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum sodium</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum bicarbonate</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum calcium</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum inorganic phosphate</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Corrected serum calcium level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Blood urea/renal function</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum creatinine</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Urea and electrolytes</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum urate level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum cholesterol/HDL ratio</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum LDL/HDL ratio</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum total protein</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum albumin</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum globulin</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum protein profile</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum lipids</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Fasting blood lipids</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Biochemical test</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum cholesterol</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum HDL cholesterol level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum LDL cholesterol level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>HDL : LDL ratio</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Total cholesterol:HDLD ratio</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Non HDL cholesterol level</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Serum triglycerides</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Urine opiates screening test</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Urine amphetamine screening test</td>
<td></td>
</tr>
<tr>
<td>WLGP</td>
<td>Random blood sugar</td>
<td></td>
</tr>
</tbody>
</table>
Blood glucose level
Fasting blood glucose level
Blood glucose result
Blood oxygen saturation
Bone profile
Serum total HCG level
Glomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation
Glomerular filtration rate
Urine examination
Urine creatinine
Urine protein
Urine albumin
Urine benzodiazepine
Urine methadone
Urine cocaine metabolite screen
Urine albumin:creatinine ratio
Urine culture
Urine microalbumin
Urine nitrite negative
Stool culture
Microscopy, culture and sensitivities
Urinary microscopy, culture and sensitivities
Enteric microscopy, culture and sensitivities
Mycology microscopy, culture and sensitivities
Genital microscopy, culture and sensitivities
Respiratory microscopy, culture and sensitivities
Wound microscopy, culture and sensitivities
Wound exudate sample
Microbiology
Sample culture
Viral studies
Urine sample for organism
MSU sent for C/S
High vaginal swab taken
Endocervical chlamydia swab
General pathology
Histology
Histology laboratory test
Cervical smear result
Cervical smear: inadequate spec
Cervical smear: negative
Cervical smear: mild dyskaryosis
Cervical smear: severe dyskaryosis
Cervical smear: mod.dyskaryosis
Cervical smear: borderline changes
Cervical smear-no inflammation
Cytology laboratory test
Cervical cytology test
Calcium level
Radiology/physics in medicine
Plain radiography
Plain X-ray hip/leg
Plain X-ray knee
Plain X-ray foot
Ultrasound scan
Contraception
Oral contraceptive prescribed
Oral contraceptive advice
Post-coital contraception
Depot contraceptive
Depot contraceptive given
Emergency contraception
Patient pregnant
Delivery booking place
Antenatal ultrasound scan
Antenatal examinations
A/N booking examination
Postnatal visits
Maternal P/N 6 week exam.
Birth details
Child health care
Child exam. - birth
Child 6 week exam.
Child 8-9 month examination
Child exam.: vision
Child exam.: squint
Child exam.: hearing
Infectious dis: prevent/control
1st haemophilus B vaccination
2nd haemophilus B vaccination
3rd haemophilus B vaccination
Booster (single) haemophilus B vaccination
First meningitis C vaccination
Second meningitis C vaccination
Third meningitis C vaccination
Single meningitis C vaccination
Meningitis ACW & Y vaccination
Booster meningitis C vaccination
First diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
Measles vaccination
Second diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
Third diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
Rubella vaccination
Influenza vaccination
Seasonal influenza vaccination
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>65F1</td>
<td>1st hepatitis B vaccination</td>
</tr>
<tr>
<td>65F2</td>
<td>2nd hepatitis B vaccination</td>
</tr>
<tr>
<td>65F3</td>
<td>3rd hepatitis B vaccination</td>
</tr>
<tr>
<td>65F5</td>
<td>Mumps vaccination</td>
</tr>
<tr>
<td>65FA</td>
<td>1st hepatitis A vaccination</td>
</tr>
<tr>
<td>65FD</td>
<td>Booster hepatitis A vaccin.</td>
</tr>
<tr>
<td>65FF</td>
<td>1st hepatitis A junior vaccination</td>
</tr>
<tr>
<td>65FS</td>
<td>First human papillomavirus vaccination</td>
</tr>
<tr>
<td>65FT</td>
<td>Second human papillomavirus vaccination</td>
</tr>
<tr>
<td>65FV</td>
<td>Third human papillomavirus vaccination</td>
</tr>
<tr>
<td>65H</td>
<td>Triple - DTP - vaccination</td>
</tr>
<tr>
<td>65H1</td>
<td>First triple vaccination - DTP</td>
</tr>
<tr>
<td>65H2</td>
<td>Second triple vaccination-DTP</td>
</tr>
<tr>
<td>65H3</td>
<td>Third triple vaccination - DTP</td>
</tr>
<tr>
<td>65J4</td>
<td>Boost double -DT- vaccination</td>
</tr>
<tr>
<td>65K4</td>
<td>Booster DT(double)+polio vacc.</td>
</tr>
<tr>
<td>65K6</td>
<td>First low dose diphtheria, tetanus and inactivated polio vaccination</td>
</tr>
<tr>
<td>65K7</td>
<td>Second low dose diphtheria, tetanus and inactivated polio vaccination</td>
</tr>
<tr>
<td>65K8</td>
<td>Third low dose diphtheria, tetanus and inactivated polio vaccination</td>
</tr>
<tr>
<td>65K9</td>
<td>First booster low dose diphtheria, tetanus and inactivated polio vaccination</td>
</tr>
<tr>
<td>65KA</td>
<td>Second booster low dose diphtheria, tetanus and inactivated polio vaccination</td>
</tr>
<tr>
<td>65M1</td>
<td>Measles/mumps/rubella vaccn.</td>
</tr>
<tr>
<td>65MA</td>
<td>Measles mumps and rubella booster vaccination</td>
</tr>
<tr>
<td>65ML</td>
<td>Measles, rubella vaccination</td>
</tr>
<tr>
<td>65ML</td>
<td>Clinical management plan agreed</td>
</tr>
<tr>
<td>65e</td>
<td>Asthma restricts exercise</td>
</tr>
<tr>
<td>65H</td>
<td>Inhaler technique - good</td>
</tr>
<tr>
<td>65N</td>
<td>Asthma disturbing sleep</td>
</tr>
</tbody>
</table>
Asthma treatment compliance satisfactory
Asthma not disturbing sleep
Asthma limiting activities
Asthma daytime symptoms
Asthma not limiting activities
Asthma never causes daytime symptoms
Asthma management plan given
Asthma causes daytime symptoms most days
Diabetic annual review
Diabetic dietary review
Ideal weight
Repeat prescription monitoring
Rep.presc. treatment stopped
Rep.presc. monitoring NOS
Asthma annual review
Asthma follow-up
Asthma review using Royal College of Physicians three questions
Counselling/health education
Advice about treatment given
Foreign travel advice
Lifestyle counselling
Advice
Screening
Ca cervix screen-no result yet
Ca cervix screen normal
Cervical smear due
Cervical smear refused
Liquid based cervical cytology screening
Diabetic retinopathy screening
Immunisation status screen
Full consent for immunisation
No consent - influenza imm.
Influenza vacc consent given
68P. Adult screening
68R. New patient screen
68R2 New patient screen done
69D2 Adult health exam.
6A.. Patient reviewed
6A1. Patient reviewed at hospital
6A6. Mental health review
745H Smoking cessation therapy
761F Diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract
7B2A Diagnostic cystoscopy
7D1C Exploration of vagina
7E0E Diagnostic endoscopic examination of uterus
7E1C Endoscopic bilateral occlusion of fallopian tubes
7E2A Other examination of female genital tract
7F12 Elective caesarean delivery
7F13 Other caesarean delivery
7F19 Normal delivery
7G03 Other excision of skin
7G22 Removal of repair material from skin
7G2A Introduction of therapeutice substance into subcutaneous tissue
7G2H Other operations on subcutaneous tissue
7H29 Diagnostic endoscopic examination of peritoneum
7K1L Other closed reduction of fracture of bone
7L17 Blood withdrawal
7L18 Intramuscular injection
81H. Dressing of wound
85D. Injection given
8A44 Pulse oximetry monitoring
8B1. Emergency treatment
8B21 Drug prescription
8B2D Hospital prescription
8B2J Prescription by supplementary prescriber
8B3. Drug therapy
Drug administration
Drug Rx stopped-medical advice
Drugs not taken/completed
Drug dosage altered
Medication requested
Medication review without patient
Asthma medication review
Prescription not collected
Drug therapy discontinued
Medication review
Medication review done
Medication review with patient
Medication review of medical notes
Previous treatment continue
Medication review done by pharmacist
Nursing care blood sample taken
Reassurance given
Patient given advice
Patient advised re diet
Patient given telephone advice out of hours
Smoking cessation advice
Advice about long acting reversible contraception
Patient given advice NOS
Had a chat to patient
Long acting reversible contraception leaflet given
Physiotherapy/remedial therapy
Crisis intervention
Referral for further care
Emergency hospital admission
Admit medical emergency unsp.
Other hospital admission NOS
Referral to physician
General medical referral
Referral to paediatrician
Dermatological referral
Cardiological referral
Neurological referral
Gastroenterological referral
Psychiatric referral
Referred to rheumatologist
Referral to surgeon
General surgical referral
ENT referral
Orthopaedic referral
Gynaecological referral
Referred to urologist
Other referral
Refer to dietician
Refer to physiotherapist
Refer to counsellor
Refer to community psych.nurse
Refer for colposcopy
Refer to Radiology department
Refer to TOP counselling
Refer to podiatry
Follow-up arranged
Planned telephone contact
No follow-up arranged
Referral to community mental health team
Referral to primary care mental health team
Admission to hospital
Discharged from hospital
Discharged from outpatients
Removed from waiting list
Referral to child and adolescent psychiatry service
Referral for termination of pregnancy
Trauma self-referral
Self-referral to accident and emergency department
Refer for X-Ray
Refer for ultrasound investigation
Referral to breast clinic
Immunisation contraindicated
Smoking cessation advice declined
Smoking cessation drug therapy declined
Requests pregnancy termination
Depression medication review
Depression interim review
Gastrointestinal tract infection due to specified organism NEC
GAVISCON ADVANCE peppermint sugar free suspension
GAVISCON ADVANCE sugar free suspension
GAVISCON peppermint liquid 500mL
PEPTAC liquid
PEPTAC peppermint liquid
*BUSCOPAN 10mg tablets
HYOSCINE BUTYLBROMIDE 10mg tablets
MEBEVERINE HYDROCHLORIDE 135mg tablets
PEPPERMINT OIL BP 0.2mL e/c capsules
Chickenpox - varicella
Herpes zoster
Herpes simplex
Herpetic gingivostomatitis
RANITIDINE 150mg tablets
OMEPRAZOLE 20mg e/c capsules
OMEPRAZOLE 10mg e/c capsules
LANSOPRAZOLE 30mg capsules
LANSOPRAZOLE 15mg capsules
Molluscum contagiosum
Viral warts
Viral infection NOS
LOPERAMIDE HYDROCHLORIDE 2mg capsules
Dermatophytosis including tinea or ringworm
Dermatophytosis of nail
Dermatophytosis of foot
Pityriasis versicolor
Candidiasis
Candidiasis of mouth and oesophagus
Candidal vulvovaginitis
SENNA 7.5mg tablets
Enterobiasis - threadworm
Pediculus capitis - head lice
Scabies
LACTULOSE 3.35g/5mL solution
MOVICOL oral powder
LAXIDO ORANGE oral powder sachets
ANUSOL cream
ANUSOL-HC ointment 30g
XYLOPROCT ointment 20g
ORLISTAT 120mg capsules
BENDROFLUMETHIAZIDE 2.5mg tablets
Benign neoplasm of skin
PROPRANOLOL 10mg tablets
PROPRANOLOL 40mg tablets
RAMIPRIL 2.5mg capsules
RAMIPRIL 5mg capsules
AMLODIPINE 5mg tablets
ASPIRIN 75mg dispersible tablets
TRANEXAMIC ACID 500mg tablets
SIMVASTATIN 20mg tablets
SIMVASTATIN 40mg tablets
ATORVASTATIN 20mg tablets
Acquired hypothyroidism
Type 2 diabetes mellitus
WLGP
c13J  SALBUTAMOL 100micrograms CFC-free inhaler
WLGP
c13T  VENTOLIN 100micrograms Evohaler
WLGP
c13U  SALBUTAMOL 100micrograms CFC-free breath-actuated aerosol inhaler
WLGP
c13v  SALBUTAMOL 100microgram inhaler
WLGP  C380  Obesity
WLGP  c61z  BECLOMETASONE DIPROPIONATE 100micrograms inhaler
WLGP  c66d  CLENIL MODULITE 100micrograms CFC-free inhaler
WLGP  c841  CHLORPHENAMINE MALEATE 4mg tablets
WLGP  c843  PIRITON 4mg tablets
WLGP  c84y  CHLORPHENAMINE MALEATE 2mg/5mL syrup
WLGP  c8lw  PROMETHAZINE 25mg tablets
WLGP  c8n1  CETIRIZINE 10mg tablets
WLGP  c8o1  LORATADINE 10mg tablets
WLGP  c8o3  LORATADINE 5mg/5mL syrup
WLGP  c8p1  FEXOFENADINE HYDROCHLORIDE 120mg tablets
WLGP  c8p3  FEXOFENADINE HYDROCHLORIDE 180mg tablets
WLGP  c8rz  DESLORATADINE 5mg tablets
WLGP  ch14  SIMPLE linctus
WLGP  ch15  SIMPLE paediatric linctus
WLGP  c1id  GALPSEUD 30mg/5mL linctus
WLGP  c1iw  PSEUDOEPHEDRINE HCL 60mg tablets
WLGP  D00.  Iron deficiency anaemias
WLGP  d1a9  TEMAZEPAM 10mg tablets
WLGP  d1d1  ZOPICLONE 7.5mg tablets
WLGP  d1d3  ZOPICLONE 3.75mg tablets
WLGP  d213  DIAZEPAM 2mg tablets
WLGP  d214  DIAZEPAM 5mg tablets
WLGP  d215  DIAZEPAM 10mg tablets
WLGP  d711  AMITRIPTYLINE 10mg tablets
WLGP  d712  AMITRIPTYLINE 25mg tablets
WLGP  d75y  DOSULEPIN HYDROCHLORIDE 25mg capsules
WLGP  d75z  DOSULEPIN HYDROCHLORIDE 75mg tablets
WLGP  d79z  LOFEPRAMINE 70mg tablets
TRAZODONE HYDROCHLORIDE 50mg capsules

FLUOXETINE 20mg capsules

SERTRALINE 50mg tablets

SERTRALINE 100mg tablets

PAROXETINE 20mg tablets

VENLAFAXINE 37.5mg tablets

VENLAFAXINE 75mg tablets

VENLAFAXINE 75mg m/r capsules

CITALOPRAM 20mg tablets

CITALOPRAM 10mg tablets

CITALOPRAM 40mg tablets

MIRTAZAPINE 30mg tablets

MIRTAZAPINE 15mg oro-dispersible tablets

MIRTAZAPINE 45mg tablets

MIRTAZAPINE 15mg tablets

ESCITALOPRAM 10mg tablets

BETAHISTINE HYDROCHLORIDE 8mg tablets

CYCLIZINE 50mg tablets

DOMPERIDONE 10mg tablets

METOCLOPRAMIDE 10mg tablets

PROCHLORPERAZINE 3mg bucc.tabs

PROCHLORPERAZINE 5mg tablets

PARACETAMOL 500mg tablets

PARACETAMOL 500mg soluble tabs

PARACETAMOL 250mg/5mL mixture

PARACETAMOL 120mg/5mL oral suspension

PARACETAMOL 500mg capsules

PARACETAMOL 120mg/5mL sugar free suspension

PARACETAMOL 250mg/5mL sugar free suspension

CALPOL PAEDIATRIC 120mg/5mL suspension

CALPOL PAEDIATRIC 120mg/5mL sugar free suspension

CO-CODAMOL 8mg/500mg tablets

CO-DYDRAMOL tablets
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>*CO-PROXAMOL tablets</td>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg tablets</td>
</tr>
<tr>
<td>CO-CODAMOL 8mg/500mg effervescent tablets</td>
<td>CO-CODAMOL 8mg/500mg capsules</td>
</tr>
<tr>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/15mg tablets</td>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg capsules</td>
</tr>
<tr>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/15mg tablets</td>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg capsules</td>
</tr>
<tr>
<td>DIHYDROCODEINE 30mg tablets</td>
<td>TRAMADOL HCL 50mg capsules</td>
</tr>
<tr>
<td>SUMATRIPTAN 50mg tablets</td>
<td>GABAPENTIN 100mg capsules</td>
</tr>
<tr>
<td>GABAPENTIN 300mg capsules</td>
<td>PREGABALIN 75mg capsules</td>
</tr>
<tr>
<td>NICOTINE 21mg/24hours patches</td>
<td>NIQUITIN CQ 21mg/24hours capsules</td>
</tr>
<tr>
<td>NIQUITIN CQ 21mg/24hours clear patches</td>
<td>VARENICLINE 500micrograms+1mg tablets</td>
</tr>
<tr>
<td>VARENICLINE 1mg tablets</td>
<td>SINGLE MAJOR DEPRESSIVE EPISODE</td>
</tr>
<tr>
<td>RECURRENT MAJOR DEPRESSIVE EPISODE</td>
<td>PHENOXYMETHYLPENICILLIN 250mg tablets</td>
</tr>
<tr>
<td>PHENOXYMETHYLPENICILLIN 125mg/5mL syrup</td>
<td>PHENOXYMETHYLPENICILLIN 250mg/5mL syrup</td>
</tr>
<tr>
<td>PSYCHOSOMATIC DYSFUNCTION</td>
<td>ANXIETY STATES</td>
</tr>
<tr>
<td>NEUROTIC DEPRESSION REACTIVE TYPE</td>
<td>NEURASTHENIA - NERVOUS DEBILITY</td>
</tr>
<tr>
<td>FLUCLOXACILLIN 250mg capsules</td>
<td>FLUCLOXACILLIN 500mg capsules</td>
</tr>
<tr>
<td>PSYCHOSEXUAL DYSFUNCTION</td>
<td>PSYCHOSEXUAL DYSFUNCTION</td>
</tr>
<tr>
<td>FLUCLOXACILLIN 125mg/5mL syrup</td>
<td>FLUCLOXACILLIN 125mg/5mL syrup</td>
</tr>
<tr>
<td>VARENICLINE 125mg/5mL oral suspension</td>
<td>ALCOHOL DEPENDENCE SYNDROME</td>
</tr>
<tr>
<td>NONDEPENDENT ALCOHOL ABUSE</td>
<td>NONDEPENDENT ALCOHOL ABUSE</td>
</tr>
</tbody>
</table>
Non-organic sleep disorders
Psychalgia
Depressive disorder NEC
AMOXICILLIN 250mg capsules
AMOXICILLIN 500mg capsules
AMOXIL 500mg capsules
AUGMENTIN 375mg tablets
CO-AMOXICLAV 375mg tablets
CO-AMOXICLAV 625mg tablets
CO-AMOXICLAV 250/62 in 5mL suspension
AMOXICILLIN 125mg/5mL sugar free suspension
AMOXICILLIN 125mg/5mL syrup
AMOXICILLIN 250mg/5mL syrup
AMOXICILLIN 250mg/5mL sugar free suspension
CEFALEXIN 250mg capsules
CEFALEXIN 500mg capsules
CEFALEXIN 250mg tablets
CEFALEXIN 500mg tablets
DOXYCYCLINE 100mg capsules
LYMECYCLINE 408mg capsules
OXYTETRACYCLINE 250mg tablets
ERYTHROMYCIN 250mg e/c tablets
ERYTHROMYCIN 125mg/5mL suspension
ERYTHROMYCIN 250mg/5mL suspension
CLARITHROMYCIN 250mg tablets
CLARITHROMYCIN 500mg tablets
TRIMETHOPRIM 100mg tablets
TRIMETHOPRIM 200mg tablets
TRIMETHOPRIM 50mg/5mL sugar free suspension
METRONIDAZOLE 200mg tablets
METRONIDAZOLE 400mg tablets
NITROFURANTOIN 50mg tablets
NITROFURANTOIN 100mg m/r capsules
<table>
<thead>
<tr>
<th>WLGP</th>
<th>eg1y</th>
<th>NITROFURANTOIN 50mg capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>eg6w</td>
<td>CIPROFLOXACIN 500mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>eg6x</td>
<td>CIPROFLOXACIN 250mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>eh71</td>
<td>NYSTATIN 100,000 units/mL suspension</td>
</tr>
<tr>
<td>WLGP</td>
<td>eh73</td>
<td>NYSTAN 100,000 units/mL suspension</td>
</tr>
<tr>
<td>WLGP</td>
<td>eh81</td>
<td>FLUCONAZOLE 50mg capsules</td>
</tr>
<tr>
<td>WLGP</td>
<td>eh82</td>
<td>FLUCONAZOLE 150mg capsules</td>
</tr>
<tr>
<td>WLGP</td>
<td>eha1</td>
<td>TERBINAFINE 250mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>ei15</td>
<td>ACICLOVIR 200mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>ei1o</td>
<td>ACICLOVIR 800mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>EMIS</td>
<td>NA</td>
</tr>
<tr>
<td>WLGP</td>
<td>eq1y</td>
<td>MEBENDAZOLE 100mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>eq1z</td>
<td>MEBENDAZOLE 100mg/5mL suspension</td>
</tr>
<tr>
<td>WLGP</td>
<td>Eu32</td>
<td>[X] Depressive episode</td>
</tr>
<tr>
<td>WLGP</td>
<td>Eu43</td>
<td>[X] Reaction to severe stress, and adjustment disorders</td>
</tr>
<tr>
<td>WLGP</td>
<td>F26.</td>
<td>Migraine</td>
</tr>
<tr>
<td>WLGP</td>
<td>f41y</td>
<td>METFORMIN HYDROCHLORIDE 500mg tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>F4C0</td>
<td>Acute conjunctivitis</td>
</tr>
<tr>
<td>WLGP</td>
<td>F4D0</td>
<td>Blepharitis</td>
</tr>
<tr>
<td>WLGP</td>
<td>F4D1</td>
<td>Hordeolum and other deep inflammation of eyelid</td>
</tr>
<tr>
<td>WLGP</td>
<td>F501</td>
<td>Infective otitis externa</td>
</tr>
<tr>
<td>WLGP</td>
<td>F502</td>
<td>Other otitis externa</td>
</tr>
<tr>
<td>WLGP</td>
<td>F504</td>
<td>Impacted cerumen (wax in ear)</td>
</tr>
<tr>
<td>WLGP</td>
<td>F51.</td>
<td>Nonsuppurative otitis media + eustachian tube disorders</td>
</tr>
<tr>
<td>WLGP</td>
<td>F510</td>
<td>Acute non suppurative otitis media</td>
</tr>
<tr>
<td>WLGP</td>
<td>F52.</td>
<td>Suppurative and unspecified otitis media</td>
</tr>
<tr>
<td>WLGP</td>
<td>F52z</td>
<td>Otitis media NOS</td>
</tr>
<tr>
<td>WLGP</td>
<td>F561</td>
<td>Other and unspecified peripheral vertigo</td>
</tr>
<tr>
<td>WLGP</td>
<td>F587</td>
<td>Otalgia</td>
</tr>
<tr>
<td>WLGP</td>
<td>F59.</td>
<td>Hearing loss</td>
</tr>
<tr>
<td>WLGP</td>
<td>f921</td>
<td>LEVOTHYROXINE SODIUM 25 micrograms tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>f922</td>
<td>LEVOTHYROXINE SODIUM 50 micrograms tablets</td>
</tr>
<tr>
<td>WLGP</td>
<td>fe62</td>
<td>PREDNISOLONE 5mg tablets</td>
</tr>
</tbody>
</table>
PREDNISOLONE 5mg e/c tablets
NORETHISTERONE 5mg tablets
Hypertensive disease
Essential hypertension
CANESTEN-1 500mg vaginal tablets
CLOTRIMAZOLE 1% cream
CANESTEN COMBI pessary+cream
CLOTRIMAZOLE 500mg+2% pessary+cream
CLOTRIMAZOLE 2% vaginal cream
CLOTRIMAZOLE 200mg vaginal tablets
CLOTRIMAZOLE 500mg vaginal tablets
CLOTRIMAZOLE 10% cream
MARVELON tablets
LOGYNON tablets
MICROGYNON-30 tablets
OVranette tablets
*SCHERING-PC4 tablets
MICROGYNON 30 ED tablets
RIGEVIDON tablets
Haemorrhoids
CILEST tablets
YASMIN tablets
MIRENA 52mg intrauterine system
*LEVONELLE-2 tablets
LEVONORGESTREL 1.5mg tablets
LEVONELLE 1500micrograms tablets
DEPO-PROVERA 150mg/1mL prefilled syringe
NORIDAY tablets 84CP
CERAZETTE 75micrograms tablets
CERELLE 75micrograms tablets
DULOXETINE 60mg gastro-resistant capsules
DULOXETINE 30mg gastro-resistant capsules
Acute nasopharyngitis
Acute sinusitis
Acute pharyngitis
Acute tonsillitis
Recurrent acute tonsillitis
Acute laryngitis
Upper respiratory infection NOS
Acute bronchitis
Acute bronchitis or bronchiolitis NOS
Chronic rhinitis
Allergic rhinitis
Allergic rhinitis due to pollens
Influenza NOS
Asthma
Acute exacerbation of asthma
DEPO-PROVERA 450mg/3mL injection
FERROUS FUMARATE 210mg tablets
FERROUS SULFATE 200mg tablets
PREGADAY tablets
FOLIC ACID 5mg tablets
FOLIC ACID 400micrograms tablets
DIORALYTE blackcurrant oral powder
THIAMINE HYDROCHLORIDE 100mg tablets
VITAMIN-B-CO STRONG tablets
Periapical abscess without a sinus
Oral aphthae
Oesophagitis
Other oesophageal disorders
ASPIRIN 300mg dispersible tablets
Gastritis and duodenitis
Other specified stomach function disorders
DICLOFENAC 50mg e/c tablets
IBUPROFEN 200mg tablets
IBUPROFEN 400mg tablets
SODIUM CROMOGLICATE 2% eye drops
Spontaneous abortion
Excessive pregnancy vomiting
Normal delivery in a completely normal case
CLIQUINOL+FLUMETASONE PIV 1%/0.02% ear drops
LOCORTEN-VIOFORM ear drops 10mL
GENTISONE HC ear drops 10mL
GENTAMICIN+HYDROCORTISONE ACETATE 0.3%/1% ear drops
Caesarean delivery
SOFRADEX EYE/EAR drops 10mL
OTOMIZE ear spray 5mL
SODIUM BICARBONATE ear drops
CERUMOL ear drops 11mL
OLIVE OIL ear drops 10mL
BECONASE AQUEOUS 50microgram nasal spray
BECLOMETASONE 50micrograms aqueous nasal spray
AVAMYS 27.5micrograms nasal spray
MOMETASONE FUROATE MONOHYDRATE 0.05% aqueous nasal spray
NASEPTIN cream 15g
DIFFLAM 0.15% oral rinse 300mL
DIFFLAM 0.15% mouth and throat spray
BENZYDAMINE HYDROCHLORIDE 0.15% oral rinse
BENZYDAMINE HYDROCHLORIDE 0.15% mouth and throat spray
DAKTARIN oral gel 80g
Boil NOS
Cellulitis and abscess of finger
Cellulitis and abscess NOS
Impetigo
Local infection skin/subcut tissue NOS
Skin and subcut tissue infection NOS
Seborrhoic dermatitis
AQUEOUS cream
Atopic dermatitis/eczema
DIPROBASE cream 50g
DIPROBASE dispenser cream 500g
Contact dermatitis and other eczemas
EMULSIFYING ointment
DIPROBASE ointment 50g
Contact dermatitis NOS
Rosacea
Other psoriasis
DOUBLEBASE gel 500g
E45 cream 500g pump
Skin atrophy/hypertrophy NOS
HYDROMOL ointment 125g
Ingrowing nail
SUDOCREM cream 30g
Alopecia
Folliculitis
OILATUM EMOLLIENT bath additive 500mL
Other acne
Sebaceous cyst - wen
DERMOL 500 lotion
Urticaria
Other skin and subcutaneous tissue disease NOS
CALAMINE lotion
HYDROCORTISONE 1% cream 30g
HYDROCORTISONE 1% cream 100g
*HYDROCORTISONE 0.5% cream 50g
HYDROCORTISONE 1% ointment 50g
CANESTEN-HC cream 30g
DAKTACORT cream 30g
FUCIDIN-H cream 30g
FUCIDIN-H cream 60g
TIMODINE cream 30g
<table>
<thead>
<tr>
<th>WLGP</th>
<th>m45v</th>
<th>DAKTACORT ointment 30g</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>m45v</td>
<td>HYDROCORTISONE+FUSETIC ACID 1%/2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>m45y</td>
<td>HYDROCORTISONE+MICONAZOLE NITRATE 1%/2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>m45z</td>
<td>HYDROCORTISONE+CLOTRIMAZOLE 1%/1% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>m483</td>
<td>BETNOVATE 0.1% cream 100g</td>
</tr>
<tr>
<td>WLGP</td>
<td>m48o</td>
<td>BETAMETHASONE 0.1% scalp application</td>
</tr>
<tr>
<td>WLGP</td>
<td>m48r</td>
<td>BETAMETHASONE 0.1% ointment</td>
</tr>
<tr>
<td>WLGP</td>
<td>m49d</td>
<td>FUCIBET cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>m49v</td>
<td>BETAMETHASONE+FUCIDIC ACID 0.1%/2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>m4b1</td>
<td>EUMOVATE 0.05% cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>m4b7</td>
<td>EUMOVATE 0.05% cream 15g</td>
</tr>
<tr>
<td>WLGP</td>
<td>m4by</td>
<td>CLOBETASONE 0.05% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>m673</td>
<td>ZINERYT lotion 30mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>m676</td>
<td>ERYTHROMYCIN+ZINC ACETATE 40mg/12mg/mL topical solution</td>
</tr>
<tr>
<td>WLGP</td>
<td>m677</td>
<td>ZINERYT lotion 90mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>m68c</td>
<td>DUAC ONCE DAILY gel 50g</td>
</tr>
<tr>
<td>WLGP</td>
<td>m816</td>
<td>SALACTOL 16.7% paint 10mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>m818</td>
<td>SALATAC 12% gel 8g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mb1v</td>
<td>KETOCONAZOLE 20mg/mL shampoo</td>
</tr>
<tr>
<td>WLGP</td>
<td>mb1z</td>
<td>CAPASAL shampoo 250mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>mc5y</td>
<td>MUPIROCIN 2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>md21</td>
<td>FUCIDIN 2% cream 15g</td>
</tr>
<tr>
<td>WLGP</td>
<td>md2v</td>
<td>FUSIDIC ACID 2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>me41</td>
<td>CANESTEN 1% cream 20g</td>
</tr>
<tr>
<td>WLGP</td>
<td>me4w</td>
<td>CLOTRIMAZOLE 1% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>me71</td>
<td>MICONAZOLE 2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>me78</td>
<td>DAKTARIN 2% cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mejz</td>
<td>TERBINAINE HYDROCHLORIDE 1% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>mf11</td>
<td>ZOVIRAX 5% cream 2g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mf1z</td>
<td>ACICLOVIR 5% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg5x</td>
<td>MALATHION 0.5% liquid</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg77</td>
<td>*FULL MARKS liquid 200mL</td>
</tr>
</tbody>
</table>
FULL MARKS 0.2% lotion 50mL
PERMETHRIN 1% scalp application
LYCLEAR 1% cream rinse 59mL
PERMETHRIN 5% cream 30g
LYCLEAR 5% cream 30g
Pain in joint - arthralgia
Cervicalgia - pain in neck
Sciatica
Backache, unspecified
Enthesopathy of the elbow region
Enthesopathy of the ankle and tarsus
Ganglion and cyst of synovium, tendon and bursa
Myalgia and myositis unspecified
Pain in limb
Other musculoskeletal limb symptoms
REVAXIS suspension for injection 0.5mL prefilled syringe
TYPHIM VI VACCINE 25microgram/0.5mL prefilled syringe
MELOLIN 5x5cm dressing
INADINE 5cmx5cm dressing
VOLUMATIC spacer device
AEROCHAMBER spacer device
STANDARD RANGE EN13826 peak flow meter
MICROPOR 2.5cmx5m tape
Syncope and collapse
Convulsions
Dizziness and giddiness
Sleep disturbances
Pyrexia of unknown origin
Other general symptoms
Rash and other nonspecific skin eruption
Local superficial swelling, mass or lump
Headache
Lymph node enlargement
Respiratory abnormalities
Cough
Chest pain
Abdominal pain
Closed fracture of radius and ulna, lower end
Fracture at wrist and hand level
Fracture of metacarpal bone
Fracture of one or more phalanges of hand
Fracture of unspecified bones
Ankle sprain
Neck sprain
Head injury
Open wound of head, neck and trunk NOS
Superficial injury
Other elbow, forearm and wrist injuries
Other knee, leg, ankle and foot injuries
Poisoning
Allergy, unspecified
Postoperative infection
Motor vehicle traffic accidents (MVTA)
Accidental falls
Dog bite
Suicide and selfinflicted injury
Assault
Contraceptive management
Outcome of delivery
Mental and behavioural problems
Other and unspecified aftercare
Administrative encounters
Person consulting for counselling or advice
Screening for malignant neoplasm
Asthma sometimes restricts exercise
<table>
<thead>
<tr>
<th>WLGP</th>
<th>1151</th>
<th>No known allergies</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>1225</td>
<td>No FH: Stroke/TIA</td>
</tr>
<tr>
<td>WLGP</td>
<td>1226</td>
<td>No FH: Ischaemic heart disease</td>
</tr>
<tr>
<td>WLGP</td>
<td>1227</td>
<td>No FH: Hypertension</td>
</tr>
<tr>
<td>WLGP</td>
<td>1228</td>
<td>No family history diabetes</td>
</tr>
<tr>
<td>WLGP</td>
<td>1252</td>
<td>FH: Diabetes mellitus</td>
</tr>
<tr>
<td>WLGP</td>
<td>1331</td>
<td>Single</td>
</tr>
<tr>
<td>WLGP</td>
<td>1361</td>
<td>Teetotaller</td>
</tr>
<tr>
<td>WLGP</td>
<td>1362</td>
<td>Trivial drinker - &lt;1u/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1363</td>
<td>Light drinker - 1-2u/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1364</td>
<td>Moderate drinker - 3-6u/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1367</td>
<td>Stopped drinking alcohol</td>
</tr>
<tr>
<td>WLGP</td>
<td>1371</td>
<td>Never smoked tobacco</td>
</tr>
<tr>
<td>WLGP</td>
<td>1372</td>
<td>Trivial smoker - &lt; 1 cig/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1373</td>
<td>Light smoker - 1-9 cigs/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1374</td>
<td>Moderate smoker - 10-19 cigs/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1375</td>
<td>Heavy smoker - 20-39 cigs/day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1379</td>
<td>Ex-moderate smoker (10-19/day)</td>
</tr>
<tr>
<td>WLGP</td>
<td>1382</td>
<td>Avoids even trivial exercise</td>
</tr>
<tr>
<td>WLGP</td>
<td>1383</td>
<td>Enjoys light exercise</td>
</tr>
<tr>
<td>WLGP</td>
<td>1384</td>
<td>Enjoys moderate exercise</td>
</tr>
<tr>
<td>WLGP</td>
<td>1465</td>
<td>H/O: depression</td>
</tr>
<tr>
<td>WLGP</td>
<td>1513</td>
<td>Last menstrual period - 1st day</td>
</tr>
<tr>
<td>WLGP</td>
<td>1514</td>
<td>Estimated date of confinement</td>
</tr>
<tr>
<td>WLGP</td>
<td>1519</td>
<td>Wishes to postpone menstruation.</td>
</tr>
<tr>
<td>WLGP</td>
<td>1683</td>
<td>Tired all the time</td>
</tr>
<tr>
<td>WLGP</td>
<td>1717</td>
<td>Night cough present</td>
</tr>
<tr>
<td>WLGP</td>
<td>1718</td>
<td>Night cough absent</td>
</tr>
<tr>
<td>WLGP</td>
<td>1719</td>
<td>Chesty cough</td>
</tr>
<tr>
<td>WLGP</td>
<td>1737</td>
<td>Wheezing</td>
</tr>
<tr>
<td>WLGP</td>
<td>1739</td>
<td>Shortness of breath</td>
</tr>
<tr>
<td>WLGP</td>
<td>1955</td>
<td>Heartburn</td>
</tr>
<tr>
<td>WLGP</td>
<td>1969</td>
<td>Abdominal pain</td>
</tr>
</tbody>
</table>
Epigastric pain
Right iliac fossa pain
Left iliac fossa pain
Nausea present
Vomiting
Patient's condition improved
Patient's condition the same
O/E - rash present
Resp. system examined - NAD
O/E - pulse rhythm regular
O/E - BP reading normal
Abdomen examined - NAD
Standard ECG
Lung vital capacity
Peak exp. flow rate: PEFR/PFR
Forced vital capacity - FVC
Blood test requested
Stool sample sent to lab.
Blood sample -> Haematol Lab
Blood sample -> Biochem Lab
Blood sample -> Lab NOS
Urine sample sent to Lab
Swab sent to Lab
Packed cell volume
Haematocrit
Nucleated red blood cell count
Serum T4 level
Free T4 level
Follicle stim. hormone - F.S.H
Serum progesterone
Serum oestradiol level
Serum testosterone
Free androgen index
Urinalysis = no abnormality
MSU sent to lab.
Urine dipstick test
Urine pregnancy test negative
High sensitivity urine pregnancy test
Urine glucose test not done
Urine glucose test negative
Urine protein test not done
Urine protein test negative
Urine ketone test negative
Urine blood test = negative
Plain X-ray cervical spine
Plain X-ray lumbar spine
U-S heart scan
U-S abdominal scan
U-S pelvic scan
Spirometry
Oral contraceptive started
Oral contraceptive repeat
Combined oral contraceptive
Progestagen only oral contrac.
IUD fitted
IUD removed
IUD checked - no problems
Patient ? pregnant
Single live birth
First typhoid vaccination
Booster typhoid vaccination
First diphtheria vaccination
Second diphtheria vaccination
Third diphtheria vaccination
Booster diphtheria vaccination
First pertussis vaccination
Second pertussis vaccination
Third pertussis vaccination
First tetanus vaccination
Second tetanus vaccination
Third tetanus vaccination
Booster tetanus vaccination
Meningitis vaccination
Pneumococcal vaccination
First polio vaccination
Second polio vaccination
Third polio vaccination
Booster polio vaccination
Inhaler technique shown
Inhaler technique observed
Sterilisation counselling
Preg. termination counselling
Contraception counselling
Health education offered
Health ed. - smoking
Health ed. - alcohol
Health ed. - cervical cytology
Health ed. - breast exam.
Health ed. - exercise
Health ed. - diet
Ca cervix screen - offered
Ca cervix screen - not wanted
Ca cervix screen -not attended
Ca cervix - screen done
Breast neoplasm screen
Depression screening using questions
Excision of tonsil
Emergency excision of appendix
Consent given for minor surgery procedure
Asthma resolved

Large loop excision transformation zone

Irrigation of external auditory canal for removal of wax

Introduction of Mirena coil

Occupations

History / symptoms

Family history

No relevant family history

FH: Neoplasm - *

FH: Cardiovascular disease

FH: Hypertension

FH: Ischaemic heart dis. <60

FH: Ischaemic heart dis. >60

FH: CVA/stroke

FH: Myocardial infarction

FH: Asthma

Marital state unknown

Alcohol consumption

Social drinker

Trying to give up smoking

Current non-smoker

Cigarette smoker

Current smoker

Ex smoker

Exercise grading

Exercise grading NOS

Diet - patient initiated

Patient initiated diet NOS

Unwanted pregnancy

Bereavement

Stress at home

Child on protection register

Employment milestones
Unemployed
Problems at work
Past medical history
H/O: viral illness
H/O: deliberate self harm
History of road traffic accident
H/O: asthma
H/O: eczema
H/O: significant knee disorder
H/O: fracture
H/O: drug allergy
H/O: penicillin allergy
H/O: non-drug allergy
H/O: regular medication
Gynaecological history
Menstrual data
Parity status
H/O: abnormal uterine bleeding
Dyspareunia
General symptoms
Temperature symptoms
Tiredness symptom
Backache symptom
Backache
C/O - low back pain
Back pain without radiation NOS
Feels unwell
Cough
Breathlessness
Nocturnal cough / wheeze
MRC Breathlessness Scale: grade 2
Palpitations
Chest pain
Rib pain
Tooth symptoms
Type of GIT pain
Lower abdominal pain
Nausea
Vomiting
Flatulence/wind
Constipation
Diarrhoea symptoms
Diarrhoea symptom NOS
Diarrhoea and vomiting
Genitourinary symptoms
Micturition frequency
Lumbar ache - renal
Dysuria
C/O pelvic pain
Vaginal discharge symptom
Breast lump symptom
Fertility problem
Anxiousness
Depressed
Cannot sleep - insomnia
Headache
Stress related problem
Symptoms of depression
Behavioural problem
Incoordination symptom
Disturbance of consciousness
Eye symptoms
Frontal headache
Suicidal ideation
Mood swings
Depressed mood
Ear/nose/throat symptoms
Hearing difficulty
Blocked ear
Earache symptoms
Nose bleed symptom
Nasal symptoms OS
Sore throat symptom
C/O: a swelling
C/O: a pain
C/O: a rash
C/O: a rash
C/O: itching
Diet good
Suspected UTI
Pain
Knee pain
Foot pain
Examination / Signs
Asthma resolved
O/E - rate of respiration
O/E - pulse rate
O/E - blood pressure reading
O/E - general breast exam.
Body Mass Index
Body mass index index 25-29 - overweight
Body mass index 30+ - obesity
Body mass index 20-24 - normal
Waist circumference
Examn. of respiratory system
O/E - rate of respiration
Exam. of cardiovascular system
O/E - weight
Exam. of genitourinary system
O/E - gravid uterus size
O/E - VE for pelvic assessment
O/E - visual acuity R-eye
O/E - visual acuity L-eye
Ear, nose + throat examination
O/E - painful ear
O/E - wax in auditory canal
O/E - tympanic temperature
O/E - level of fever
O/E - temperature normal
O/E - dry skin
O/E - skin cyst
O/E - Right diabetic foot at low risk
O/E - Left diabetic foot at low risk
O/E - a lump
Electrocardiography
Tuberculin test - mantoux
Peak flow rate before bronchodilation
Peak flow rate after bronchodilation
FEV1/FVC ratio
Forced expired volume in 1 second
FEV1/FVC percent
Percent predicted FEV1
Patient health questionnaire (PHQ-9) score
HAD scale: depression score
QRISK2 cardiovascular disease 10 year risk score
Biopsychosocial assessment
Laboratory procedures
Laboratory procedures -general
Laboratory test requested
Sample sent to lab. for test
Blood test due
Patient informed - test result
<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>41C2.</td>
<td>Test result to pat. by 'phone</td>
</tr>
<tr>
<td>41C3.</td>
<td>Test result to pat. personally</td>
</tr>
<tr>
<td>41D0.</td>
<td>Blood sample taken</td>
</tr>
<tr>
<td>42...</td>
<td>Haematology</td>
</tr>
<tr>
<td>421B.</td>
<td>Blood film microscopy</td>
</tr>
<tr>
<td>423..</td>
<td>Haemoglobin estimation</td>
</tr>
<tr>
<td>424..</td>
<td>Full blood count - FBC</td>
</tr>
<tr>
<td>425..</td>
<td>Haematocrit - PCV</td>
</tr>
<tr>
<td>426..</td>
<td>Red blood cell (RBC) count</td>
</tr>
<tr>
<td>428..</td>
<td>Mean corpuscular haemoglobin (MCH)</td>
</tr>
<tr>
<td>429..</td>
<td>Mean corpuscular Hb. conc. (MCHC)</td>
</tr>
<tr>
<td>42A..</td>
<td>Mean corpuscular volume (MCV)</td>
</tr>
<tr>
<td>42B..</td>
<td>Plasma viscosity</td>
</tr>
<tr>
<td>42B6.</td>
<td>Erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>42d1.</td>
<td>Transferrin saturation index</td>
</tr>
<tr>
<td>42G..</td>
<td>Haematology test</td>
</tr>
<tr>
<td>42H..</td>
<td>Total white cell count</td>
</tr>
<tr>
<td>42h0.</td>
<td>Clotting screening test</td>
</tr>
<tr>
<td>42I..</td>
<td>Neutrophil count</td>
</tr>
<tr>
<td>42J..</td>
<td>APTT</td>
</tr>
<tr>
<td>42K..</td>
<td>Eosinophil count</td>
</tr>
<tr>
<td>42L..</td>
<td>Basophil count</td>
</tr>
<tr>
<td>42M..</td>
<td>Lymphocyte count</td>
</tr>
<tr>
<td>42N..</td>
<td>Monocyte count</td>
</tr>
<tr>
<td>42P..</td>
<td>Platelet count</td>
</tr>
<tr>
<td>42Q5.</td>
<td>Prothrombin time</td>
</tr>
<tr>
<td>42QE.</td>
<td>International normalised ratio</td>
</tr>
<tr>
<td>42Qn.</td>
<td>Fibrinogen level</td>
</tr>
<tr>
<td>42R4.</td>
<td>Serum ferritin</td>
</tr>
<tr>
<td>42R7.</td>
<td>Serum iron level</td>
</tr>
<tr>
<td>42T..</td>
<td>Serum vitamin B12</td>
</tr>
<tr>
<td>42U5.</td>
<td>Serum folate</td>
</tr>
<tr>
<td>42W4.</td>
<td>HbA1c level (DCCT aligned)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>42W5</td>
<td>Haemoglobin A1c level - International Federation of Clinical Chemistry and Laboratory Medicine standardised</td>
</tr>
<tr>
<td>42YD</td>
<td>B12/folate level</td>
</tr>
<tr>
<td>42Z5</td>
<td>Mean platelet volume</td>
</tr>
<tr>
<td>42Z7</td>
<td>Red blood cell distribution width</td>
</tr>
<tr>
<td>43A..</td>
<td>Infectious mononucleosis test</td>
</tr>
<tr>
<td>43aC</td>
<td>Anti-tissue transglutaminase level</td>
</tr>
<tr>
<td>43ad</td>
<td>Tissue transglutaminase IgA level</td>
</tr>
<tr>
<td>43F..</td>
<td>Rheumatoid factor</td>
</tr>
<tr>
<td>43J3</td>
<td>IgG</td>
</tr>
<tr>
<td>43J4</td>
<td>IgM</td>
</tr>
<tr>
<td>43J5</td>
<td>IgA</td>
</tr>
<tr>
<td>43U..</td>
<td>Chlamydia antigen test</td>
</tr>
<tr>
<td>43U3</td>
<td>Chlamydia trachomatis antigen test</td>
</tr>
<tr>
<td>43W9</td>
<td>Helicobacter pylori IgG antibody level</td>
</tr>
<tr>
<td>43WA</td>
<td>Helicobacter pylori antibody level</td>
</tr>
<tr>
<td>442..</td>
<td>Thyroid hormone tests</td>
</tr>
<tr>
<td>442A</td>
<td>TSH - thyroid stim. hormone</td>
</tr>
<tr>
<td>442J</td>
<td>Thyroid function test</td>
</tr>
<tr>
<td>442V</td>
<td>Serum free T4 level</td>
</tr>
<tr>
<td>442W</td>
<td>Serum TSH level</td>
</tr>
<tr>
<td>443e</td>
<td>Serum LH level</td>
</tr>
<tr>
<td>443h</td>
<td>Serum FSH level</td>
</tr>
<tr>
<td>443j</td>
<td>Serum prolactin level</td>
</tr>
<tr>
<td>445..</td>
<td>Serum pregnancy test (B-HCG)</td>
</tr>
<tr>
<td>44a60</td>
<td>Serum CA 125 (cancer antigen 125) level</td>
</tr>
<tr>
<td>44CB</td>
<td>Serum transferrin</td>
</tr>
<tr>
<td>44CC</td>
<td>Plasma C reactive protein</td>
</tr>
<tr>
<td>44CD</td>
<td>Serum sex hormone binding globulin level</td>
</tr>
<tr>
<td>44CN</td>
<td>Serum amylase level</td>
</tr>
<tr>
<td>44CS</td>
<td>Serum C reactive protein level</td>
</tr>
<tr>
<td>44D..</td>
<td>Liver function tests - general</td>
</tr>
<tr>
<td>44D6</td>
<td>Liver function test</td>
</tr>
</tbody>
</table>
Serum LDL/HDL ratio
Serum total protein
Serum albumin
Serum globulin
Serum protein profile
Serum lipids
Fasting blood lipids
Biochemical test
Serum cholesterol
Serum HDL cholesterol level
Serum LDL cholesterol level
HDL : LDL ratio
Total cholesterol:HDL ratio
Non HDL cholesterol level
Serum triglycerides
Urine opiates screening test
Urine amphetamine screening test
Random blood sugar
Blood glucose level
Fasting blood glucose level
Blood glucose result
Blood oxygen saturation
Oxygen saturation at periphery
Bone profile
Serum total HCG level
Renal function tests
Glomerular filtration rate calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation
Glomerular filtration rate
Urine examination
Urine exam. - general
Urine pregnancy test
Urine test for glucose
Urine protein test
Urine creatinine
Urine protein
Urine albumin
Urine benzodiazepine
Urine methadone
Urine cocaine metabolite screen
Urine albumin:creatinine ratio
Urine culture
Urine microalbumin
Urine nitrite negative
Stool culture
Microscopy, culture and sensitivities
Urinary microscopy, culture and sensitivities
Enteric microscopy, culture and sensitivities
Mycology microscopy, culture and sensitivities
Genital microscopy, culture and sensitivities
Respiratory microscopy, culture and sensitivities
Wound microscopy, culture and sensitivities
Wound exudate sample
Microbiology
Sample culture
Viral studies
Urine sample for organism
MSU sent for C/S
High vaginal swab taken
Endocervical chlamydia swab
General pathology
Histology
Histology laboratory test
Cervical smear result
Cervical smear: inadequate spec
Cervical smear: negative
Cerv. smear: mild dyskaryosis
Cerv. smear: severe dyskaryosis
Cerv. smear: mod. dyskaryosis
Cerv. smear: borderline changes
Cervical smear-no inflammation
Cytology laboratory test
Cervical cytology test
Calcium level
Calcium adjusted level
Radiology/physics in medicine
Radiology - general
Plain radiography
Plain X-ray spine
Plain X-ray pelvis
Plain X-ray hand
Plain X-ray hip/leg
Plain X-ray knee
Plain X-ray foot
Standard chest X-ray
Soft tissue X-ray breast
Computerised axial tomography
Nuclear magnetic resonance
Other diagnostic ultrasound
Ultrasound scan
Contraception
General contraceptive advice
Oral contraceptive
Oral contraceptive prescribed
Oral contraceptive advice
Post-coital contraception
Depot contraceptive
Depot contraceptive given
Emergency contraception
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP 62...</td>
<td>Patient pregnant</td>
</tr>
<tr>
<td>WLGP 621..</td>
<td>Patient currently pregnant</td>
</tr>
<tr>
<td>WLGP 62B..</td>
<td>Delivery booking place</td>
</tr>
<tr>
<td>WLGP 62G..</td>
<td>Antenatal ultrasound scan</td>
</tr>
<tr>
<td>WLGP 62N..</td>
<td>Antenatal examinations</td>
</tr>
<tr>
<td>WLGP 62N1.</td>
<td>A/N booking examination</td>
</tr>
<tr>
<td>WLGP 62R..</td>
<td>Postnatal visits</td>
</tr>
<tr>
<td>WLGP 62S..</td>
<td>Maternal P/N 6 week exam.</td>
</tr>
<tr>
<td>WLGP 63...</td>
<td>Birth details</td>
</tr>
<tr>
<td>WLGP 633..</td>
<td>Outcome of delivery</td>
</tr>
<tr>
<td>WLGP 635..</td>
<td>Maturity of baby</td>
</tr>
<tr>
<td>WLGP 64...</td>
<td>Child health care</td>
</tr>
<tr>
<td>WLGP 64B..</td>
<td>Child exam. - birth</td>
</tr>
<tr>
<td>WLGP 64D..</td>
<td>Child 6 week exam.</td>
</tr>
<tr>
<td>WLGP 64E..</td>
<td>Child 8-9 month examination</td>
</tr>
<tr>
<td>WLGP 64M1.</td>
<td>Child exam.: vision</td>
</tr>
<tr>
<td>WLGP 64M3.</td>
<td>Child exam.: squint</td>
</tr>
<tr>
<td>WLGP 64M5.</td>
<td>Child exam.: hearing</td>
</tr>
<tr>
<td>WLGP 65...</td>
<td>Infectious dis: prevent/control</td>
</tr>
<tr>
<td>WLGP 652..</td>
<td>Typhoid vaccination</td>
</tr>
<tr>
<td>WLGP 653..</td>
<td>Tuberculosis (BCG) vaccination</td>
</tr>
<tr>
<td>WLGP 657A.</td>
<td>1st haemophilus B vaccination</td>
</tr>
<tr>
<td>WLGP 657B.</td>
<td>2nd haemophilus B vaccination</td>
</tr>
<tr>
<td>WLGP 657C.</td>
<td>3rd haemophilus B vaccination</td>
</tr>
<tr>
<td>WLGP 657D.</td>
<td>Booster (single) haemophilus B vaccination</td>
</tr>
<tr>
<td>WLGP 657E.</td>
<td>First meningitis C vaccination</td>
</tr>
<tr>
<td>WLGP 657F.</td>
<td>Second meningitis C vaccination</td>
</tr>
<tr>
<td>WLGP 657G.</td>
<td>Third meningitis C vaccination</td>
</tr>
<tr>
<td>WLGP 657I.</td>
<td>Single meningitis C vaccination</td>
</tr>
<tr>
<td>WLGP 657J.</td>
<td>Meningitis ACW &amp; Y vaccination</td>
</tr>
<tr>
<td>WLGP 657S.</td>
<td>Booster meningitis C vaccination</td>
</tr>
<tr>
<td>WLGP 65a0.</td>
<td>First diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination</td>
</tr>
</tbody>
</table>
Measles vaccination
Second diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
Third diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination
Rubella vaccination
Influenza vaccination
PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given
Seasonal influenza vaccination
1st hepatitis B vaccination
2nd hepatitis B vaccination
3rd hepatitis B vaccination
Mumps vaccination
1st hepatitis A vaccination
Booster hepatitis A vaccin.
1st hepatitis A junior vaccination
First human papillomavirus vaccination
Second human papillomavirus vaccination
Third human papillomavirus vaccination
Triple - DTP - vaccination
First triple vaccination - DTP
Second triple vaccination-DTP
Third triple vaccination - DTP
First DTP (triple)+polio vacc.
Second DTP (triple)+polio vacc
Third DTP (triple)+polio vacc.
Booster diphtheria, tetanus, acellular pertussis and inactivated polio vaccination
Boost double -DT - vaccination
Booster DT(double)+polio vacc.
First low dose diphtheria, tetanus and inactivated polio vaccination
Second low dose diphtheria, tetanus and inactivated polio vaccination
Third low dose diphtheria, tetanus and inactivated polio vaccination
First booster low dose diphtheria, tetanus and inactivated polio vaccination
Second booster low dose diphtheria, tetanus and inactivated polio vaccination
Measles/mumps/rubella vaccn.
Measles/rubella vaccination
Measles mumps and rubella booster vaccination
First hepatitis A and typhoid vaccination
Clinical management plan agreed
Cardiac disease monitoring
Respiratory disease monitoring
Inhaler technique - good
Asthma disturbing sleep
Asthma treatment compliance satisfactory
Asthma not disturbing sleep
Asthma limiting activities
Asthma daytime symptoms
Asthma not limiting activities
Asthma never causes daytime symptoms
Asthma management plan given
Asthma causes daytime symptoms most days
Diabetic annual review
Ideal weight
Repeat prescription monitoring
Rep.presc.treatment stopped
Rep.presc. monitoring NOS
Asthma annual review
Asthma follow-up
Asthma review using Royal College of Physicians three questions
Counselling/health education
Advice about treatment given
Health education - subject
Foreign travel advice
Lifestyle counselling
Advice
Screening
Screening - general
Cervical neoplasia screening
Ca cervix screen-no result yet
Ca cervix screen normal
Cervical smear due
Cervical smear refused
Liquid based cervical cytology screening
Diabetic retinopathy screening
Immunisation status screen
Full consent for immunisation
Influenza vacc consent given
Consent given for seasonal influenza vaccination
Adult screening
New patient screen
New patient screen done
Adult health exam.
Patient reviewed
Patient reviewed at hospital
Mental health review
Smoking cessation therapy
Diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract NOS
Other excision of appendix NOS
Colposcopy NEC
Diagnostic endoscopic examination of uterus NOS
Endoscopic bilateral occlusion of fallopian tubes
Papanicolau smear NEC
Normal delivery
Removal of repair material from skin
Diagnostic endoscopic examination of peritoneum
Blood withdrawal
Blood withdrawal for testing
Intramuscular injection
Dressing of wound
Injection given
Informed consent for procedure
Pulse oximetry monitoring
Emergency treatment
Drug prescription
Hospital prescription
Prescription by supplementary prescriber
Drug therapy
Medication given
Medication commenced
Medication review
Medication changed
Medication increased
Medication decreased
Medication requested
Medication review without patient
Asthma medication review
Prescription not collected
Drug therapy discontinued
Medication review
Medication review done
Medication review with patient
Medication review of medical notes
Previous treatment continue
Medication review done by pharmacist
Nursing care blood sample taken
Reassurance given
Patient given advice
Patient advised re diet
Patient given telephone advice out of hours
Smoking cessation advice
Advice about long acting reversible contraception
Patient given advice NOS
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8CB..</td>
<td>Had a chat to patient</td>
</tr>
<tr>
<td>8CEG.</td>
<td>Long acting reversible contraception leaflet given</td>
</tr>
<tr>
<td>8E...</td>
<td>Physiotherapy/remedial therapy</td>
</tr>
<tr>
<td>8GA0.</td>
<td>Crisis intervention</td>
</tr>
<tr>
<td>8H...</td>
<td>Referral for further care</td>
</tr>
<tr>
<td>8H2..</td>
<td>Emergency hospital admission</td>
</tr>
<tr>
<td>8H3Z.</td>
<td>Other hospital admission NOS</td>
</tr>
<tr>
<td>8H4..</td>
<td>Referral to physician</td>
</tr>
<tr>
<td>8H41.</td>
<td>General medical referral</td>
</tr>
<tr>
<td>8H42.</td>
<td>Referral to paediatrician</td>
</tr>
<tr>
<td>8H43.</td>
<td>Dermatological referral</td>
</tr>
<tr>
<td>8H44.</td>
<td>Cardiological referral</td>
</tr>
<tr>
<td>8H46.</td>
<td>Neurological referral</td>
</tr>
<tr>
<td>8H48.</td>
<td>Gastroenterological referral</td>
</tr>
<tr>
<td>8H49.</td>
<td>Psychiatric referral</td>
</tr>
<tr>
<td>8H4B.</td>
<td>Referred to rheumatologist</td>
</tr>
<tr>
<td>8H5..</td>
<td>Referral to surgeon</td>
</tr>
<tr>
<td>8H51.</td>
<td>General surgical referral</td>
</tr>
<tr>
<td>8H53.</td>
<td>ENT referral</td>
</tr>
<tr>
<td>8H54.</td>
<td>Orthopaedic referral</td>
</tr>
<tr>
<td>8H58.</td>
<td>Gynaecological referral</td>
</tr>
<tr>
<td>8H5B.</td>
<td>Referred to urologist</td>
</tr>
<tr>
<td>8H7..</td>
<td>Other referral</td>
</tr>
<tr>
<td>8H76.</td>
<td>Refer to dietitian</td>
</tr>
<tr>
<td>8H77.</td>
<td>Refer to physiotherapist</td>
</tr>
<tr>
<td>8H78.</td>
<td>Refer to counsellor</td>
</tr>
<tr>
<td>8H7B.</td>
<td>Refer to community psych. nurse</td>
</tr>
<tr>
<td>8H7N.</td>
<td>Refer for colposcopy</td>
</tr>
<tr>
<td>8H7O.</td>
<td>Refer to Radiology department</td>
</tr>
<tr>
<td>8H7W.</td>
<td>Refer to TOP counselling</td>
</tr>
<tr>
<td>8H7X.</td>
<td>Refer to podiatry</td>
</tr>
<tr>
<td>8H8..</td>
<td>Follow-up arranged</td>
</tr>
</tbody>
</table>
Planned telephone contact
No follow-up arranged
Referral to community mental health team
Referral to primary care mental health team
Admission to hospital
Discharged from hospital
Discharged from outpatients
Removed from waiting list
Referral to child and adolescent psychiatry service
Referral for termination of pregnancy
Trauma self-referral
Self-referral to accident and emergency department
Refer for X-Ray
Refer for ultrasound investigation
Referral to breast clinic
Immunisation contraindicated
Smoking cessation advice declined
Smoking cessation drug therapy declined
Requests pregnancy termination
Depression medication review
Depression interim review
Viral gastroenteritis
GAVISCON ADVANCE peppermint sugar free suspension
GAVISCON ADVANCE sugar free suspension
GAVISCON peppermint liquid 500mL
PEPTAC liquid
PEPTAC peppermint liquid
*BUSCOPAN 10mg tablets
HYOSCINE BUTYLBROMIDE 10mg tablets
MEBEVERINE HYDROCHLORIDE 135mg tablets
PEPPERMINT OIL BP 0.2mL e/c capsules
Chickenpox - varicella
Herpes zoster
Herpes simplex

Herpetic gingivostomatitis

RANITIDINE 150mg tablets

OMEPRAZOLE 20mg e/c capsules

OMEPRAZOLE 10mg e/c capsules

LANSOPRAZOLE 30mg capsules

LANSOPRAZOLE 15mg capsules

Molluscum contagiosum

Viral warts

Verruca plantaris

Plain wart

Viral infection NOS

LOPERAMIDE HYDROCHLORIDE 2mg capsules

Dermatophytosis including tinea or ringworm

Dermatophytosis of nail

Dermatophytosis of foot

Pityriasis versicolor

Candidiasis

Candidal vulvovaginitis

Candidiasis of vagina

SENNA 7.5mg tablets

Enterobiasis - threadworm

Pediculus capitis - head lice

Scabies

LACTULOSE 3.35g/5mL solution

MOVICOL oral powder

LAXIDO ORANGE oral powder sachets

ANUSOL cream

ANUSOL-HC ointment 30g

XYLOPROCT ointment 20g

ORLISTAT 120mg capsules

BENDROFLUMETHIAZIDE 2.5mg tablets

Benign neoplasm of skin
PROPRANOLOL 10mg tablets
PROPRANOLOL 40mg tablets
RAMIPRIL 2.5mg capsules
RAMIPRIL 5mg capsules
AMLODIPINE 5mg tablets
ASPIRIN 75mg dispersible tablets
TRANEXAMIC ACID 500mg tablets
SIMVASTATIN 20mg tablets
SIMVASTATIN 40mg tablets
ATORVASTATIN 20mg tablets
Acquired hypothyroidism
Type 2 diabetes mellitus
SALBUTAMOL 100micrograms CFC-free inhaler
VENTOLIN 100micrograms Evohaler
SALBUTAMOL 100micrograms CFC-free breath-actuated aerosol inhaler
SALBUTAMOL 100microgram inhaler
Obesity
BECLOMETASONE DIPROPIONATE 100micrograms inhaler
CLENIL MODULITE 100micrograms CFC-free inhaler
CHLORPHENAMINE MALEATE 4mg tablets
CHLORPHENAMINE MALEATE 2mg/5mL syrup
PROMETHAZINE 25mg tablets
CETIRIZINE 10mg tablets
LORATADINE 10mg tablets
LORATADINE 5mg/5mL syrup
FEXOFENADINE HYDROCHLORIDE 120mg tablets
FEXOFENADINE HYDROCHLORIDE 180mg tablets
DESLORATADINE 5mg tablets
SIMPLE linctus
SIMPLE paediatric linctus
GALPSEUD 30mg/5mL linctus
PSEUDOEPHEDRINE HCL 60mg tablets
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D00..</td>
<td>Iron deficiency anaemias</td>
</tr>
<tr>
<td>d1a9.</td>
<td>TEMAZEPAM 10mg tablets</td>
</tr>
<tr>
<td>d1d1.</td>
<td>ZOPICLONE 7.5mg tablets</td>
</tr>
<tr>
<td>d1d3.</td>
<td>ZOPICLONE 3.75mg tablets</td>
</tr>
<tr>
<td>d213.</td>
<td>DIAZEPAM 2mg tablets</td>
</tr>
<tr>
<td>d214.</td>
<td>DIAZEPAM 5mg tablets</td>
</tr>
<tr>
<td>d215.</td>
<td>DIAZEPAM 10mg tablets</td>
</tr>
<tr>
<td>d711.</td>
<td>AMITRIPTYLINE 10mg tablets</td>
</tr>
<tr>
<td>d712.</td>
<td>AMITRIPTYLINE 25mg tablets</td>
</tr>
<tr>
<td>d75y.</td>
<td>DOSULEPIN HYDROCHLORIDE 25mg capsules</td>
</tr>
<tr>
<td>d75z.</td>
<td>DOSULEPIN HYDROCHLORIDE 75mg tablets</td>
</tr>
<tr>
<td>d79z.</td>
<td>LOFEPRAMINE 70mg tablets</td>
</tr>
<tr>
<td>d7ex.</td>
<td>TRAZODONE HYDROCHLORIDE 50mg capsules</td>
</tr>
<tr>
<td>da41.</td>
<td>FLUOXETINE 20mg capsules</td>
</tr>
<tr>
<td>da51.</td>
<td>SERTRALINE 50mg tablets</td>
</tr>
<tr>
<td>da52.</td>
<td>SERTRALINE 100mg tablets</td>
</tr>
<tr>
<td>da61.</td>
<td>PAROXETINE 20mg tablets</td>
</tr>
<tr>
<td>da71.</td>
<td>VENLAFAXINE 37.5mg tablets</td>
</tr>
<tr>
<td>da72.</td>
<td>VENLAFAXINE 75mg tablets</td>
</tr>
<tr>
<td>da77.</td>
<td>VENLAFAXINE 75mg m/r capsules</td>
</tr>
<tr>
<td>da91.</td>
<td>CITALOPRAM 20mg tablets</td>
</tr>
<tr>
<td>da93.</td>
<td>CITALOPRAM 10mg tablets</td>
</tr>
<tr>
<td>da95.</td>
<td>CITALOPRAM 40mg tablets</td>
</tr>
<tr>
<td>da81.</td>
<td>MIRTAZAPINE 30mg tablets</td>
</tr>
<tr>
<td>da85.</td>
<td>MIRTAZAPINE 15mg oro-dispersible tablets</td>
</tr>
<tr>
<td>da8y.</td>
<td>MIRTAZAPINE 45mg tablets</td>
</tr>
<tr>
<td>da8z.</td>
<td>MIRTAZAPINE 15mg tablets</td>
</tr>
<tr>
<td>daC1.</td>
<td>ESCITALOPRAM 10mg tablets</td>
</tr>
<tr>
<td>dh1z.</td>
<td>BETAHISTINE HYDROCHLORIDE 8mg tablets</td>
</tr>
<tr>
<td>dh4y.</td>
<td>CYCLIZINE 50mg tablets</td>
</tr>
<tr>
<td>dh7x.</td>
<td>DOMPERIDONE 10mg tablets</td>
</tr>
<tr>
<td>dhb1.</td>
<td>METOCLOPRAMIDE 10mg tablets</td>
</tr>
<tr>
<td>dhed.</td>
<td>PROCHLORPERAZINE 3mg bucc.tabs</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>dher.</td>
<td>PROCHLORPERAZINE 5mg tablets</td>
</tr>
<tr>
<td>di21.</td>
<td>PARACETAMOL 500mg tablets</td>
</tr>
<tr>
<td>di22.</td>
<td>PARACETAMOL 500mg soluble tabs</td>
</tr>
<tr>
<td>di24.</td>
<td>PARACETAMOL 250mg/5mL mixture</td>
</tr>
<tr>
<td>di2n.</td>
<td>PARACETAMOL 120mg/5mL oral suspension</td>
</tr>
<tr>
<td>di2q.</td>
<td>PARACETAMOL 500mg capsules</td>
</tr>
<tr>
<td>di2s.</td>
<td>PARACETAMOL 120mg/5mL sugar free suspension</td>
</tr>
<tr>
<td>di2u.</td>
<td>PARACETAMOL 250mg/5mL sugar free suspension</td>
</tr>
<tr>
<td>di2x.</td>
<td>CALPOL PAEDIATRIC 120mg/5mL suspension</td>
</tr>
<tr>
<td>di2y.</td>
<td>CALPOL PAEDIATRIC 120mg/5mL sugar free suspension</td>
</tr>
<tr>
<td>dia2.</td>
<td>CO-CODAMOL 8mg/500mg tablets</td>
</tr>
<tr>
<td>dia6.</td>
<td>CO-DYDRAMOL tablets</td>
</tr>
<tr>
<td>dia7.</td>
<td>*CO-PROXAMOL tablets</td>
</tr>
<tr>
<td>dian.</td>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg tablets</td>
</tr>
<tr>
<td>diap.</td>
<td>CO-CODAMOL 8mg/500mg effervescent tablets</td>
</tr>
<tr>
<td>diaq.</td>
<td>CO-CODAMOL 8mg/500mg capsules</td>
</tr>
<tr>
<td>diaU.</td>
<td>PARACETAMOL+CODEINE PHOSPHATE 500mg/30mg capsules</td>
</tr>
<tr>
<td>dj81.</td>
<td>DIHYDROCODEINE 30mg tablets</td>
</tr>
<tr>
<td>dji2.</td>
<td>TRAMADOL HCL 50mg capsules</td>
</tr>
<tr>
<td>d15A.</td>
<td>SUMATRIPTAN 50mg tablets</td>
</tr>
<tr>
<td>dnj1.</td>
<td>GABAPENTIN 100mg capsules</td>
</tr>
<tr>
<td>dnj2.</td>
<td>GABAPENTIN 300mg capsules</td>
</tr>
<tr>
<td>dpnx.</td>
<td>PREGABALIN 75mg capsules</td>
</tr>
<tr>
<td>du3A.</td>
<td>NICOTINE 21mg/24hours patches</td>
</tr>
<tr>
<td>du3m.</td>
<td>NIQUITIN CQ 21mg/24hours patches</td>
</tr>
<tr>
<td>du3s.</td>
<td>NIQUITIN CQ 21mg/24hours clear patches</td>
</tr>
<tr>
<td>du8x.</td>
<td>VARENICLINE 500micrograms+1mg tablets</td>
</tr>
<tr>
<td>du8z.</td>
<td>VARENICLINE 1mg tablets</td>
</tr>
<tr>
<td>E112.</td>
<td>Single major depressive episode</td>
</tr>
<tr>
<td>E113.</td>
<td>Recurrent major depressive episode</td>
</tr>
<tr>
<td>e153.</td>
<td>PHENOXYMETHYLPENICILLIN 250mg tablets</td>
</tr>
<tr>
<td>e155.</td>
<td>PHENOXYMETHYLPENICILLIN 125mg/5mL syrup</td>
</tr>
</tbody>
</table>
WLGP e157. PHENOXYMETHYLPenicillin 250mg/5mL syrup
WLGP E200. Anxiety states
WLGP E2001 Panic disorder
WLGP E2003 Anxiety with depression
WLGP E204. Neurotic depression reactive type
WLGP E205. Neurasthenia - nervous debility
WLGP e221. FLUCLOXACILLIN 250mg capsules
WLGP e222. FLUCLOXACILLIN 500mg capsules
WLGP e22j. FLUCLOXACILLIN 125mg/5mL syrup
WLGP e22v. FLUCLOXACILLIN 125mg/5mL oral suspension
WLGP E23.. Alcohol dependence syndrome
WLGP E24.. Drug dependence
WLGP E250. Nondependent alcohol abuse
WLGP E2781 Tension headache
WLGP E28.. Depressive disorder NEC
WLGP e311. AMOXICILLIN 250mg capsules
WLGP e312. AMOXICILLIN 500mg capsules
WLGP e316. AMOXIL 500mg capsules
WLGP e31h. AUGMENTIN 375mg tablets
WLGP e31t. CO-AMOXICLAV 375mg tablets
WLGP e31U. CO-AMOXICLAV 625mg tablets
WLGP e31z. CO-AMOXICLAV 250/625 in 5mL suspension
WLGP e32k. AMOXICILLIN 125mg/5mL sugar free suspension
WLGP e3zm. AMOXICILLIN 125mg/5mL syrup
WLGP e3zn. AMOXICILLIN 250mg/5mL syrup
WLGP e3zu. AMOXICILLIN 250mg/5mL sugar free suspension
WLGP e691. CEFALEXIN 250mg capsules
WLGP e692. CEFALEXIN 500mg capsules
WLGP e693. CEFALEXIN 250mg tablets
WLGP e694. CEFALEXIN 500mg tablets
WLGP e758. DOXYCYCLINE 100mg capsules
WLGP e76z. LYMECYCLINE 408mg capsules
WLGP e782. OXYTETRACYCLINE 250mg tablets
WLGP F502. Other otitis externa
WLGP F502z Otitis externa NOS
WLGP F504. Impacted cerumen (wax in ear)
WLGP F51.. Nonsuppurative otitis media + eustachian tube disorders
WLGP F52.. Suppurative and unspecified otitis media
WLGP F52z. Otitis media NOS
WLGP F5611 Benign paroxysmal positional vertigo or nystagmus
WLGP F587. Otalgia
WLGP F59.. Hearing loss
WLGP f921. LEVOTHYROXINE SODIUM 25micrograms tablets
WLGP f922. LEVOTHYROXINE SODIUM 50micrograms tablets
WLGP fe62. PREDNISOLONE 5mg tablets
WLGP fe6i. PREDNISOLONE 5mg e/c tablets
WLGP fg51. NORETHISTERONE 5mg tablets
WLGP G2... Hypertensive disease
WLGP G20.. Essential hypertension
WLGP g427. CANESTEN-1 500mg vaginal tablets
WLGP g429. CLOTRIMAZOLE 1% cream
WLGP g42A. CANESTEN COMBI pessary+cream
WLGP g42r. CLOTRIMAZOLE 500mg+2% pessary+cream
WLGP g42v. CLOTRIMAZOLE 2% vaginal cream
WLGP g42x. CLOTRIMAZOLE 200mg vaginal tablets
WLGP g42y. CLOTRIMAZOLE 500mg vaginal tablets
WLGP g42z. CLOTRIMAZOLE 10% cream
WLGP g811. MARVELON tablets
WLGP g832. LOGYNON tablets
WLGP g834. MICROGYNON-30 tablets
WLGP g837. OVRANETTE tablets
WLGP g838. *SCHERING-PC4 tablets
WLGP g83D. MICROGYNON 30 ED tablets
WLGP g83G. RIGEVIDON tablets
WLGP G84.. Haemorrhoids
WLGP g891. CILEST tablets
WLGP g8A1. YASMIN tablets
WLGP ga27. MIRENA 52mg intrauterine system
WLGP ga29. *LEVONELLE-2 tablets
WLGP ga2B. LEVONORGESTREL 1.5mg tablets
WLGP ga2D. LEVONELLE 1500micrograms tablets
WLGP ga36. DEPO-PROVERA 150mg/1mL prefilled syringe
WLGP ga53. NORIDAY tablets 84CP
WLGP ga8B. CERAZETTE 75micrograms tablets
WLGP ga8C. CERELLE 75micrograms tablets
WLGP gdew. DULOXETINE 60mg gastro-resistant capsules
WLGP gdx. DULOXETINE 30mg gastro-resistant capsules
WLGP H00.. Acute nasopharyngitis
WLGP H01.. Acute sinusitis
WLGP H02.. Acute pharyngitis
WLGP H03.. Acute tonsillitis
WLGP H037. Recurrent acute tonsillitis
WLGP H040. Acute laryngitis
WLGP H05z. Upper respiratory infection NOS
WLGP H060. Acute bronchitis
WLGP H06z0 Chest infection NOS
WLGP H06z1 Lower resp tract infection
WLGP H17.. Allergic rhinitis
WLGP H170. Allergic rhinitis due to pollens
WLGP H27z. Influenza NOS
WLGP H33.. Asthma
WLGP H333. Acute exacerbation of asthma
WLGP hc21. DEPO-PROVERA 450mg/3mL injection
WLGP i11t. FERROUS FUMARATE 210mg tablets
WLGP i151. FERROUS SULFATE 200mg tablets
WLGP i16d. PREGADAY tablets
WLGP i332. FOLIC ACID 5mg tablets
WLGP i334. FOLIC ACID 400micrograms tablets
WLGP i81j. DIORALYTE blackcurrant oral powder
THIAMINE HYDROCHLORIDE 100mg tablets
VITAMIN-B-CO STRONG tablets
Dental abscess
Oral aphthae
Oesophageal reflux without mention of oesophagitis
ASPIRIN 300mg dispersible tablets
Gastritis and duodenitis
Dyspepsia
DICLOFENAC 50mg e/c tablets
IBUPROFEN 200mg tablets
IBUPROFEN 400mg tablets
IBUPROFEN 600mg tablets
IBUPROFEN 100mg/5mL syrup
IBUPROFEN 100mg/5mL sugar free syrup
MEFENAMIC ACID 250mg capsules
MEFENAMIC ACID 500mg tablets
NAPROXEN 250mg tablets
NAPROXEN 500mg tablets
NAPROXEN 500mg e/c tablets
Other non-infective inflammatory gastroenteritis and colitis
Constipation NOS
Irritable colon - Irritable bowel syndrome
Haemorrhage of rectum and anus
ALGESAL 10% cream
IBUPROFEN 5% gel
CAPSAICIN 0.025% cream
IBUPROFEN 10% gel
Cystitis
Urinary tract infection, site not specified
Urinary tract infection, site not specified NOS
Inflammatory breast disease
Mastodynia - pain in breast
CHLORAMPHENICOL 0.5% eye drops
CHLORAMPHENICOL 1% eye ointment

FUSIDIC ACID 1% eye drops

*FUCITHALMIC 1% eye drops 5g

Bacterial vaginitis

Dysmenorrhea

Menstruation disorders

Absence of menstruation

Menorrhagia

Irregular menstrual cycle

Metrorrhagia

SODIUM CROMOGLICATE 2% eye drops

Spontaneous abortion

Excessive pregnancy vomiting

Normal delivery in a completely normal case

CLIOQUINOL+FLUMETASONE PIV 1%/0.02% ear drops

LOCORTEN-VIOFORM ear drops 10mL

GENTISONE HC ear drops 10mL

GENTAMICIN+HYDROCORTISONE ACETATE 0.3%/1% ear drops

SOFRADEX EYE/EAR drops 10mL

OTOMIZE ear spray 5mL

SODIUM BICARBONATE ear drops

CERUMOL ear drops 11mL

OLIVE OIL ear drops 10mL

BECONASE AQUEOUS 50microgram nasal spray

BECLOMETASONE 50micrograms aqueous nasal spray

AVAMYS 27.5micrograms nasal spray

MOMETASONE FURATE MONOHYDRATE 0.05% aqueous nasal spray

NASEPTIN cream 15g

DIFFLAM 0.15% oral rinse 300mL

DIFFLAM 0.15% mouth and throat spray

BENZYMINE HYDROCHLORIDE 0.15% oral rinse

BENZYMINE HYDROCHLORIDE 0.15% mouth and throat spray

DAKTARIN oral gel 80g
Skin and subcutaneous tissue infections

- Boil NOS
- Cellulitis NOS
- Abscess NOS
- Impetigo
- Local infection skin/subcut tissue NOS
- Skin and subcut tissue infection NOS
- Seborrhoeic dermatitis
- AQUEOUS cream
- Atopic dermatitis/eczema
- DIPROBASE cream 50g
- DIPROBASE dispenser cream 500g
- Contact dermatitis and other eczemas
- EMULSIFYING ointment
- DIPROBASE ointment 50g
- Dermatitis NOS
- Eczema NOS
- Psoriasis NOS
- DOUBLEBASE gel 500g
- E45 cream 500g pump
- Skin tag
- HYDROMOL ointment 125g
- Ingrowing nail
- Ingrowing great toe nail
- SUDOCREM cream 30g
- Folliculitis
- OILATUM EMOLLIENT bath additive 500mL
- Acne vulgaris
- Sebaceous cyst - wen
- DERMOL 500 lotion
- Urticaria
- Other skin and subcutaneous tissue disease NOS
- CALAMINE lotion
HYDROCORTISONE 1% cream 30g
HYDROCORTISONE 1% cream 100g
HYDROCORTISONE 0.5% cream 50g
HYDROCORTISONE 1% ointment 50g
HYDROCORTISONE 0.5% cream 50g
HYDROCORTISONE ACETATE+FUSIDIC ACID 1%/2% cream
HYDROCORTISONE+MICONAZOLE NITRATE 1%/2% cream
HYDROCORTISONE+CLOTRIMAZOLE 1%/1% cream
BETNOVATE 0.1% cream 100g
BETAMETHASONE 0.1% cream
BETAMETHASONE 0.1% ointment
BETAMETHASONE+FUCIDIC ACID 0.1%/2% cream
BETAMETHASONE+FUCIDIC ACID 0.1%/2% cream
EUMOVATE 0.05% cream 30g
EUMOVATE 0.05% cream 15g
CLOBETASONE 0.05% cream
ZINERYT lotion 90mL
ERYTHROMYCIN+ZINC ACETATE 40mg/12mg/mL topical solution
ZINERYT lotion 30mL
DUAC ONCE DAILY 5%/1% gel 50g
SALACTOL 16.7% paint 10mL
SALATA 12% gel 8g
KETOCONAZOLE 20mg/mL shampoo
CAPASAL shampoo 250mL
MUPIROCIN 2% cream
FUCIDIN 2% cream 15g
FUSIDIC ACID 2% cream
<table>
<thead>
<tr>
<th>WLGP</th>
<th>me41.</th>
<th>CANESTEN 1% cream 20g</th>
</tr>
</thead>
<tbody>
<tr>
<td>WLGP</td>
<td>me4w.</td>
<td>CLOTRIMAZOLE 1% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>me71.</td>
<td>MICONAZOLE 2% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>me78.</td>
<td>DAKTARIN 2% cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mejz.</td>
<td>TERBINAFINE HYDROCHLORIDE 1% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>mf11.</td>
<td>ZOVIRAX 5% cream 2g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mf1z.</td>
<td>ACICLOVIR 5% cream</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg5x.</td>
<td>MALATHION 0.5% liquid</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg77.</td>
<td>*FULL MARKS liquid 200mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg7C.</td>
<td>*FULL MARKS 0.2% lotion 50mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg81.</td>
<td>PERMETHRIN 1% scalp application</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg82.</td>
<td>LYCLEAR 1% cream rinse 59mL</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg83.</td>
<td>PERMETHRIN 5% cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>mg84.</td>
<td>LYCLEAR 5% cream 30g</td>
</tr>
<tr>
<td>WLGP</td>
<td>N094.</td>
<td>Pain in joint - arthralgia</td>
</tr>
<tr>
<td>WLGP</td>
<td>N094K</td>
<td>Arthralgia of hip</td>
</tr>
<tr>
<td>WLGP</td>
<td>N131.</td>
<td>Cervicalgia - pain in neck</td>
</tr>
<tr>
<td>WLGP</td>
<td>N142.</td>
<td>Pain in lumbar spine</td>
</tr>
<tr>
<td>WLGP</td>
<td>N143.</td>
<td>Sciatica</td>
</tr>
<tr>
<td>WLGP</td>
<td>N145.</td>
<td>Backache, unspecified</td>
</tr>
<tr>
<td>WLGP</td>
<td>N2132</td>
<td>Lateral epicondyritis of the elbow</td>
</tr>
<tr>
<td>WLGP</td>
<td>N2410</td>
<td>Myalgia unspecified</td>
</tr>
<tr>
<td>WLGP</td>
<td>N245.</td>
<td>Pain in limb</td>
</tr>
<tr>
<td>WLGP</td>
<td>N2450</td>
<td>Hand pain</td>
</tr>
<tr>
<td>WLGP</td>
<td>N2452</td>
<td>Pain in leg</td>
</tr>
<tr>
<td>WLGP</td>
<td>N2453</td>
<td>Pain in arm</td>
</tr>
<tr>
<td>WLGP</td>
<td>n45n.</td>
<td>REVAXIS suspension for injection 0.5mL prefilled syringe</td>
</tr>
<tr>
<td>WLGP</td>
<td>n4h2.</td>
<td>TYPHIM VI VACCINE 25 microgram/0.5mL prefilled syringe</td>
</tr>
<tr>
<td>WLGP</td>
<td>p161.</td>
<td>MELOLIN 5x5cm dressing</td>
</tr>
<tr>
<td>WLGP</td>
<td>p1n1.</td>
<td>INADINE 5cmx5cm dressing</td>
</tr>
<tr>
<td>WLGP</td>
<td>p436.</td>
<td>VOLUMATIC spacer device</td>
</tr>
<tr>
<td>WLGP</td>
<td>p43F.</td>
<td>AEROCHAMBER spacer device</td>
</tr>
<tr>
<td>WLGP</td>
<td>p46E.</td>
<td>STANDARD RANGE EN13826 peak flow meter</td>
</tr>
</tbody>
</table>
MICROPORE 2.5cmx5m tape
[D]Vertigo NOS
[D]Rash and other nonspecific skin eruption
[D]Rash and other nonspecific skin eruption NOS
[D]Lump, localized and superficial
[D]Headache
[D]Cough
[D]Musculoskeletal chest pain
[D]Abdominal pain
[D]Groin pain
Fracture of metacarpal bone
Fracture of one or more phalanges of hand
Fracture of unspecified bones
Ankle sprain
Whiplash injury
Head injury
Open wound of head, neck and trunk NOS
Superficial injury
Other knee injury
Other ankle injury
Poisoning
Postoperative wound infection, unspecified
Motor vehicle traffic accidents (MVTA)
Accidental falls
Dog bite
Suicide and self inflicted injury
[X] Assault
[V] Outcome of delivery
[V] Mental and behavioural problems
[V] Attention to surgical dressings or sutures
[V] Administrative encounters
[V] Issue of medical certificate
[V] Issue of repeat prescription
Screening for malignant neoplasm of cervix

EDDS

Admission Count

Count of distinct Emergency Department admissions for the time period

EDDS + PEDW

Combined ED Admissions

Count of distinct Emergency Department and Emergency Hospital admissions for the time period

POLICE

PPN Count

Count of all the PPN submissions following the index submission

POLICE

Multiple Police Visits (PPNs)

Binary of yes/no for if they have multiple police visits to the victim after the index PPN submission

POLICE

SYSTEM_ID_PE

Unique identifier - for each PPN call

POLICE

EXTRACT_DT

Date of incident/ PPN call

POLICE

REFERRED_TO_MARAC_1

Referral to MARAC (if 14 or more YES on the DASH risk assessment)

POLICE

INJURY_1

Has the current incident resulted in an injury?

POLICE

INJURYDETAILS_1

Injury details (name of abusers(s))

POLICE

FIRSTINJURY_1

Please state whether this is the first injury?

POLICE

FRIGHTENED_2

Are you very frightened?

POLICE

FURTHERVIOLENCE_3

Is it further injury or violence? (name of abusers(s)) What are you afraid of? History of violence?

POLICE

ATTEMPTTOKILL_3

Has (...) ever attempted to kill you or someone else and you believed them?

POLICE

ATTEMPTTOKILLDETAILS_3

Attempt to kill details

POLICE

FURTHERVIOLENCEINJURY_3

Is it further injury or violence? (name of abusers(s))

POLICE

FURTHERVIOLENCEDETAILS_3

Further violence details

POLICE

AFRAIDOF_3

What are you afraid of?

POLICE

ISOLATED_4

Do you feel isolated from family/friends?

POLICE

FORCEDISOLATION_4

Does (name of abuser(s)) try to stop you from seeing friends/family/Dr or others?

POLICE

DEPRESSED_SUICIDAL_5

Are you feeling depressed or having suicidal thoughts

POLICE

SEPERATED_6

Have you separated or tried to separate from (name of abuser(s)..) within the past year?

POLICE

CHILDCONFLICT_7

Is there conflict over child contact?

POLICE

CHILDCONFLICTDETAILS_7

Child conflict details

POLICE

HARRASSED_8

Does (name of abuser(s)) constantly text, call, contact, follow, stalk or harass you?

POLICE

HARRASSEDHISTORY_8

Previous record of harassment?

POLICE

PROPERTYDAMAGE_8

Does (name of abuser(s)) damage furniture?

POLICE

UNANNOUNCEDVISIT_8

Uninvited visits to victim’s home or workplace?

POLICE

FOLLOWINGYOU_8

Does (name of abuser(s)) constantly follow you?

POLICE

THIRDPARTYHARRASSMENT_8

Is there any other person that has threatened you or that you are afraid of?
POLICE  ENGAGEDOTHERS_8  Do you know if (...) has hurt anyone else? (inside or outside of the family)

POLICE  PREGNANT_9  Is anyone in the household pregnant? (may be the victim)

POLICE  PASTPREGNANT_9  (If no) Has anyone in the household had a child in last 18 months?

POLICE  OTHERCHILDREN_10  Are there any children or step-children either in the household or elsewhere?

POLICE  OTHERDEPENDANTS_10  Are there any other dependants either in the household or elsewhere?

POLICE  DEPENDANTSHARMED_11  Has (...) ever hurt the children/dependants?

POLICE  DEPENDANTSHARMEDDETAILS_11  Dependant harm details

POLICE  DEPENDANTSTHREATENED_12  Has (...) ever threatened to hurt or kill the children/dependants?

POLICE  ABUSEFREQUENCY_13  Is the abuse happening more often?

POLICE  ABUSEWORSE_14  Is the abuse getting worse?

POLICE  CONTROLLING_15  Does (...) try to control everything you do and/or are they excessively jealous?

POLICE  CONTROLLINGDETAILS_15  Control details

POLICE  WEAPONSUSED_16  Has (...) ever used weapons or objects to hurt you?

POLICE  THREATSTOKILL_17  Has (...) ever threatened to kill you or someone else and you believed them?

POLICE  ATTEMPTEDSTRANGLE_18  Has (...) ever attempted to strangle/choke/suffocate/drown you?

POLICE  ATTEMPTEDSTRANGLEDETAILS_18  Attempt to strangle/choke/suffocate/drown details

POLICE  SEXUALHARM_19  Does (...) do or say things of a sexual nature that makes you feel bad or do physically to you or someone else.

POLICE  SEXUALHARMDETAILS_19  Harm details

POLICE  THREATSFROMOTHERS_20  Is there any other person that has threatened you or that you are afraid of?

POLICE  THREATSFROMOTHERSDETAILS_20  Threat details

POLICE  HARMOTHERS_21  Do you know if (...) has hurt anyone else? (inside or outside of the family)

POLICE  HARMOTHERSDETAILS_21  Harm other details

POLICE  ANIMALHARM_22  Has (...) ever mistreated an animal or family pet?

POLICE  FINANCIALISSUES_23  Are there any financial issues?

POLICE  HASFINANCIALISSUES_23  Has (...) had problems in the past year with drugs (prescription or other), alcohol or mental health leading to problems in leading a normal life

POLICE  SUBSTANCEABUSE_24  Substance abuse details

POLICE  SUICIDE_25  Has (...) ever threatened or attempted suicide?

POLICE  INJUNCTIONBREACHED_26  Has (...) ever breached bail/an injuction and/or any agreement for when they can see you and/or the children?

POLICE  INJUNCTIONBREACHEDTYPE_26  Type of injunction breach

POLICE  INJUNCTIONBREACHEDDETAILS_26  Injunction breach details
<table>
<thead>
<tr>
<th>POLICE</th>
<th>CRIMINALHISTORY_27</th>
<th>Do you know if (...) has ever been in trouble with the police or has a criminal history?</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLICE</td>
<td>OFFICERS_OBSERVATIONS</td>
<td>Free text for officers observations</td>
</tr>
<tr>
<td>POLICE</td>
<td>DV_RISK_ASSESSMENT_LEVEL</td>
<td>High, Medium, Standard or NULL category</td>
</tr>
<tr>
<td>POLICE</td>
<td>RISK_ASSESSMENTDETAILS</td>
<td>Free text on the risk assessment details</td>
</tr>
<tr>
<td>POLICE</td>
<td>REFERRED_TO_MARAC</td>
<td>Referral to MARAC (if 14 or more YES on the DASH risk assessment)</td>
</tr>
<tr>
<td>POLICE</td>
<td>SAFETYMEASURES</td>
<td>Free text for officers observations</td>
</tr>
<tr>
<td>PEDW+EDDS</td>
<td>Outcome</td>
<td>Whether the individual experienced the outcome</td>
</tr>
</tbody>
</table>